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Hereditary diffuse gastric cancer (HDGC) is a cancer syndrome caused by germline 
mutation of the CDH1 gene that encodes the cell adhesion tumor suppressor protein 
E-cadherin. Mutation carriers have a lifetime risk higher than 70% of developing 
diffuse gastric cancer, along with an elevated risk of lobular breast cancer. Mutation 
carriers develop multi focal stage T1a signet ring cell carcinoma as early as 16-years. 
Development of these foci follow after somatic inactivation of the second CDH1 
allele by mechanisms that include DNA promoter hypermethylation, followed by an 
indolent stage that can last years before further tumor progression. Valproic acid 
(VPA) and Decitabine (DAC) were to be used as an epigenetic therapy, they each 
have been identified in the literature for their anticancer properties.  
In this study a combination of VPA and DAC were used to test chemopreventive 
capabilities on three cell lines, non-malignant breast MCF10a cells, positive control 
non-small lung carcinoma NCI-H460 cells and a gastric adenocarcinoma AGS cells. 
Gene expression of CDH1 was analysed by real-time qPCR and western blotting. 
VPA was further characterised in MCF10a cells by analysing transcriptome sequence 
(RNA-Seq) and DNA methylation status changes (Illumina 450k Methyl-array).  
Both VPA and DAC increased E-cadherin expression in each of the cell lines, 
however E-cadherin up regulation was transient after VPA treatment withdrawal in 
MCF10a cells. No synergistic effects between VPA and DAC were detected in 
MCF10a cells, but a synergistic effect was observed in NCI-H460 cells. VPA 
treatment in MCF10a cells resulted in gene expression changes associated with cell 
proliferation and cell cycle. VPA had no measurable effect on DNA methylation 
levels in MCF10a cells.  
To further study VPA gene expression changes eleven migraine and epilepsy patients 
treated with VPA from the Dunedin hospital had buccal and whole blood samples 
taken before and after VPA treatment. No identifiable trends were detected by real-
time qPCR either in the target gene, CDH1 or potential VPA surrogate genes 




Overall the characterised effects of VPA in MCF10a cells, were, down-regulation of 
genes associated with cell proliferation and cell cycle. Because of the transient 
increase in CDH1 expression in MCF10a cells and the inability to detect a change in 
expression in neurological patients after VPA treatment, VPA will require further 
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Chapter 1: Hereditary gastric cancer 
Cancer is the third leading cause of death world-wide, following cardiovascular 
disease, and infectious and parasitic diseases (Mathers, Fat et al. 2008). Seven 
hallmarks of cancer have been defined (Figure 1.1): sustaining proliferative signalling 
and angiogenesis, resisting growth inhibitors and cell death, limitless replicative 
potential, activating invasion and an inflammatory microenvironment (Hanahan and 
Weinberg 2011). Drugs that interfere with these cancer enabling characteristics have 
been developed and are either in clinical trials or have been approved for clinical use 
(Hanahan and Weinberg 2011). Also, investigational drugs that hold promise as 
cancer therapeutics have been developed to target these enabling characteristics and 
the emerging hallmarks shown in (Figure 1.1). The drugs listed are illustrative 
examples only; there are more candidate drugs in the pipeline with different targets 
and modes of action in development for most of these hallmarks (Hanahan and 
Weinberg 2011).  
 
Figure 1.1. Drug targets of cancer enabling characteristics.  
Examples of therapeutic targets of the hallmarks of cancer; Epidermal growth 
factor (EGFR) inhibitors, Immune activating tremelimumab monoclonal antibodies 
(anti-CTLA4 mAb), inhibitors of hepatocyte growth factor/met tyrosine kinase 
receptor (HGF/c-Met), inhibitors of vascular endothelial growth factors (VEGF) 
signalling, poly ADP ribose polymerase (PARP) inhibitors.  Data from (Hanahan 




Cancer-related inflammation is the most recent addition to 'the hallmarks of cancer' 
(Colotta, Allavena et al. 2009, Hanahan and Weinberg 2011). The literature has 
previously exemplified external factors contributing to chronic inflammation and 
wound healing triggering cancers (Dvorak 1986, Coussens and Werb 2002, Schäfer 
and Werner 2008). The role of inflammation in initiating cancer growth is supported 
by human epidemiological data that demonstrate decreased breast and other cancer 
risk in users of non-steroidal anti-inflammatory drugs (NSAIDs) (Moran 2002). 
Chronic inflammation that contributes to cancer is not restricted to a subset of tumors, 
although, cancer-related inflammation is best documented in colon, gastric and 
hepatocellular carcinomas (Colotta, Allavena et al. 2009). An inflammatory 
component is present in the microenvironment of most neoplastic tissues, including 
those not causally related to an obvious inflammatory process (Colotta, Allavena et al. 
2009). There is an increased awareness that inflammatory agents can cause aberrant 
methylation in tumor suppressor genes resulting in a heightened risk to inflammation-
associated cancers, such as liver cancers, ulcerative colitis–associated colon cancers, 
and gastric cancers (Niwa, Tsukamoto et al. 2010). Interestingly, aspirin (a form of 
NSAID) has recently been shown to repress methylation of CDH1 (a tumor 
suppressor gene) in human gastric epithelia and perhaps plays a suppressive role 
against methylation-related gastric carcinogenesis (Tahara, Shibata et al. 2010). 
Moreover, chronic inflammation causes genome instability by a variety of 
mechanisms either directly by DNA damage or by affecting DNA repair systems and 
altering cell cycle check points. Genomic instability, in turn, can be the driving force 
to malignant progression.  
Research over the last decade has shown that cancer cell traits alone can no longer be 
considered the sole contributor to tumorigenesis and that the whole “tumor 
microenvironment” must be considered (Hanahan and Weinberg 2011). From this 
perspective, the biology of the tumor can only be fully understood by studying all the 
specialised cell types that can contribute to tumor growth including; cancer stem cells 
(CSCs), activated fibroblasts, immune cells, epithelial cells and vascular and 
lymphatic endothelial cells within the microenvironment (Singh and Kaur 2013). 
Fibroblasts are the predominant cell in the stroma and are responsible for expansion 




collagens and structural proteoglycans as well as various classes of proteolytic 
enzymes, their inhibitors and various growth factors (Tlsty and Coussens 2006). 
Through a transient action, oncogenic signals from cancer associated fibroblasts 
(CAFs) can stimulate late non-tumorigenic cells toward a malignant state. 
Interestingly, stromal fibroblasts change their phenotype and function in response to 
varying physiologic signals, be they normal or pathologic (Tlsty and Coussens 2006). 
Treating the tumor microenvironment by treating factors that contribute to creating a 
cancer environment could prevent neoplastic growth.  
The microenvironment of a distant organ can also influence a tumor’s ability to 
metastasise. Metastasis is the cause of 90% of human cancer deaths (Mehlen and 
Puisieux 2006). The metastatic process is very inefficient, as only a small proportion 
of the primary tumor cells successfully colonise distant sites. Microenvironments 
influence the tumor’s ability to move, degrade the extracellular matrix, survive in the 
blood and finally establish itself in a new tissue environment. It has been proposed 
that tumor cells can only metastasise to distant sites (other microenvironments) that 
are compatible with their growth (Paget 1989). For example the diffuse and intestinal 
subtypes of gastric cancer show distinct metastatic patterns, with the diffuse-type 
more likely to colonise the peritoneal cavity and ovaries (Guilford, P., personal 
communication).  
Attention has also been paid to cancer stem cells (CSCs) (Hanahan and Weinberg 
2011). The cancer stem cell concept theorises that the growth of tumors is driven by a 
small number of cells that are able to self-renew, avoid senescence and differentiate 
into a hierarchy of cells. Similar to normal stem cells, CSCs can produce 
differentiating daughter cells (asymmetric division) or increase their own pool 
(symmetric division) for an unlimited time. Cancer stem cells are believed to originate 
from normal stem cells or partially differentiated progenitor cells that have undergone 
an initial oncogenic transformation.  
1.1.  Inherited susceptibility to cancer 
An estimated 5-10% of all cancers are inherited (Anand, Kunnumakara et al. 2008). 
Knudson was the first to confirm the role of tumor suppressor genes in cancer 




retinoblastoma where he showed that cancer was initiated after a mutation of the 
second copy of RB1. This became known as “Knudson's two hit hypothesis” 
(Knudson 1971). Knudson found the hits leading to cancer development could be 
either germline or somatic. In hereditary retinoblastoma, one RB1 mutation was 
dominantly inherited via the germinal cells while the second alteration occurred in 
somatic cells (Figure 1.2). In the non-hereditary form, Knudson found that both 
genetic events occurred in the somatic cells. Unsurprisingly, in hereditary cases, 
cancer occurrence is more likely to be early onset compared to the non-hereditary 
form as only one genetic event is needed to eliminate the tumor suppressor protein 
from the cell. Knudson’s two hit hypothesis has now been expanded to include 
epigenetic mechanisms of gene inactivation (Jones and Laird 1999). 
 
Figure 1.2. The Knudson hypothesis, showing somatic and germline (with one 
germline mutation) cells ability to be affected by the “two hit hypothesis”.  
Many genes have now been identified to be responsible for hereditary cancer (Table 
1.1). Similar to the RB1 gene, most inherited cancer syndromes occur in an autosomal 
dominant pattern, with a loss of function in a single allele (Guilford 2000, Guilford, 
Humar et al. 2010). Germline homozygous mutations are rarely observed in tumor 





Table 1.1. Genes implicated in common inherited cancer predispositions.  
Data from (Nasri 2011).  
 
Gene Syndrome Principal function Principal malignancy(s)
RB1 Familial retinoblastoma; dominant Transcriptional/ cell cycle regulator Retinoblastoma
p16INK4a Familial melanoma; dominant Cyclin-dependent kinase inhibitor Melanoma
CDKN2A, CDK4 Familial melanoma; dominant Cyclin-dependent kinase Melanoma
P53 Li-Fraumeni; dominant Transcription factor Sarcomas, breast cancer
Familial adenomatous polyposis;
Dominant




SMAD4 Juvenile polyposis coli; dominant Growth factor signaling Gastrointestinal cancer
LKB1 Peutz Jeghers; dominant Serine threonine kinase Gastrointestinal cancer
MET Hereditary papillary renal cancer; dominant Receptor tyrosine kinase Papillary renal cancer
MEN1 Multiple endocrine neoplasia type 1; dominant Transcription co-factor Endocrine
RET Multiple endocrine neoplasia type 2; dominant Receptor tyrosine kinase Endocrine
KIT Familial GI stromal tumours; dominant Receptor tyrosine kinase
Gastrointestinal cancer 
(stromal)
PTCH Basal cell nevus syndrome; dominant Membrane receptor Basal cell (skin)
NF1 Neurofibromatosis type 1; dominant GTPase activating protein Neurofibrosarcomas
NF2 Neurofibromatosis type 2; dominant Cytoskeletal protein? CNS tumours
Protein maturation?
RNA elongation
WT1 Wilm Tumour; dominant Transcription factor Nephroblastoma
BLM Bloom syndrome; recessive dsDNA repair Leukemia, lymphoma
FANCA; others Fanconi anemia; recessive DsDNA repair Leukemia
XPB; others Xeroderma pigmentosum; recessive Helicases, nucleotide excision repair
Basal cell and squamous 
cell carcinomas
ATM Ataxia telangiectasia; recessive Serine-threonine protein kinase Lymphoma, leukemia
NBS1 Nijmegen breakage syndrome; recessive Transcription factor, dsDNA repair Lymphoma
BRCA1 Familial breast/ovarian cancer; dominant Transcription factor, dsDNA repair Breast, ovarian cancer




HSNF5 Familial posterior fossa brain tumours; dominant Actin dependent chromatin regulation Brain tumour
EXT1; EXT2 Multiple exostoses; dominant Heparan sulfate biosynthesis
Chondrosarcoma bone 
cancer
STK11 Peutz-Jeghers syndrome; dominant Cell metabolism Intestinal cancer
TERC Dyskeratosis congenita, Scoggins type; dominant
Telomerase RNA component, cellular 
senescence
Leukemia
RPS19 Diamond-Blackfan syndrome; dominant  Encodes a ribosomal protein Leukemia
FAS (TNFRSF6)
Autoimmune lymphoproliferative syndrome, type I; 
Canale-Smith syndrome; dominant
Apoptosis Lymphoma
FH Hereditary multiple leiomyoma ; dominant Cellular respiration Renal cell cancer
SDHB; SDHC; 
SDHD
Hereditary paraganglioma; dominant Respiratory chain
gastro-entero-pancreatic 
neoplasm
HRPT2 Hyperparathyroidism-jaw tumour; dominant
Transcriptional and post-transcriptional 
control pathways
Osteosarcoma of the jaw
CYLD1 Familial cylindromatosis; dominant deubiquitination Tumours of skin adnexa
EVER1; EVER2 Epidermodysplasia verruciformis; dominant Zinc transportation Skin carcinoma
Hereditary non-polyposis colorectal cancer; dominant DNA mismatch repair
Colorectal, endometrial 
cancer
PTEN Cowden syndrome; Juvenile polyposis coli; dominant
Breast cancer, 
gastrointestinal cancer
VHL Von Hippel-Lindau; dominant
Renal clear cell 
carcinomas
APC Growth factor signaling Colorectal cancer




1.1.1 Gastric cancer 
A total of 989,600 new cases worldwide of gastric cancer and 738,000 deaths were 
recorded in 2008 (Jemal, Bray et al. 2011). Gastric cancer is the second leading cause 
of cancer in men, and third in women, when ranked against all other cancers 
(Mathers, Fat et al. 2008). Over 70% of new gastric cancer cases and deaths occur in 
developing countries. The highest incidences for gastric cancer are in Eastern Asia, 
Eastern Europe, and Southern America. The lowest rates are in South Asia, North and 
East Africa, North America, Australia, and New Zealand (Crew and Neugut 2006, 
Jemal, Bray et al. 2011).  
1.1.2 Normal stomach features 
The stomach lies between the oesophagus and the duodenum. Primary functions are: 
storing food, partial digestion of food by the churning action of the stomach muscles 
and mixing enzymes for protein and lipid breakdown, as well as releasing food in a 
controlled and regulated manner into the small intestine. The sphincters found at each 
end of the stomach control mixing and emptying. The wall of the stomach has four 
layers, ordered inside to outside: mucosa, submucosa, muscularis propria and 









Figure 1.3. Normal stomach anatomy. 
There are five anatomical zones in the stomach; fundus, cardia, body, antrum and 
pylorus. The cardiac sphincter separates the oesophagus from the stomach and the 





The general anatomy of the stomach is shown in Figure 1.3, however, these are not 
fixed anatomical zones, owing to variations between individuals and also with age 
(Owen 1986). Different zones are characterised by epithelial cell shape and type, and 
by gland depth. The histological transition between zones is gradual rather than 
abrupt, and oesophageal junctional mucosa, which is commonly up to a centimetre in 
width, shows mixed cell features (Owen 1986). Six primary types of epithelial cells 
cover the surface of the stomach and extend into the gastric glands (Figure 1.4). These 
are; surface pit cells, mucous neck cells, parietal cells, chief cells, G-cells (endocrine 
cells) and undifferentiated cells. Surface cells are found at the apical region of the 
gastric gland, closest to the stomach contents. They produce mucus that protects the 
gastric epithelium from self-digestion, acid and other erosive substances (Karam and 
Leblond 1992). Mucous neck cells secrete the alkaline mucous (only under vagal 
stimulation, not in the resting stomach) shielding the epithelium from hydrochloric 
acid. These cells are found in all types of gastric glands. Parietal cells secrete 
hydrogen ions that combine with chloride ions to form hydrochloric acid; 
subsequently this activates the release of pepsin for protein digestion. Parietal cells 
are located in the body and fundic regions of the stomach. Parietal cells also produce 
glycoproteins such as intrinsic factor, which is essential to the maturation of red blood 
cells, vitamin B12 absorption, and the health of other particular cells. Chief cells 
secrete pepsinogen and a weak lipase. Pepsinogen is converted to the proteolytic 
enzyme pepsin upon contact with the acidic gastric juice. Chief cells are located in the 
body region. G cells secrete gastrin which stimulates the secretion of hydrochloric 
acid, both secretions occur in the antrum. Secreted gastrin enters the blood stream and 
is carried to the mucosa of the body of the stomach where it binds to receptor sites on 
the outer membrane of the parietal cells. Undifferentiated cells (stem cells) found in 
the isthmus (Barker, van Es et al. 2007) produce progeny that move to the surface 
(Karam and Leblond 1993), where they are replaced within 4-5 days. A small number 
migrate downwards to replace parietal, chief and endocrine cells, whose lifespan is 





Figure 1.4. Diagrammatic representation of a gastric gland. 
The gastric glands are located in different regions of the stomach. The glands are 
found in the gastric pits of the stomach lining. The various epithelial cells are 
located in different areas of the gastric gland; surface pit cells (apical region of the 
pit), mucous cells (neck), parietal cells (isthmus and neck), chief cells (base), G-
cells (endocrine cells found in the base) and undifferentiated cells (isthmus). Data 
from (Owen 1986). 
1.1.3 Staging, Symptoms and Survival 
The most widely used tumor staging system among clinicians is the TNM system 
(Tumor, Nodes, and Metastases) (Edge and Compton 2010). Essential to prognosis is 
the ‘T-stage’, which describes whether the tumor is confined to the mucosa (favorable 
prognosis) or has penetrated as far as the serosa or beyond (poor prognosis). Gastric 
cancer TNM staging is separable into six stages: 
Tis carcinoma in situ – no invasion of the lamina propria 
T1a penetrates lamina propria, intramucosal 
T1b invades submucosa 
T2 invades muscularis propria or subserosa 




T4 invasion of adjacent structures 
Stage T1 gastric cancer, has a 5-year survival rate of >64.1% and is considered a 
curable malignancy (SEER 2004-2010). However, >64% of gastric cancer patients 
present with stage T3 and T4, and at this late stage the 5 year survival rate is 
approximately 28.8 and 4.2% respectively (SEER 2004-2010). 
1.1.2 Gastric cancer histological subtypes 
Gastric adenocarcinomas make up more than 90% of all gastric cancers (Correa and 
Piazuelo 2011). Historically, gastric adenocarcinoma is divided into two histo-
morphological types: a diffuse-type, which is characterised by non-cohesive cells and 
pools of intracellular mucus, and an intestinal type, characterised by irregular tubular 
structures in areas of mucosal inflammation (Lauren 1965). Mixed-type tumors, 
which contain components of both diffuse and intestinal histology occur with a 
frequency of 10-15% (Correa and Piazuelo 2011).  
 
Figure 1.5. Histology of gastric adenocarcinoma of the A. diffuse type, signet 
ring. and B. intestinal. 
Extracted from (Correa and Piazuelo 2011) 
Diffuse gastric cancer (DGC) can be further subdivided into signet ring cell 
carcinoma (SRCC) and poorly differentiated carcinoma (PDC) (Humar, Fukuzawa et 
al. 2007). Signet-ring cells are round with intracytoplasmic mucin; nuclei are flattened 
against the periphery of the cells (Figure 1.5) (Correa and Piazuelo 2011). The initial 
development process of DGC is unknown. DGCs can be distributed throughout the 
stomach. Histopathology shows no apparent gastritis; however, Helicobacter pylori 
(H. pylori) has been described as an associated risk factor (Shah, Khanin et al. 2011). 





onset and a poorer prognosis than the intestinal-type tumors (Correa and Piazuelo 
2011).  
Intestinal gastric cancer is microscopically composed of cohesive tumor cells forming 
irregular glandular or papillary structures, or they may be arranged in sheets in a solid 
pattern (Correa and Piazuelo 2011) (Figure 1.5). The multistep development of 
intestinal type carcinoma consists of the following: non-atrophic gastritis, multifocal 
atrophic gastritis, intestinal metaplasia, and dysplasia (Correa, Piazuelo et al. 2010). 
The intestinal type typically involves the distal stomach. Histopathology shows 
gastritis, with H. pylori infection a known risk factor (Shah, Khanin et al. 2011). 
Intestinal type tumors predominate in gastric cancer’s high-risk geographic areas and 
account for much of the international variation in gastric cancer rates (Reed and Hill 
1988). Intestinal gastric cancers are more frequent in men (Correa and Piazuelo 2011).  
1.1.3 Risk factors 
Gastric cancer risk increases with certain environmental factors and/or host-related 
factors. The most well-known environmental risk factor is the H. pylori bacterial 
infection (Jemal, Bray et al. 2011). In gastric cancer, H. pylori attributable risk has 
been estimated to be 75% in the population (i.e. the proportion of gastric cancer in the 
population that would only occur were the H. pylori infection has caused infection in 
the previous 10 years) (Parkin 2006). Other environmental factors such as diet (high 
intake of salt and salt-preserved foods, nitroso compounds; and low intake of fruits, 
vegetables, fibre and folate (Compare, Rocco et al. 2010)), obesity (Yang, Zhou et al. 
2009), smoking (Steevens, Schouten et al. 2010), Epstein-Barr virus (Fukayama 2010, 
Camargo, Koriyama et al. 2013), socioeconomic status, reproductive hormones 
(Freedman, Chow et al. 2007) and radiation (Dhalla, da Silva et al. 2011) can all have 
an effect on gastric cancer risk. Host-related factors such as blood group (type A), 
familial predisposition, genetic alterations, immunodeficiency syndromes (Dhalla, da 
Silva et al. 2011), and pernicious anaemia can also increase risk (Crew and Neugut 
2006). 
Stomach cancer incidence has decreased worldwide in the last few decades, probably 
due to a decrease in risk factors. There is increased use and availability of 




on salted and preserved foods, reductions in H. pylori infection in most parts of the 
world and reduced smoking in some parts of the developing world (Jemal, Bray et al. 
2011). While intestinal gastric cancer incidence is decreasing, two epidemiology 
studies covering several countries indicated an increase in the diffuse-form (Henson, 
Dittus et al. 2004, Miyahara, Niwa et al. 2007). 
1.1.4 The Role of Helicobacter pylori 
Over half of the world’s population has been infected with the H. pylori bacteria, 
although the prevalence in industrialised countries is less than 40% (Bauer and Meyer 
2011). In intestinal type gastric cancer, H. pylori infection is accompanied by atrophy 
and intestinal metaplasia; these are the precursors of the dysplastic changes 
progression (Sipponen, Kekki et al. 1983).  
The H. pylori virulence marker CagA is responsible for morphologic changes of the 
host epithelial cells such as disruption of intercellular junctions, and loss of cell 
polarity (Correa and Piazuelo 2011). Interaction between CagA and signal 
transduction proteins promotes inappropriate ERK signalling in conjunction with Ras, 
Mek, and NF-kB, inducing gastric carcinogenesis. ERK, also known as mitogen-
activated protein kinase (MAPK), aids in regulation of numerous oncogene responses. 
ERK interacts with a range of substrates including cytoskeletal components, apoptosis 
regulators, and a range of other signalling–related molecules (Yang, Cho et al. 2011). 
Interestingly, H. pylori infected individuals frequently show promoter 
hypermethylation of the E-cadherin gene (CDH1) in the noncancerous gastric 
epithelium (Leung, Man et al. 2006). H. pylori eradication causes a significant 
reduction in methylation density in CDH1, and consequently is predicted to reduce  
the possibility of subsequent neoplastic transformation (Leung, Man et al. 2006). 
1.2 Hereditary diffuse gastric cancer 
The only known high penetrance gastric cancer syndrome is Hereditary Diffuse 
Gastric Cancer (HDGC) as clinically defined in 1.3.1. HDGC is genetically defined 
by CDH1 mutations. Approximately 300 families have been identified with the CDH1 
mutation around the world (Guilford, P., personal communication). HDGC presents at 




(Guilford, Hopkins et al. 1998) and the oldest aged 82 (Guilford, Blair et al. 2007). 
Germline CDH1 mutation carriers’ lifetime risk of DGC is >70% in both men and 
women, additionally women have a lifetime risk of lobular breast cancer of 40% 
(Guilford, P., personal communication). Other cancers such as colorectal, lung, 
salivary gland and prostate have been observed in HDGC families, however these are 
most likely to be sporadic cases (Guilford, Blair et al. 2007, Humar, Blair et al. 2009). 
The first hereditary diffuse gastric cancer family was described in NZ in 1964 (Jones 
1964). This family and two other NZ Māori HDGC families were subsequently shown 
to carry inactivating germline CDH1 mutations (Guilford, Hopkins et al. 1998) 
(Figure 1.6).  
 
Figure 1.6. The multi-generation gastric cancer kindred family A. 
Adapted from (Guilford, Hopkins et al. 1998). 
1.2.1 Clinical criteria, diagnosis and management 
The current clinical criteria of HDGC are:  








 three confirmed GC cases in 1st or 2nd degree relatives with at least one being 
confirmed DGC independent of age  
 A person diagnosed with DGC before 45 years 
 A person diagnosed with both DGC and lobular breast cancer 
 A person diagnosed with DGC and another family member with LBC 
 A person diagnosed with DGC and another family member diagnosed with 
signet cell adenocarcinoma of the colon  
This is a relaxation of the earlier criteria which required two or more documented 
cases of diffuse gastric cancer in first or second degree relatives, with at least one 
diagnosed before the age of 50, or three or more cases of documented diffuse 
gastric cancer in first/second degree relatives, independent of age of onset 
(Caldas, Carneiro et al. 1999). 
1.2.1.1  Prophylactic gastrectomy 
Currently, prophylactic total gastrectomy is the “gold standard” for the care of CDH1 
germline mutation carriers and eliminates the inherited risk of gastric cancer 
(Fitzgerald, Hardwick et al. 2010, Guilford, Humar et al. 2010). The mortality 
associated with total gastrectomy ranges from 0-6%, although many of the casualties 
have been elderly, whereas young, healthy patients have a 1% mortality rate for total 
gastrectomy (Lewis, Mellinger et al. 2001, Lehnert and Buhl 2004). All recipients of a 
total gastrectomy experience a ‘dumping syndrome’ (a combination of gastrointestinal 
and cardiovascular symptoms after eating) (Guilford, Humar et al. 2010). Other side 
effects of total gastrectomy include vitamin B12 and iron deficiency (Guilford, Humar 
et al. 2010). Furthermore, Roux-en-Y reconstruction means that food bypasses 
proximal intestinal sites causing variable degrees of calcium, vitamin D, iron and 
folate absorption (Guilford, Humar et al. 2010). Also, lower intestinal transit time 
contributes to fat malabsorption in most patients, reducing the absorption of vitamins 
A, D, E and K (Guilford, Humar et al. 2010). Importantly, women can have 
pregnancies with healthy babies following total gastrectomy, provided they take 




1.2.1.2  Surveillance endoscopy 
Surveillance of HDGC individuals is controversial due to the high risk of missing a 
potential positive diagnosis by gastroscopy. DGC is notoriously difficult to detect by 
gastroscopy due to its often subtle presentation, such as the absence of normal 
distensibility (Guilford, Humar et al. 2010). Even advanced stage DGC can be 
difficult to identify by gastroscopy as it can infiltrate beneath an intact epithelium. In 
spite of these limitations, the surveillance management method is required for 
mutation carriers who: (i) decline prophylactic surgery, (ii) are younger than the age 
at which prophylactic surgery is recommended (approximately 20 years of age), and 
prior to prophylactic surgery in newly diagnosed carriers (Guilford, Humar et al. 
2010).  
It is recommended that surveillance endoscopy is carried out annually, using a white 
light, high definition endoscope, ideally in a centre with a special interest in HDGC 
(Guilford, Humar et al. 2010). Ideally both the careful inspection of the mucosa for 
inflation and deflation and the taking of biopsies of all suspicious lesions, including 
any pale areas with a defined margin (Guilford, Humar et al. 2010). Methylene blue 
can be used for enhanced detection of carcinoma foci 4-10 mm in size (Shaw, Blair et 
al. 2005). It has been theoretically estimated that to capture at least 1 cancer focus in a 
CDH1+/- stomach, 1768 random biopsies would need to be taken to assure a 90% 
detection rate (Fujita, Lennerz et al. 2012). The cancer focus distribution can be 
determined by the geography of the individual and this has been recommended to be 
incorporated into a biopsy protocol (Chun, Lindor et al. 2001, Charlton, Blair et al. 
2004, Fujita, Lennerz et al. 2012). It is currently recommended that any 
endoscopically visible lesions are targeted and random sampling of six biopsies are 
taken from each of the following anatomical zones: antrum, transitional zone, body, 
fundus and cardia (Fitzgerald, Hardwick et al. 2010). Endoscopic technologies are 
advancing and the use of trimodal imaging, confocal endomicroscopy and molecular 
techniques have the potential to be explored (Fitzgerald, Hardwick et al. 2010). 
CDH1 mutation carriers have an elevated risk of lobular breast cancer (LBC) and 
have the option to decrease this risk by undergoing prophylactic mastectomy 




development as it does not create distinct masses. An annual mammography and 
breast magnetic resonance imaging (MRI), and a biannual clinical breast examination 
are recommended from the age of 35 years (Fitzgerald, Hardwick et al. 2010). 
1.2.2 E-cadherin gene (CDH1) mutation 
E-cadherin is a cell adhesion protein, expressed at the adherens junction of epithelial 
tissue which joins the cytoskeletons of adjacent cells (Humar and Guilford 2009). 
Downregulation of expression leads to loss of apical-basal cell polarity and 
consequently disrupts numerous fundamental processes that require spatial asymmetry 
such as specialised membrane function, cytoskeletal organisation, intracellular vesicle 
trafficking, stem cell division and cell migration (Humar and Guilford 2009).  
In HDGC families, over 122 CDH1 germline mutations have now been identified 
(Guilford, Blair et al. 2007, Corso, Marrelli et al. 2012). There are no recognised 
major mutational hotspots; however, some mutations including 1003C>T (Suriano, 
Yew et al. 2005, Kaurah, MacMillan et al. 2007, Norton, Ham et al. 2007), 1901C>T 
(Suriano, Oliveira et al. 2003, Kaurah, MacMillan et al. 2007, More, Humar et al. 
2007) and 1137G>A (Frebourg, Oliveira et al. 2006, Kaurah, MacMillan et al. 2007, 
More, Humar et al. 2007) have been observed in multiple families. Additionally, a 
founder mutation (2398delC) was found in four families from Newfoundland 
(Kaurah, MacMillan et al. 2007). The most common types of mutations are small 
insertions or deletions (35%), followed by missense (28%), nonsense (16%), splice 
site (16%) and large exonic deletions (5%) (Guilford, Humar et al. 2010). Some 
authors have hypothesised that the type and location of CDH1 mutation could impact 
on the individual’s cancer susceptibility, i.e. certain missense mutations could have a 
lower penetrance (Guilford, Blair et al. 2007).  
E-cadherin is inactivated by somatic mutations in 18-56% of sporadic DGCs (Becker 
and Höfler 1995, Muta, Noguchi et al. 1996, Berx, Becker et al. 1998, Machado, 
Oliveira et al. 2001, Graziano, Arduini et al. 2004). In contrast to germline mutations, 
somatic DGC are predominantly splice site mutations resulting in exon skipping 
(Guilford, Humar et al. 2010). Promoter methylation of CDH1 is observed in 40-80% 
of all sporadic or hereditary DGC cases (Machado, Oliveira et al. 2001, Graziano, 




1.2.3 E-cadherin disease initiation and tumorigenesis 
Somatic down regulation of the 2
nd
 CDH1 allele initiates the development of stage 
T1a gastric cancers in germline mutation carriers. These early lesions in HDGC 
patients are referred to here as eHDGC. The most common mechanism of 2
nd
 allele 
downregulation in eHDGC is promoter hypermethylation, occurring at a rate of at 
least 50% (Humar, Blair et al. 2009), whereas loss of heterozygosity (LOH) has been 
reported to be present in 12.5% of advanced HDGC cases (Oliveira, Senz et al. 2009). 
It is as yet unknown whether the second hit is a purely stochastic event or if it can be 
attributed to environmental or physiological pressures. Perhaps, as previously noted, 
H. pylori and/or inflammatory processes are associated with inducing sustained E-
cadherin down-regulation in transient episodes.  
 
Figure 1.7. Proposed model for early progression in E-cadherin mutation 
carriers. 
Adapted from (Guilford, Humar et al. 2010). 
Small stage T1a signet ring cells (<3 mm diameter) can be seen in HDGC patients 
from 15-years-old (Charlton, Blair et al. 2004) and are relatively hypoproliferative 
(Humar, Fukuzawa et al. 2007). These eHDGC cells have low expression of 
additional junctional proteins such as; β-actin, p120 catenin and Lin-7, suggesting 
dysfunctional adhesion is central to disease initiation (Humar, Fukuzawa et al. 2007). 
In the larger eHDGCs (>3 mm), there are a small proportion of cells that are poorly 
differentiated, display mesenchymal features and express activated c-Src and its 
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are observed in more advanced stages (>T2) of HDGC progression, suggesting that an 
epithelial–mesenchymal transition (EMT) is required for tumor invasion beyond the 
muscularis mucosae (Figure 7). E-cadherin down-regulation alone is not enough for 
EMT progression (Chen, Beetham et al. 2014). 
To explore HDGC onset in a mouse model, Humar et.al promoted carcinogenesis 
with N-methyl-N-nitrosourea (MNU) in wild-type (WT) and CDH1+/- mice. After 35 
weeks of periodic treatment, the stomachs were examined for macroscopic and 
microscopic lesions (Humar, Blair et al. 2009). Their results showed MNU treatment 
in mice caused gastric signet ring cell carcinoma (SRCC) in a predictable way with an 
11-fold incidence increase in CDH1+/- compared to wild type litter mates. 
Immunofluorescence showed these murine gastric SRCC had minimal CDH1 
expression, were hypo-proliferative neoplasms and showed no evidence for the 
activation of WNT signalling. In a separate study, mice that had E-cadherin knocked 
out in the parietal cell lineage also showed indolent signet ring-like cells that 
accumulated in the stroma but did not become invasive (Mimata, Fukamachi et al. 
2011), suggesting further genomic instability is required for metastasis. 
The proposed mechanism of HDGC progression by Humar et al. aligns with the 
cancer stem cell hypothesis. Immunofluorescence studies using differentiated markers 
and the proliferation marker Ki67 suggested that T1a SRCC in HDGC patients 
originates from the upper isthmus of the neck region of the gastric gland (Humar, 
Fukuzawa et al. 2007). From here the SRCC migrate towards the luminal surface, 
where they express mucin markers characteristic of differentiated surface pit cells. 
Moreover, Humar et al. have hypothesised that abnormal mitotic spindle orientation 
results in the displacement of the stem or precursor cells (with self-renewal 
capabilities) into the lamina propria, leading to the formation of SRCCs (Humar and 
Guilford 2009). Indirect evidence of the importance of E-cadherin regulation on 
spindle orientation was demonstrated with Drosophila. E-cadherin was shown to 
regulate both the attachment of stem cell to their niches and correct spindle 
orientation during asymmetric divisions to separate progeny with a distinct fate by 
division out of the epithelial plane (Humar and Guilford 2009, Inaba, Yuan et al. 




centrosomes are disorientated (the centrosome orientation checkpoint) (Inaba, Yuan et 
al. 2010) (Figure 1.8.). 
 
Figure 1.8. Model of the early development of eHDGC.  
Mis-orientation of the mitotic spindle due to loss of E-cadherin subsequently 
causes daughter cells to divide out of the epithelial plane and accumulating in the 
lamina propria, adapted from Guilford, P (personal communication). 
In summary the development of eHDGC requires the inactivation of the 2
nd
 CDH1 
allele by mechanisms which are likely to be epigenetic. Methylation of the 2
nd
 CDH1 
allele has been observed in 50% of eHDGC. Other epigenetic mechanisms (e.g. 
histone modification) may account for the remaining 50% (Guilford, P., personal 
communication). This raises the possibility that HDGC development can be prevented 
by inhibiting this 2
nd
 hit using epigenetic drugs which maintain the expression of the 
wildtype CDH1 allele. 
1.3 Epigenetics 
1.3.1 What is epigenetics?  
The term epigenetics is used to describe all meiotic and mitotically heritable changes 
in gene expression that are not due to changes in the DNA sequence itself (Russo, 
Martienssen et al. 1996, Egger, Liang et al. 2004). Epigenetics describes why cells in 
a multicellular organism have identical DNA sequences, yet maintain different 
terminal phenotypes (Riddihough and Zahn 2010). One cause for the complex 




and internal environments (i.e. developmental cues) (Petronis 2010). Epigenetic 
modifications include DNA methylation, histone modification, nucleosome 
remodelling and non-coding RNA-mediated pathways (Riddihough and Zahn 2010). 
Unsurprisingly, disruption of at least one of these interacting systems can lead to 
inappropriate expression or silencing of genes resulting in ‘epigenetic diseases’, such 
as ageing, diabetes, cardiovascular disease, obesity, infertility and cancer (Calvanese, 
Lara et al. 2009, Ling and Groop 2009, Campión, Milagro et al. 2010, Ordovás and 
Smith 2010, Sharma, Kelly et al. 2010, Denomme and Mann 2012)  
Here, major mechanisms in epigenetic regulation will be reviewed; with a focus on 
the role of stable, long term epigenetic modifications that involve DNA methylation 
and the role of histone modifications such as methylation and acetylation that are 
more flexible and short-term.  
1.3.1.1 Histone modification 
In eukaryotic cells, DNA is packaged into chromatin, organised by both histone and 
non-histone proteins (Vaquero, Loyola et al. 2003, Lee and Workman 2007). The 
individual unit of chromatin, the nucleosome (Figure 1.9.) can have covalent post-
translational modifications either at the canonical protein or at the amino terminal, 
which can modify the accessibility of the underlying DNA (Lee and Workman 2007). 
Examples of such modifications include acetylation, methylation, phosphorylation, 
sumoylation and ubiquitination (Szyf 2009). Combinations of different modifications 
on the histone proteins constitute the ‘histone code’ that can be recognised by non-
histone protein, which form complexes that are necessary for the regulation of gene 
transcription. Histone modifications act in diverse biological processes such as gene 
expression, DNA repair, chromosome condensation, differentiation and disease 







Figure 1.9. The nucleosome.  
A graphic view of the histone octamer, with the histone tails showing the possible 
acetylation sites (yellow circles) and methylation sites (blue circles) when this 
occurs on the same residue (Minucci and Pelicci 2006).147 base pairs of DNA 
wrapped 1.6 times around an octamer of core histone proteins, called H2A, H2B, 
H3 and H4. H1 histone allied with the linker DNA is located between the 
nucleosomes. 
The histone code determines the nucleosome proximity with corresponding 
chromosomes packaged into either euchromatin or heterochromatin. Basically, 
euchromatin refers to DNA which is relaxed and transcriptionally active, where most 
genes reside, while heterochromatin refers to condensed DNA with repressed gene 
expression. Euchromatin structure is highly acetylated and is characterised by the 
presence of transcription complexes associated with histone acetyltransferases 
(HATs) on the gene promoters (Quivy, Calomme et al. 2004). Heterochromatin is 
poorly acetylated and contains histone deacetylases (HDACs) potentially associated 
with DNA methyltransferases (DNMTs) (Quivy, Calomme et al. 2004). It is generally 
accepted that histone acetylation, typically on lysine residues is generally associated 
with gene activation (Zhang, Wen et al. 2012). In contrast, methylation of lysine or 
arginine residues either induce an active or a silent state of gene expression, 
depending on the residues methylated, and whether other nearby modifications such 
as acetylation exist (Strahl and Allis 2000, Zhang, Wen et al. 2012). Several authors 
have suggested histone modification precedes DNA methylation, for example histone 
modification in the short term silences the genes while DNA methylation is 




1.3.2 Histone deacetylases 
There are eighteen mammalian histone deacetylase (HDAC) enzymes that can be 
subdivided into classes I-IV, according to their homology with yeast orthologues 
(Witt, Deubzer et al. 2009). The ‘classical’ HDACs, Class I, II and IV, are recognised 
as being anti-cancer drug targets. Class III HDACs are also called 'sirtuins'. The two 
different groups, classical and sirtuins have different catalytic mechanisms. Classical 
family members are Zn
2+
 dependent enzymes that can be inhibited by chelating 
enzymes, such as hydroxamic acid. The sirtuins domain requires NAD+ as an 
essential cofactor. 
 
Figure 1.10. The histone deacetylase enzymes.  
Data from (Minucci and Pelicci 2006).  
1.3.3 Histone deacetylase inhibitors and cancer 
Classical HDACs are cancer drug targets as family members are aberrantly expressed 
in several tumors. In gastric cancer, HDAC1, HDAC2, HDAC3 can be aberrantly 
expressed compared with normal tissue (Witt, Deubzer et al. 2009). An imbalance in 
HDAC regulation affects normal global transcription profiles. Aberrant HDAC 
expression is associated with poor differentiation, enhanced proliferation, invasion 
and poor prognosis in advanced disease. Class I HDACs are the main anticancer drug 
targets as disruption in mice and siRNA-mediated knockdown in cultured cancer cells 
revealed strong anti-proliferative effects. However, class II HDACs are also 
promising targets as they regulate differentiation, proliferation, stress response, 
migration and angiogenesis. A histone deacetylase inhibitor (HDACi) that targets 




undergo multiple hits on key cellular functions simultaneously. Two HDAC 
inhibitors, vorinostat (suberoylanilide hydroxamic acid, SAHA, Merck & Co., Inc), 
and depsipeptide (Romidepsin, FK-228, Gloucester Pharmaceutical Inc.) have been 
approved by the FDA for treatment of hematologic malignancies, including cutaneous 
T- cell lymphoma. 
Historically, HDACs most significant target were considered the histones (Gregoretti, 
Lee et al. 2004). Now, based on phylogenetic studies, the primary substrates of 
HDAC enzymes are considered to be non-histone proteins (Gregoretti, Lee et al. 
2004). Over 50 non-histone proteins have been identified to be HDAC substrates 
including transcription factors, heat shock proteins and shuttle proteins which induce 
cell growth arrest, differentiation or apoptosis in vitro and in vivo (Minucci and 
Pelicci 2006, Kim and Bae 2011) (Figure 1.11.).  
 
Figure 1.11. The functioning acetylome.  
A representational list of biological processes that are regulated by acetylation is 
shown. (Minucci and Pelicci 2006). 
HDAC inhibitors (HDACi) can be either synthetic or natural products and can be 









aliphatic acid, and benzamides (Dokmanovic, Clarke et al. 2007). They are 
structurally different but share the capacity to enhance differentiation, induce 
apoptosis, inhibit cancer cell growth, and reverse oncogene-transformed cell 
morphology. The sensitivity of tumor cells and relative resistance of normal cells to 
HDAC inhibition reflect the multiple defects of cancer cells compared to normal cells. 
The inability of tumor cells to compensate for the inhibition of one or more pro-
survival factors or activation of a pro-death pathway shows its vulnerabilities. For 
example, at lower concentrations of a HDACi, vorinostat, normal cells are unaffected 
while tumor cells undergo cell growth arrest and death; and at higher concentration 
both cells are affected by toxicity (Marks and Breslow 2007). 
Surprisingly, despite the ubiquitous distribution of HDACs in chromatin, HDACi 
selectively altered a varying proportion of expressed genes (2-22%) in transformed 
cells, and cell lines of diverse origins with a similar number of genes down-regulated 
as they were up-regulated (Peart, Smyth et al. 2005, Dokmanovic, Clarke et al. 2007, 
Halsall, Gupta et al. 2012). Genes are often sheltered from hyperacetylation induced 
by HDAC inhibitors (Halsall, Gupta et al. 2012). It is important to bear in mind that 
HDAC inhibitors are not acetylating the histones; rather they are allowing histone 
acetyltransferase to do so by inhibiting the opposing deacetylation reaction. HDACi 
studies have had the most reported success in haematological disorders. To have an 
effect the HDACi do not have to alter a significant number of genes. Interestingly, 
HDAC inhibitors such as valproic acid, trichostatin A and suberoylanilide 
hydroxamic acid do not act on the same gene populations within the same cell lines 
despite inducing histone acetylation to the same degree (Halsall, Gupta et al. 2012). 
Unsurprisingly, acetylation of a large number of proteins occurs in response to HDAC 
inhibitors, including essential transcription factors and metabolic enzymes not just 
global histone hyperacetylation contribute to HDACi activity.  
1.3.4 DNA methylation 
DNA methylation is a covalent addition of a methyl group to the 5-position of the 
cytosine ring within the context of the CpG dinucleotide (Bird 1992). Until recently, 
most studies focused on DNA methylation associated with gene promoter sequences. 




example, hyper-methylation in promoter regions leads to gene repression of tumor 
suppressor genes, such as with CDH1 promoter hypermethylation that has been 
associated with tumorigenesis in HDGC. CpG islands are identified as regions of 
DNA 500-2000 bp long, G+C content equal to or >55% and observed CpG frequency 
of 0.65. Often (60 -70% of genes) these sequences overlap the promoter regions of 
human genes that perhaps influences gene regulation. Protection from methylation 
occurs in CpG islands of normal cells by mechanisms which remain unclear. DNA 
methylation is prevalent throughout the genome including gene bodies, endogenous 
repeats and transposable elements. Methylation in repeat regions such as centromeres 
is important for chromosomal stability and is also likely to suppress the expression of 
transposable elements and may also have a role in genomic stability (Jones 2012).  
DNA methylation mechanisms for establishing, maintaining and removing methyl 
groups are catalysed by DNA methyltransferases. De novo DNA methyltransferase 
enzymes DNMT3A and DNMT3B are essential for establishing DNA methylation 
patterns in early development (Chen and Li 2004). Maintaining an established pattern 
of DNA methylation requires DNMT1 but also DNMT3A and DNMT3B (Jones and 
Liang 2009) (Figure 1.12). As previously suggested methyltransferases ability to 
methylate nucleosomal DNA can be hampered by other modifications to the histones, 
and instead serves as the long-term ‘lock’ to reinforce a previously short-term 
silenced state. So, methylation adds stability to an epigenetic state. Overexpression of 
DNMT1, 3A and 3B, have been reported in various solid tumors, including lung, 





Figure 1.12. Proposed model for the maintenance of DNA methylation 
patterns.  
(a) The DNA methyltransferase 3-A, B enzymes (represented by DNMT3) remain 
bound to chromatin in somatic cells that contain methylated CpG sites. (b) During 
DNA replications, the bulk of methylation maintenance is performed by DNMT1. 
(c) After DNA replication, DNMT3 complete the methylation process and correct 
errors that remain by the DNMT1 enzyme. (Jones and Liang 2009). 
1.3.5 DNA methylation and cancer 
Global DNA methylation levels are often decreased in malignant cells. At the same 
time, hypermethylation is often present in specific regions of the cancer cell genome 
(Oki, Aoki et al. 2007). Two small molecule inhibitors of DNA methyltransferases are 
FDA approved as anticancer agents; Vidaza (5-azacytidine, Boulder, Co, USA) for 
chemotherapy against myelodysplastic syndrome (MDS), Dacogen (5-aza-2’-
deoxycytidine, decitabine, or DAC, Bloomington, MN, USA) to treat MDS patients 
(Ghoshal and Bai 2007). There is renewed interest in these drugs after clinical trials 
have shown both to have therapeutic potential against MDS, acute myeloid 




1.3.6 Epigenetics and chemoprevention 
Epigenetic therapy as a chemopreventive approach is a relatively new medical 
science. Cancer chemoprevention means the use of a chemical compound to prevent, 
inhibit, or reverse carcinogenesis (Kelloff, Hawk et al. 1996). The primary distinction 
between chemoprevention and cancer therapy is that chemoprevention is applied 
before invasive disease develops. Chemopreventive treatment is intended to be long 
term, conceivably up to a lifetime in high-risk subjects. Consequently, very low 
toxicity agents are a requirement. Kelloff et al., in collaboration with the FDA, 
identified “three critical components to the successful development of 
chemopreventive drugs: well-characterised agents with the potential for inhibiting the 
target cancer; biomarkers correlating with cancer incidence for measuring 
chemopreventive effect; and suitable cohorts for clinical efficacy studies” (Kelloff, 
Hawk et al. 1996). 
1.4 Valproic acid 
Valproic acid (VPA), derived from valeric acid (naturally produced by valerian, 
Valeriana officinalis), was first synthesised in 1882 (Burton 1882). The anti-epileptic 
potential of VPA was discovered in 1963 and in the last 35 years has been commonly 
used as an anticonvulsant drug in epileptics and a mood stabilising drug in bipolar 
disorder (Jones 2009). VPA is less commonly used to treat major depression and 
migraine headaches.  
Although VPA is a small branched fatty acid, its chemical properties allow easy 
delivery to the organism and cells. VPA is slightly soluble in water, highly soluble in 
organic solvents and is stable at room temperature in both (Duenas-Gonzalez, 
Candelaria et al. 2008). VPA can be delivered to organisms in the form of water 
soluble sodium or magnesium salts (Duenas-Gonzalez, Candelaria et al. 2008). 
Interestingly, these two preparations are bioequivalent; magnesium valproate appears 
to be a drug without bioavailability problems and with reduced inter-subject 
variability compared to that of sodium valproate (Balbi, Sottofattori et al. 1991). For 
therapeutic drug monitoring unbound (to albumin plasma proteins) VPA levels should 
be measured not total VPA levels, which varies 6.4-10.7% between adults (Bauer, 








for VPA unbound of 6-22 μg/mL (0.3-1.1 mM) and the equivalent VPA total is 50-
125 μg/mL (Bentley 2013). The toxic level for VPA unbound is greater than 50 
μg/mL, as plasma albumin becomes saturated (Bentley 2013). Common reported 
adverse effects from VPA include transient gastrointestinal symptoms such as 
anorexia, nausea and vomiting in about 16% of the patients (Löscher 1999). 
Uncommon VPA side-effects are neurotoxicity (such as sedation, ataxia, and tremor) 
and hair loss (Löscher 1999). The liver is the main metaboliser of VPA and in severe 
cases renal failure can occur (Faught 2001). Unfortunately VPA is teratogenic, and 
cannot be taken by pregnant women without risk of birth defects such as neural tube 
closure defects and, very rarely, liver failure (DiLiberti, Farndon et al. 1984). 
VPA has recently been shown to be a HDACi (Göttlicher 2004, Sharma, Symanowski 
et al. 2008). It is part of the aliphatic acids classification and is a relatively weak 
inhibitor of the HDACs, with activity at millimolar concentrations (Göttlicher, 
Minucci et al. 2001, Phiel, Zhang et al. 2001, Gurvich, Tsygankova et al. 2004, 
Marchion, Bicaku et al. 2005). VPA acts via inhibition of multiple HDACs, which 
differ between cell types with unequal inhibition of HDAC isoforms (Göttlicher, 
Minucci et al. 2001). Class II HDACs are less susceptible to inhibition by VPA than 
class I enzymes (Göttlicher, Minucci et al. 2001). Class II, HDAC10 and sometimes 
HDAC6 are only weakly inhibited (Gurvich, Tsygankova et al. 2004). HDAC 
inhibition of classes I and II have an IC50 range of 0.4 to 2.8 mM with VPA treatment 
(Göttlicher, Minucci et al. 2001, Phiel, Zhang et al. 2001, Gurvich, Tsygankova et al. 
2004, Marchion, Bicaku et al. 2005). VPA induces hyperacetylation of core histones 
H3 and H4 in intact cells at 0.25 mM VPA as early as 1 hour after exposure 
(Göttlicher, Minucci et al. 2001, Marchion, Bicaku et al. 2005). After VPA exposure 
chromatin decondensation may occur earlier than the expected 48 hour time frame 
(Marchion, Bicaku et al. 2005). This allows transcription of previously inaccessible 
genes. 
1.4.1 Valproic acid and cancer 
The anticancer properties of VPA are unspecific as dysregulation of the methylation 
and deacetylation machinery are common hallmarks of neoplasia (Takai, Desmond et 




mechanisms include targeting chromatin via HDACs and DNMTs and also by 
transcription factors. The antitumor effects of VPA have been proven in a variety of 
in vitro and in vivo systems, and there are encouraging results in early clinical trials of 
VPA either alone or in combination with demethylating and/or cytotoxic agents. 
Anticancer activity varies by cell type and experimental systems which include; anti-
inflammatory, differentiation, apoptosis, growth arrest, inhibition of metastasis, anti-
angiogenesis, chemosensitisation, radiosensitisation and facilitation of immune 
response (Göttlicher, Minucci et al. 2001, Blaheta and Cinatl 2002, Duenas-Gonzalez, 
Candelaria et al. 2008, Zhang, Zhang et al. 2008).  
Preclinical studies of VPA in solid tumor models in a variety of in vitro and in vivo 
systems have shown potent antitumor effects in bladder, breast, carcinoid, cervix, 
colon, EBV-related tumors, endometrial, fibrosarcoma, glioma, hepatoma, melanoma, 
medulloblastoma, ovarian, prostate, thyroid, neuroblastoma, neuroectodermal, 
neratocarcinoma and thoracic tumors (Duenas-Gonzalez, Candelaria et al. 2008). In 
combination with demethylating and/or cytotoxic agents, VPA has reached phase I 
and II clinical trials in solid tumors, breast cancer, cervical cancer, neural tumors and 
brain metastases, non-small lung cancer, melanoma, ovarian cancer, prostate cancer 
and thyroid cancer (Duenas-Gonzalez, Candelaria et al. 2008). 
The only phase III clinical trial to date was completed in solid tumors of cervical 
cancer patients with VPA administrated in combination with a DNA demethylase 
(hydralazine) (Coronel, Cetina et al. 2011). VPA treatment leads to a significant up-
regulation of genes belonging to multiple pathways including; oxidative 
phosphorylation, MAPK signalling, ERK, focal adhesion, cell cycle, apoptosis, PI3K, 
Wnt signalling, calcium signalling, TGF-β signalling, NOTCH1, Wnt/β-catenin, 
among others (Duenas-Gonzalez, Candelaria et al. 2008, Gerstner, Bell et al. 2008). 
Pathways implicated in stem cell biology could be a useful chemoprevention 
approach in inhibiting HDGC SRCC initiation and progression. For example; 
NOTCH regulation to determine cell fate and regulate pattern formation, along with 
TGF-β signalling that regulates cell polarity and tight junction formation and 
influences other EMT regulators are promising candidates. Also, focal adhesion 
kinase molecules regulate EMT which consequently may help prevent/delay the 




VPA has induced DNA de-methylation of TSGs (THBS1 and RASSF1a) at gene 
promoters and reduced overall methylation levels in neuroblastoma (Gu, Tian et al. 
2012). VPA can cause de-methylation independent of DNMT (active de-methylation), 
however it can also reduce DNMTs catalysis (passive de-methylation) (Gravina, 
Biordi et al. 2009, Lin, Lin et al. 2010, Liu, Zhou et al. 2012). Individual methylation 
of TSGs can increase cancer susceptibility therefore reducing DNA methylation could 
prevent cancer progression. Conversely, reducing global methylation levels are often 
associated in malignant cells. The benefit of VPA treatment is that its effect on 
normal cells is documented as minimal, whereas, tumor cells are vulnerable to VPA 
and this leads to growth inhibition or death of tumor cells. 
VPA can lead to re-expression of CDH1 in some (including endometrial, lung, and 
pancreatic) cancer cell lines; however, there no known data on gastric and breast cells 
(Kakihana, Ohira et al. 2009, von Burstin, Eser et al. 2009, Zhang, Wang et al. 2011, 
Yi, Li et al. 2012). Furthermore, de-methylation may or may not occur at the CDH1 
promoter after VPA treatment; however this may not be necessary for CDH1 re-
expression. For example, in an endometrial cell study with VPA, increased CDH1 
mRNA levels after 24 hours and no demethylation of the CDH1 promoter region in 
vitro and in vivo (nude mice) occurred (Yi, Li et al. 2012).  
Although VPA has not yet been shown to actively de-methylate the CDH1 promoter 
region resulting in re-expression of CDH1, VPA has the potential to induce 
demethylation (Detich, Bovenzi et al. 2003, Gu, Tian et al. 2012). HDGC is indolent 
at the T1a SRCC stage and at this stage a de-methylating agent could target the 
second allele of CDH1 that is commonly methylated here. VPA has been shown to 
actively de-methylate genes in other studies. This mechanism could be pivotal in 
eHDGC, however an increase in CDH1 expression could be sufficient to prevent or 
delay malignant progression.  
Clinically, VPA has several advantages as a chemopreventive drug including; low 
toxicity, high oral bioavailability and a long half-life (9-16 hours) (Chateauvieux, 
Morceau et al. 2010). VPA is the only epigenetic drug with long term safety data 
(Guilford, P., personal communication). Maintaining an optimal effective range of 
>0.5 mM in mice has been shown to be not a determining factor in VPA treatment 




(Göttlicher, Minucci et al. 2001). It has been disputed that VPA would be a good 
chemopreventive drug as in the general population it does not cause a significant 
change in cancer incidence (Hallas, Friis et al. 2009). However, HDGC families who 
are predisposed to gastric cancer and breast cancer at a high penetrance have a higher 
benefit as their pre-disposition to lowered gene expression induced by the second 
CDH1 hit has the potential to be prevented or delayed by VPA treatment. 
1.5 Decitabine and demethylation 
Decitabine (DAC) also known as 5-aza-2'-deoxycytidine, was first synthesised in 
1964 (Pliml and Sorm 1964). It is an analog of the natural nucleoside 2’deoxycytidine 
in which the carbon at the 5-position of the cytosine is replaced by nitrogen. The 
potential ant leukemic activity of DAC was reported in 1968 (Sorm and Veselý 1968), 
but was not FDA approved for the treatment of myelodysplastic syndrome until 2006, 
perhaps due to the lack of understanding of the importance of epigenetic changes in 
malignancy during early years of development. Common adverse reactions from DAC 
use include neutropenia, thrombocytopenia and anaemia, with less common side 
effects including fatigue, pyrexia, nausea, diarrhoea and hyperglycaemia.  
DAC is believed to work as a passive demethylase at low concentrations. Following 
phosphorylation, decitabine is integrated into DNA instead of cytosine during the S-
phase of cell division and covalently binds to the DNMTs, inhibiting their catalytic 
activity (Oki, Aoki et al. 2007). This leads to DNMT degradation without cell cycle 
arrest. DNA replication in the absence of DNMTs leads to both gene specific and 
global hypomethylation. At high concentrations, once phosphorylated and 
incorporated into DNA, DAC can inhibit DNA synthesis and induce cell cycle arrest 
(Oki, Aoki et al. 2007). 
1.5.1 Decitabine and cancer 
DAC treatment for common cancers had mostly been abandoned as the high 
concentrations tested resulted in excessive toxicity. Renewed interest in DAC has 
occurred due to recent evidence of low doses of DAC re-activating genes that halt 
cancer growth without causing immediate cell necrosis or DNA damage (Juergens, 




higher hypomethylation at lower concentrations than at high concentrations (Oki, 
Aoki et al. 2007). In a phase I/II clinical trial for advanced lung cancer using a low-
dose DAC regime (~3 μM) durable responses were observed in a subset of patients 
who had previously failed multiple chemotherapy regimens (Juergens, Wrangle et al. 
2011). DAC was suggested to have the ability to reset abnormal epigenetic status in 
treated cells. Also, drug treatment sustained gene expression which was maintained 
for significant periods of time after withdrawal. DAC appears to target self-renewing 
and/or tumorigenic cell sub-populations in both cell lines and primary samples of 
leukaemia and breast cancers (Tsai, Li et al. 2012). DAC depleted DNMT1, DNMT3a 
and DNMT3b in breast and leukaemia cells for time periods after transient exposure 
ranging from 72 hours to 25 days (Tsai, Li et al. 2012).  
DAC can modulate E-cadherin re-expression through demethylation of the promoter 
region both in vitro and in vivo (oesophageal and endometrial cancer), however this 
has not yet been observed in breast or gastric cancers (Ling, Li et al. 2011, Yi, Li et 
al. 2012). DAC and VPA in combination exhibited the greatest suppression of tumor 
growth in mice (Yi, Li et al. 2012). However, VPA had superior efficacy on CDH1 
expression compared with DAC, suggesting that histone acetylation dictated the 
regulation of their target gene more potently than DNA methylation. DAC and VPA 
alone can effect E-cadherin gene expression differently i.e. E-cadherin up-regulation 
after treatment with VPA occurred in pancreatic cells; however, DAC treatment had 
no effect (von Burstin, Eser et al. 2009).  
Reactivation of E-cadherin expression can occur without apparent alteration of 
histone modifications or CpG methylation (Tachibana, Takeda et al. 2004). Similar to 
VPA, other factors, such as transcription accessibility due to lack of repressors at 
alternative transcription sites, may affect gene transcription. 
1.6 Epithelial mesenchymal transition 
Transcriptional downregulation of E-cadherin by promoter methylation, but not 
mutational inactivation, is part of a programme resulting in the epithelial-
mesenchymal transition (EMT) (Lombaerts, Van Wezel et al. 2006). EMT is utilised 
in embryogenesis, fibrosis and tumor progression. In HDGC, the EMT is thought to 




cadherin loss is a hallmark of the EMT, E-cadherin inactivation by itself is not enough 
for EMT induction (Chen, Beetham et al. 2014).  
Conversion of epithelial cells to mesenchymal cells causes profound phenotypic 
changes such as loss of cell-cell adhesion, the loss of cell polarity and the acquisition 
of migratory and invasive properties that cause drug resistance (Thiery, Acloque et al. 
2009, von Burstin, Eser et al. 2009, Singh and Settleman 2010). Factors affecting 
EMT and corresponding markers are described in Figure 1.13. It is hypothesised that 
VPA could reverse or inhibit the EMT, via re-expression of CDH1 or through 
regulation of signalling pathways such as TGF-β, focal adhesion kinase signalling or 






Figure 1.13. The cycle of epithelial-cell plasticity. 





1.7 Thesis overview 
The first part of this research described whether the HDAC inhibitor, VPA can re-
express CDH1 in gastric/breast cell lines in the presence and absence of DAC (de-
methylating agent). CDH1 expression was measured by RT-qPCR and E-cadherin 
expression confirmed by western blot. 
The second part of this thesis identified the effects of VPA on gene expression 
globally in a non-tumorigenic “normal” MCF10a breast cell line using RNA 
sequencing (RNA-Seq). The data were also used to search for epigenetic markers that 
indicated response to this drug. Finally, VPA epigenetic markers identified were 
tested in clinical samples. 
Part three examined the effects of VPA on methylation levels in the MCF10a cell line 
using a 450K Illumina methyl array to confirm whether changes in methylation of 
CpG sites are associated with critical gene expression changes after VPA exposure. In 
addition the overall effect of VPA on the methylome was examined. 
Part four analysed a small, local clinical study investigating gene expression change 
in patients receiving VPA. The study consisted of 15 patients being treated for 
migraine or epilepsy with VPA for the first time. CDH1 expression was measured 
before and after VPA treatment by examining blood and buccal samples.  
The overall goal of these experiments was to obtain data to support the use of 





Chapter 2: Materials and methods 
2.1 Materials 
2.1.1 Reagents 
Reagents used in this study were of analytical grade and obtained from the suppliers 
stated in the text. Frequently used reagents and suppliers not stated in the text are 
listed below: 
BDH Limited, England: Ammonium Persulfate (APS), Sodium Dodecyl Sulfate 
(SDS). 
Bio-Rad, USA: Acrylamide/ Bis-acrylamide (30%/0.8% w/v) solution. 
GE Healthcare USA, USA: ECLplus reagents. 
Invitrogen, USA: Dulbecco’s modified Eagle’s medium and F12 medium (DMEM-
F12) (# 30-2004), Fetal Bovine Serum (FBS), GC Rich 5x, Horse Serum (#16050-
122), Novex Sharp pre-stained Protein Standards, Penicillin/Streptomycin (100x 
solution) ( #15070-063), RNaseOUT, ROX reference dye, RPMI- 1640 (# 30-2001), 
Superscript III, TrypLE express (#12604-0130),  Ultra-pure distilled water (#10977-
015). 
Lab prepared Stocks: MgSO4 50 mM, Phosphate buffered saline (PBS) tween-20, 
Phosphate Buffered Saline (PBS), protein loading buffer, Lab control RNA, 1.5 M 
Tris-HCl pH 8.8, 0.5 M Tris-HCl pH 6.8.  
Pams, NZ: Low fat milk powder. 
Promega, USA: Passive Lysis buffer. 
Roche, USA: DNA polymerase dNTPack 10 mM, DTT 0.1 M, FastStart Taq, PCR 
buffer 10X. 
Santa Cruz, USA: α-actin (A2066 and A5060) antibodies, E-cadherin rabbit 
polyclonal antibody (H108), β-Actin rabbit polyclonal antibody (N-21), HRP goat α-




Sarstedt, NZ: 96-well plate BCA assay. 
Scharlau, Spain: Bromophenol blue, Tetramethylethylenediamine (TEMED).  
Sigma-Aldrich Chemical Company, USA: Cholera Toxin, Dimethyl Sulfoxide 
(DMSO), Hydrocortisone, MERCK: 2-Mercaptoethanol, 0.5% trypsin 0.2% EDTA 
(59418C), Trypan blue (0.4%), Tween20 (polyoxyethylenesorbitan monolaurate).  
Takara Bio, Europe: Primescript QT reagent. 
Thermo Fisher-Scientific, NZ and Australia: Pierce BCA Protein assay Kit (# 23227). 
Zymo Research, USA: Quick-RNA miniprep kit (R1055), RNA Clean and 
Concentrator (R1017 and R1018), EZ DNA methylation kit (D5002), Quick gDNA 
miniprep (D3025), whole-blood RNA miniprep (R1021). 
ZyGem, NZ: RNA-Gem tissue (#RTI0200). 
Primers 
The sequences of primers used in this study are outlined in Table 2.1. These include 
primers used in quantitative PCR (qPCR). 




















































































2.1.2 Equipment  
Agilent Technologies, Inc, USA: RNA 6000 Pico kit, RNA 6000 Nano kit, 2100 
bioanalyzer.  
Applied Biosystems, USA: HT7900 Real-time PCR system, HT7000 Real-time PCR 
system, 96 well optical plates and 384 well optical plates. 
Axygen, USA: 600 µL microtubes, 1.5 mL microtubes, Falcon Pipetteboy. 
BD Bioscience, USA: Falcon Strippettes, Falcon Cell Scrapers, 25 mL Falcon Cell 
Culture Flasks, Falcon 6 well plates, 15 mL and 50 mL Falcon tubes. 
Binder, Germany: Cell incubator.   
Biolab Scientific, NZ and Australia: Esco Glass Cover Slips. 
Bio Rad, USA: Automated TC10 cell counter, c1000 thermal cycler, CFX connect 
Real-time system 96-well, digital dry-block heater, Mini-Protean II system, Mini-
TransBlot system, Immuno-Blot PVDF membrane, Thick Criterion Sheet. 
Corbett Life Sciences, Australia: CAS1200 Robot. 
EMAIL, Australia: Tissue Culture Class II hood. 
Eppendorf, Germany: Themomixer comfort heat block. Centrifuge 5415R. 
Grenier Bio-one, Germany: Flat bottom Opaque walled 96 well plates, 75ml Cellstar 
Flasks, cryovials.  
International equipment company (IEC), USA: Centra 3C centrifuge, 4X centrifuge. 
Invitrogen, USA: 0.5 mL optical-grade real-time PCR tubes, Life Technologies Qubit 
2.0 fluorometer. 
Millipore, USA: Milli-Q Ultrapure Water Purification System. 
Olympus, New Zealand: DP12 microscope, CK2 microscope. 
Semco, New Zealand: Temperature controlled water bath. 
Sigma-Aldrich, USA: 1-200 µL gel loading tip round. 




Thermo Fisher-Scientific, NZ and Australia: Fuji ECL imaging system LAS3000, 
Multiskan Go, IKA Vibrax VXR shaker. 
2.1.3 Software 
Applied Biosystems, USA: Real-Time PCR System Sequence Detection Software 
(SDS) 1.4.  
BioRad, USA: CFX manager software version 2.1 amplification Real-time PCR, 
Quantity1 densitometry software. 
Edge R., differential expression analysis of RNA sequencing data (Robinson, 
McCarthy et al. 2010). 
Gather, gene ontology profiling  (Chang and Nevins 2006). 
Limma, RNA sequencing data analysis (Smyth 2005). 
SeqMonk Mapped Sequence Data Analyser. Version 0.21.0. (C. at) Simon Andrews, 
Babraham Bioinformatics, 2007-2011 
(http://www.bioinformatics.bbsrc.ac.uk/projects/seqmonk). 
Thermo Fisher-Scientific, NZ and Australia: SkanIt Software 2.5.1 for Multiskan FC. 
R, Version 2.14.2. Software environment for computational statistics and graphics. 
Packages used include: 
 Limma, (Smyth 2005). RNA sequencing (RNA Seq) data analysis 
 EdgeR, (Robinson, McCarthy et al. 2010). Differential expression analysis of 
RNA seq. 
2.1.4 Cell line models 
AGS, NCI-H460, and MCF10a cell lines were obtained from the American Type 





 ATCC Number  Source  Growth and Morphology  Doubling time 
 CRL-1739 
 Gastric adenocarcinoma 
(AGS)   Adherent/Epithelial  20 hours 
 HTB-177 
 Large cell lung carcinoma 
(NCI-H460)  Adherent/Epithelial  23 hours 
 CRL-10317 
 Mammary gland; breast 
(MCF10a)  Adherent/Epithelial  20 hours 
 CLLS1042 
 Mammary gland; breast 
(MCF10a CDH1-/-)  Adherent/Epithelial  48 hours 
Table 2.2. Cell lines used in this study 
2.2 Methods 
2.2.1 Cell recovery 
Stocks of cells were regularly recovered from liquid nitrogen. Cell vials were 
immediately fast thawed in a 37ºC water bath. Thawed cells were transferred to a 15 
mL conical centrifuge tube containing 9 mL of prewarmed media. This was then 
centrifuged for 5 min at 800 rpm to remove traces of DMSO. Media was aspirated and 
appropriate media (Table 2.3) was added and transferred to a T25 flask to enable 
growth. After 24 hours of incubation, media would be replaced to ensure residual 






Table 2.3. Individual cell lines media conditions for growth and storage in 
liquid nitrogen.  
A. These additives were made up according to methods provided in Appendix A. 
2.2.2 Cell culture maintenance 
Cells were maintained in their ATCC recommended media (Table 2.3). All cell 
culture manipulations were carried out in a class II hood using aseptic techniques. 
Cells were incubated at 37ºC in 5% CO2 humidified controlled environment for 
predictable growth.   
Cells were regularly passaged at subcultivation ratios and densities recommended by 
their ATCC depositors (Table 2.4). Cells were trypsinised in log phase when the cells 
were in a stable growth stage. Before passaging cells, all liquids were pre-warmed to 
37ºC in a water bath to prevent shock to the cell
Component Volume Component Volume
DMEM F12 (Catalog 
No. 30-2004) 500 mL
AGS Complete 

















(Invitrogen #16050-122 25 mL (5% final) DMSO 0.5 mL
Acrapid Penfil Neutral 
InsulinΑ (Novo Nordisk 
Pharmaceutical Ltd) 1.4 mL (10 µ/mL final)
Penicillin/Streptomycin
5.0 mL (100 µg/mL 
final)
HydrocortisoneΑ
250 µL (0.5 µl/mM 
final)
EGFΑ 100 µL (20 ng/mL final)
Cholera ToxinΑ 50 µL (1 ng/mL final
10% FBS 50 mL (10% final)
Cell line







0.5 mLHorse Serum 
(Invitrogen 
#16050-122)






Table 2.4. Cell line maintenance conditions and seeding conditions 
 
 
Seeding 24 hour 
experiment
Seeding 96 hour 
experiment





1:3 to 1:8/ 2 per 
week
1:3 to 1:8/ 2 per 
week
1:3 to1:4/ 2 to 3 
days
1:3 to1:4/ 2 to 3 
days
3 x 104 3.9 x 103
MCF10a CDH1-/- 20 1.5 x 105 4.5 x 105 N/A 3 x 105 5 x 104 N/A
MCF10a 20 1.0 x 105 3.0 x 105 3.0 x 103 2 x 105
N/A
NCI-H460 5 1.0 x 105 3.0 x 105 N/A 2 x 105 3 x 104 N/A
Seeding 96 hour maintenance Seeding 48 hour experiment





Growth media was aspirated using a sterile Pasteur pipette. Cells were then washed 
with phosphate buffered saline (PBS) which was then aspirated and discarded. After 
the addition of excess (i.e. 2 mL for T75) 0.05% trypsin solution, cells were incubated 
at 37ºC until cells detached from the plate or flask (Table 2.4). Once detached, the 
cells were re-suspended in 10 mL of growth medium containing serum. These were 
gently pipetted up and down to separate cell clumps and transferred to a 15 mL falcon 
tube to be centrifuged at 800 rpm for 5 min. The cell pellet was re-suspended in 5 mL 
growth media and then counted (refer to section 2.2.3) before re-plating at the 
appropriate subcultivation densities for T25 or T75 flasks or dishes as described 
(Table 2.4). 
2.2.3 Cell counting 
Cells were counted by two methods, manually and by an automated cell counter (Bio 
Rad, USA). Firstly, pelleted cells were resuspended in 5 mL of media. A 50 µL 
aliquot was mixed with Trypan blue at a 1:1 ratio. Trypan blue selectively stains dead 
cells due to cell wall permeability. A live viable cell will exclude the negatively 
charged dye due to the plasma membrane potential. The cell suspension was 
incubated in Trypan blue for 2 min for automatic cell counting and manual counting.  
For manual counting, cells were counted using a haemocytometer under 10X 
objective. To prevent clumping, cell suspension was thoroughly mixed prior to the 
addition to the haemocytometer. If a clump could not be dispersed, it was counted as a 
single cell. Due to Trypan blue staining, both live and dead cells were able to be 
counted, providing not only a cell count but also a cell viability percentage. To 
calculate the total number of cells, mean number of cells were multiplied by 10
4 
in 
order to show cells per mL (Equation 2.1). This number was then doubled to account 
for 1:1 dilution with Trypan blue (Equation 2.1). 
𝑀𝑒𝑎𝑛 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 × 104 = 𝑐𝑒𝑙𝑙𝑠
𝑚𝐿
 ×  𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟  
Equation 2.1. Manual cell counting  
2.2.4 Cryopreservation of Cells 
Stocks of cell lines used in this work were regularly frozen at low passage numbers 




trypsinised (Table 2.4) at log phase (80–90% confluence). After counting, cells were 
centrifuged, the growth media was aspirated and discarded. The cell pellet was 
resuspended in appropriate freezing media to give 1X10
6 
cells/mL (Table 2.3). This 
was then transferred to cryovials in 1 mL aliquots, which were placed in a Nalgene 
freezing container at -80ºC overnight. The isopropanol within the freezing container 
cooled the cells slowly at -1ºC/min to prevent lysing of cell membranes. Cells were 
then placed in the liquid nitrogen for long term storage.  
Cells of low passage number were required to minimise genetic drift in culture and to 
ensure reproducibility, especially for the MCF10a cell line which is classified as non-
malignant. MCF10a were not experimented on after passage 10, whereas NCI-H460 
and AGS cells were not experimented on after passage 20. 
2.2.5 Cell line experiments, treatment design with VPA, DAC and in combination 
All cell lines were induced for E-cadherin expression with trial titrations of valproic 
acid (VPA) alone and in combination with decitabine (DAC). Seeding densities were 
optimised to give 90% cell confluence after the desired time in the desired plate setup. 
This ensured that for the 48, 96 or 120 hours experiments in either the 6-well, 24-well 
and 96-well plates, the drug treatment exposure was in the optimal log phase of cell 
growth and to compensate for the different proliferation rates in each of the cell lines. 
The initial NCI-H460 optimisation experiment allowed for an adherence delay of 4 
hours, however, for all experiments thereafter 24 hours was allowed for adherence to 
ensure cells were in log phase before treatment. Drug treatment began 24 hours post 
seeding. All cells were treated with various drug concentrations and combinations in 
either duplicate or triplicate (dependent on downstream analysis) for 24 hours in 
either 6-well or 24-well plates (Figure 2.1.). Treated cells either had RNA, protein and 
gDNA extracted for downstream analysis by reverse transcription real-time 





Figure 2.1. Experiment design for cell line experiments with downstream 
experiments of RT-qPCR, RNA-Seq, western blot and methyl array analysis. 
MCF10a cells were treated with various drug treatments in triplicate for 72 hours in a 
24-well plate (Figure 2.2). In this experiment a 72 hour treatment followed by a 24 
hour withdrawal was conducted. During the 72 hour drug exposure, drug treatment 
was replaced every 24 hours to maintain optimal working concentration in media and 
similarly the negative control cells growth media was renewed every 24 hours. The 
cells were passaged after the 72 hour drug treatment (as cells could not be maintained 
in log phase for longer); cells were split into two different populations with the first 
population used for RNA extraction and the second seeded in a 96-well plate with 







Three different extraction methods 
were performed depending on the 
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Figure 2.2. Experiment design for MCF10a cell line experiment with 
downstream experiments of RT-qPCR. 
2.2.5.1 Valproic acid 
Valproic acid sodium salt (VPA) was freshly made before use when practicably 
possible, but was also stored at -20ºC at 20 mM in cell specific media as it is water 
soluble for no longer than 2 weeks. Only one freeze thaw was acceptable per aliquot. 
VPA stocks of 20 mM were filter sterilised through a 0.22 µM filter. A serial dilution 
in media was completed to obtain working stock concentration. 
2.2.5.2 Decitabine 
Decitabine (DAC) was used fresh when possible, but was stored at -80ºC at 20 mM in 
cell specific media for no longer than 2 weeks. Only one freeze thaw was acceptable 
per aliquot. A serial dilution was completed to obtain the working stock 
concentration. 
2.2.6 RNA extraction 
RNA was extracted with two methodologies based on either the Quick-RNA miniprep 
kit (Zymo, USA) or RNA-Gem (ZyGEM, NZ) protocols. The Quick-RNA miniprep 
was required with the cells 24 hour post drug treatment in the 6-well or 24-well plate 
as these were analysed by RNA-Seq which required high quality RNA samples which 
were reproducible when examined for gene expression by real-time qPCR. Whereas 
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treatments used RNA-Gem due to the low cell numbers and the higher amount of 
samples required to be processed. This provided a sensitive, low-cost solution for 
gene expression analysis by real-time qPCR that minimised cross contamination and 
protected sample integrity.  
The following RNA extraction method was used for cells post 24 hour drug treatment 
that were either in a 6-well or 24-well plate (Figure 2.1). 
 Media was aspirated and the cells were washed twice in ice-cold PBS and   
600 µL Zymo lysis buffer was added.  
 This was then transferred to a 1.5 mL microfuge tube and RNA extraction was 
performed according to the manufacturer protocol. In brief, this kit involves a 
lysis followed by a column clean up. The following alterations were made to 
the manufacturers’ protocol (Zymo Research, USA):  
 Lysate was centrifuged at 10,000 g for 2 min to bind to the 
column,  
 After RNA prewash buffer column spun at 10,000 g for 2 min,  
 RNA wash buffer column was spun for 2 min,  
 Wash buffer spun for 3 min,  
 35 µL of elution buffer was incubated on the column for 5-10 
min before being centrifuged at 12,000 g for 1 min. 
 Samples were stored at -80ºC for no longer than 6 months.  
The subsequent RNA extraction method was used at two time points following the 72 
hours drug exposure (Figure 2.2). Firstly, directly after the 72 hours drug exposure in 
a 24-well plate and secondly after a 24 hour drug withdrawal in a 96-well plate, 
allowing cell recovery.  
 Harvested cells were washed, trypsinised and then transferred to an 8-well 
strip tube and spun for 5 min at 500 rpm.  
 Media was then aspirated and 6 µL of RNA-Gem (ZyGEM, NZ) master mix 
was added into each well, along with 44 µL of nuclease free water.  
 These were then vortexed and incubated at 75ºC for 10 min in the C1000 
thermal cycler (Bio-Rad).  





RNA clean and concentrate  
Following RNA extraction, RNA was DNase treated before being cleaned and 
concentrated (Appendix B).  
 10 µg of RNA sample was added to each DNase reaction (refer to Appendix 
B) to give an appropriate yield. After the addition of reagents to make up the 
DNase reaction, samples were allowed to stand at room temperature for 15 
min.  
 1 µL of 25 mM EDTA was added to each reaction and then incubated for 10 
min at 65 ºC.  
 The RNA Clean and Concentrate manufacturer’s protocol (Zymo) was 
followed, with the following alterations:  
 Lysate after the first elute was reloaded and re-centrifuged,  
 In the last step RNAse DNase free water was incubated on the 
column at room temperature for 5 min.   
2.2.7 RNA quantification 
The RNA was quantified by two methods, each offering different advantages. 
Spectrophotometer quantification by a Nanodrop (Nanodrop Technologies, USA) was 
used to indicate purity and estimate of RNA concentration. A fluorometer using 
picogreen dye by the Qubit RNA assay (Invitrogen, USA) was used for more accurate 
RNA quantitation. 
The Nanodrop measures nucleic acids spectrophotometrically at 260 nm, to quickly 
inform the user of the concentration of RNA present. It also gives spectrophotometric 
measurements across a range (220-350 nm) allowing an indication of sample 
contaminants. The Nanodrop was cleaned with nuclease free water and calibrated 
with sterile elutent before measurements were made.  
The Qubit can distinguish true RNA from contaminants using a fluorescent 
intercalating dye. RNA was quantified using Quant-iT™ RiboGreen RNA assay kit 
(Invitrogen, USA) along with the Qubit spectrofluorometer. The Qubit RNA assay 
used two standards, prepared alongside the working reagent according to the 
manufacturer’s protocol. A reaction dilution based on Nanodrop indication of 




solution. Samples were read by the Qubit 2.0 Fluorometer, and stock concentrations 
were calculated manually according to the dilutions made.  
2.2.8 Agilent RNA 2100 bioanalyzer 
The RNA quality and quantity was measured by the Agilent 2100 bioanalyzer 
(Agilent Technologies, USA) in conjunction with the RNA 6000 Nano and the RNA 
6000 Pico LabChip kits. RNA samples were diluted to 4.0 ng/µL in deionised water 
and then heated to 95ºC for 5 min before loading 1 µl onto the Agilent RNA 6000 
Pico chip using the chip priming station. Chips were then vortexed for 1 min at 2400 
rpm using the IKA vortex mixer. The chip was then read using the Agilent 2100 
bioanalyzer.  
The Agilent RNA bioanalyzer electrophoretically drives denatured RNA by a voltage 
gradient. The constant mass-to-charge ratio and the presence of a sieving polymer 
matrix caused the molecules to be separated by size. Dye molecules intercalate into 
RNA strands and these complexes are detected by laser-induced fluorescence. Data 
are translated into gel-like images (bands) and electropherograms (peaks) showing 
relative 18s and 28s rRNA bands. The bioanalyzer system provides a reliable score of 
the RNA quality in each sample (Mueller, Lightfoot et al. 2004). This RNA integrity 
number (RIN) is calculated from an algorithm involving the rRNA ratio of 28S and 
18S peaks, and the presence or absence of degradation products. The RIN score is 
largely independent of the amount of RNA used, or the origin of the sample. The 
maximum RIN score is 10 and indicates intact RNA, whereas RIN 3 indicates 
severely degraded RNA. A RIN value higher than 5 is acceptable RNA quality and 
higher than eight is perfect total RNA for downstream analysis (Fleige and Pfaffl 
2006). 
2.2.9 One step reverse transcriptase real-time quantitative PCR 
RNA from the cell line experiments with VPA and DAC treatment exposure of 24 
hours had CDH1 detection alongside β-actin (ACTB) as a reference gene; this allowed 
a multiplex reaction to be performed (Figure 2.1). GAPDH (not shown) was also 
trialled but after examination of cycle threshold (Ct) ref changes under experimental 




software (Pfaffl, Tichopad et al. 2004), it was decided it was more precise to use 
ACTB alone. Expression levels of GAPDH were observed to vary between treated and 
untreated samples. Therefore GAPDH was not used for a reliable reference gene. 
Moreover, ACTB expression was validated in subsequent RNA-Seq data of MCF10a 
treated with 3 mM VPA, showing no change in expression following drug addition. 
More than two reference genes are required for accurate quantification of internal 
transcripts (Vandesompele, De Preter et al. 2002) but only one reference gene was 
used at the time. The transcriptome data had not been performed so no other reliable 
reference genes had been identified that were not affected by VPA treatment. 
Reverse transcription real-time quantitative PCR (RT-qPCR) for CDH1 was 
performed in 384 well optical plates using the ABI PRISM 7900HT instrument 
(Applied Biosystems, Inc., Foster City, CA). Multiplex reactions were performed with 
CDH1 Taqman gene expression assays (Applied Biosystems, Inc., Foster City, CA) 
and ACTB control primers and probe (Integrated DNA technologies, USA). All 
samples were in triplicate. A positive and negative control for each gene was on each 
plate. The positive control was the lab reference RNA (comprising multiple pooled 
cell line RNAs, refer to Appendix C), this was at a concentration of 100 ng, and was 
used at 100, 10, 1, 0.1, 0.01 and 0.001%.  Two negative controls were used; no 
template controls (i.e. reactions containing no RNA) and no reverse transcriptase 
(SuperScript III, Invitrogen, USA). 
Master mix was manually made (Appendix D) and reactions were plated using a 
CAS1200 robot (Corbett Technology). The plates were briefly vortexed and then 
centrifuged at 1000 rpm for 3 min to ensure mixing and to remove air bubbles before 
loading onto the RT-qPCR machine. The instrument settings included an RNA 
denaturation and reverse transcription step at 50ºC for 15 min followed by Taq 
activation at 95ºC for 8 min. Fluorescence emission was measured for 40 cycles 
consisting of a 15 s denaturation step followed by a 60ºC one min primer and probe 
hybridisation and extension. Results were analysed by SDS 1.4 software. 
2.2.10 Two step real time reverse transcriptase quantitative PCR expression 
MCF10a samples were assessed for CDH1 gene expression after a longer VPA 
exposure time of 72 hours, followed by 24 hour withdrawal of VPA and DAC 




RNA. ACTB and GUSB reference were chosen only after the transcriptome data, 
subsequent literature search and conditions were scrutinised after standardised RNA 
input. Moreover, the GUSB reference gene was used in the literature for mammary 
tumors and cell lines for RNA quantification and was unchanged after VPA exposure 
(Drury, Anderson et al. 2009, Kaur, Mao et al. 2012, Cho, Dimri et al. 2013). BAZ2A 
was also trialled but only the two top reference genes were chosen due to limited 
samples. Furthermore, because of the limited samples and amount of target and 
reference genes required, two step qPCR was performed. This allowed the cDNA 
from the reverse transcription to be used across multiple reactions without the need to 
harvest more RNA. 
2.2.10.1 cDNA synthesis 
The reverse transcription (RT) step using the Takara Primescript kit (Takara Bio, 
Europe was conducted to increase the stability of the samples so re-testing was 
possible. All samples were in a total reaction of 30 µL to ensure an efficient reaction. 
Positive controls (lab control RNA, Appendix C) and negative controls (minus sample 
template) were also included. Conditions for the RT were followed as per the 
manufacturer’s guidelines. Resulting cDNA was stored at - 20 ºC for up to 1 month. 
2.2.10.2 Real-Time quantitative PCR 
Real-time quantitative PCR (qPCR) for CDH1 was performed in 384 well optical 
plates using the ABI PRISM 7900HT instrument (Applied Biosystems, Inc., Foster 
City, CA). Singleplex reactions were performed using pre-made CDH1 assay on 
demand (Applied Biosystems, Inc., Foster City, CA), GUSB PrimeTime assay 
(Integrated DNA Technologies, USA) gene expression assays. Furthermore, ACTB 
primers and probes (Integrated DNA Technologies, USA) were separate. All samples 
were in duplicate rather than triplicate due to low template availability. Negative and 
positive controls were run alongside each gene; negative controls were minus sample 
template and minus RT control. Positive control was the lab control RNA (Appendix 
C.), at a RNA concentration of 50 ng, this was used at 100% and then at subsequent 
10, 1, 0.1, 0.01 and 0.001% concentrations. To reduce inhibition from the reagents in 
the RT reaction, RT end-product samples were used at 10% final concentration in the 




Master mix was manually made as detailed in (Appendix E) and reactions plated 
using the CAS1200 robot (Corbett Technology). The plates were vortexed and spun at 
1000 rpm for 3 min to ensure mixing and to remove air bubbles before loading onto 
the qPCR machine.  
The qPCR run included Taq activation at 95ºC for 8 min. This was followed by 40 
cycles consisting of 15 s denaturation step followed by 60ºC for one min to allow 
primer and probe hybridisation and extension. Fluorescence emission was measured 
during the extension stage. Results were analysed using SDS 1.4 software. 
2.2.11 Quantitation of expression 
2.2.11.1 Pfaffl equation  
After RT-qPCR relative expression levels of target sequences were determined by the 
Pfaffl method (Pfaffl 2001) (Equation 2.2). The efficiency (E) was calculated by two 
methods, the standard curve method or LinReg. The LinReg method is a more 
accurate adjustment for inter-well variances than the standard curve method as it 
measures PCR efficiencies sample by sample and was used when gene quantification 
reactions were in singleplex (Vandesompele, De Preter et al. 2002, Ruijter, van der 
Velden et al. 2009). Whereas, the standard curve method was satisfactory and reliable 
when used in multiplex. The control calibrator was untreated samples with the same 
growth conditions as treated cells except with media only. The target was the gene 
being measured and the refs (reference genes) were used to adjust for inter-well 
variances and quality of RNA. Rox reference dye was used as a passive reference to 
detect pipetting inaccuracies and normalise fluorescence fluctuations. 






Equation 2.2. Pfaffl equation. 
From (Pfaffl 2001) 
Quantitative PCR must meet certain criteria to be considered reproducible. These 
standards were: ≤0.5 standard deviation of Cts within sample replicates, Ct values 
between 15 and 35, R
2 
≥0.98. The two methods of efficiency calculation had two 




amplication curve and the standard curve calculated average efficiencies (≥1.90 and 
≤2.10).  
2.2.11.2 Gene expression analysis in vitro  
In the cell line experiments with 24 hour exposure to VPA and DAC combinations, 
average reaction efficiency (E) for each gene was determined by the standard curve 
method (Morrison, Weis et al. 1998) using standard curve lab control RNA (Figure 
2.1). Target CDH1 gene expression was analysed relative to the expression of the 
reference gene ACTB (Leng and Chuang 2006, Drury, Anderson et al. 2009). 
In the MCF10a experiment with 72 hour exposure, followed by 24 hour drug 
withdrawal, individual efficiencies of the reaction for each gene per well was 
determined by LinReg (Figure 2.2). Target CDH1 gene expression levels were 
analysed against the expression of the reference genes ACTB and GUSB.  
2.2.12 RNA sequencing 
New Zealand Genomics Limited (NZGL) carried out the RNA transcriptome 
sequencing of the prepared RNA samples. The library was prepared by NZGL using 
Illumina TruSeq RNA preparation version 2. One lane of the Illumina HiSeq 2000 
was used and the libraries were loaded at a yield of 8 pM. The quality and quantity of 
the cDNA library generated from the RNA sent for RNA sequencing was 
independently verified by NZGL. The libraries for RNA sequencing were pooled and 
prepared using TruSeq
TM 
RNA Sample Preparation v2. The libraries were then 
sequenced using 208 cycles of chemistry and imaging.   
The reproducibility of the RNA-Seq data was evaluated using technical replicates (of 
two identically prepared RNAs) of matched VPA exposed vs. negative control normal 
breast cell lines MCF10a. 
2.2.13 Bioinformatics analysis 
NZGL performed the bioinformatic analysis of the RNA transcriptome results. R 
version 2.12.2 (Team 2005) was used to run Limma for RNA sequencing analysis 
(Smyth 2005). Mapped sequences were annotated using biomaRt using the Ensemble 




were removed, and remaining count data were normalised (Robinson, McCarthy et al. 
2010). Gene counts were normalised using TMM (trimmed mean of M values), and 
lmFit command was used to fit a linear model to the data for each gene. Normalised 
data were converted to log cpm (counts per million reads) prior to analysis using 
voom command in limma. 
Expression profiles in response to VPA were studied by comparing control and VPA-
exposed libraries normalised gene read counts, using edgeR and limma package from 
R-Bioconductor. The EdgeR package was used to detect differentially expressed (DE) 
genes as it has unique abilities to model transcript specific variations even in small 
samples, which essentially prioritises genes or transcripts that have consistent effects 
across replicates.  
Differential expression results for the VPA treated vs. control were written to CSV 
files, viewable in Excel (limma moderated t-statistic produced for the comparison, per 
gene, with false discovery rate (FDR) p-value adjustment applied and log odds). The 
Benjamini & Hochberg (BH) p-value adjusted for FDR control of ≤0.05 and  ≥3 log 
odds was considered significant (Benjamini and Hochberg 1995). 
2.2.14 Protein extraction 
Twenty four hours after drug exposure, proteins were extracted (Figure 2.1). The 6-
well plate was placed on a pre-cooled steel plate maintained on ice in an insulated 
container. Media was aspirated from the wells and the cells washed twice in ice-cold 
PBS. 200 µL of protein passive lysis buffer (Promega 1X) was added. Adherent cells 
were then scraped off the dish using a plastic cell scraper. The cell suspension was 
then gently transferred into a precooled 1.5 mL microfuge tube. This was then passed 
twice through a 0.8 mm needle to further lyse the cells before being vortexed for 15 s, 
and centrifuged at 10, 000 g for 3 min at 4 ºC. The BCA was performed immediately 
where possible; otherwise the supernatant was stored at -20ºC or -80ºC for 1 month or 
6 months, respectively. 
2.2.14.1 Bicinchoninic acid assay 
The bicinchoninic acid assay (BCA) assay is for assessment of protein concentration. 









change is clear to light blue. In the second step the BCA reacts with the reduced 
copper which results in a purple colour. The BCA/copper complex is water-soluble 
and exhibits a strong linear absorbance at 562 nm with increasing protein 
concentrations.  
The assay used eight standards (1000, 500, 250, 125, 50, 25, 5 and 0 µg BSA). These 
were prepared fresh in 1X Promega passive lysis buffer alongside the working 
reagent, according to the manufacturer’s protocol (Thermo Scientific Pierce, 
Rockford, IL, USA). Samples were defrosted on ice and vortexed for 5 s before BCA 
analysis. To measure protein concentration an aliquot of the defrosted samples were 
each diluted 1/10 in 1X Promega passive lysis. Manufacturer prescribed clear optical 
grade real-time 96 well plates were used. Ten µl of the standard or the unknown were 
added to each well, and then 200 µL of working reagent was added to each. The plate 
was then covered and vortexed at 300 rpm for 1 min before being incubated for 30 
min at 37 ºC. The plate was then cooled to RT and absorbance measured at 562 nm in 
a 96-well plate reader (Sarstedt, NZ) with the MultiSkan GO software.  
2.2.15 Western blotting  
Lysed cells were vortexed and each sample was normalised to an equal protein 
concentration by a dilution with deionised water; each experiment was in the  range of 
5-20 µg. Sample PAGE buffer (5X) with fresh 2-mercaptoethanol (25%) was added to 
each sample to impart a negative charge on the protein to enable separation during gel 
electrophoresis. The protein mixture made a final volume of 20-30 µL. Samples were 
vortexed and heated to 70ºC for 10 min. Samples were  vortexed again and briefly 
centrifuged and loaded on 1.5 mm polyacrylamide gel, cast using the Bio-Rad Mini-
Protean II system (Bio-Rad, Hercules, CA, USA) (Laemmli 1970). The stacking gel 
consisted of 4% polyacrylamide and the resolving gel, 10% polyacrylamide. Gel 
layers were set with 0.1% TEMED and 0.1-.15% APS respectively. Electrophoresis 
was carried out in running buffer (25 mM Tris, 200 mM Glycine, 01% SDS) at 100 V 
for 2 hours.  
Next, proteins were transferred to PVDF membranes using the Bio-Rad mini-
TransBlot system. The transfer was performed at 4ºC in ice-cold transfer buffer (25 




Membranes were incubated with agitation in blocking solution comprised of 5% 
skimmed milk in 0.2% Tween PBS (T-PBS) for 1 h at room temperature. The 
membrane was then incubated overnight with agitation in E-cadherin antibody (H108 
sc-7870, Santa Cruz Biotechnology Inc.) diluted 1:200 in T-PBS with 5% milk. 
Membranes were then incubated in the secondary antibody, goat α-rabbit HRP 
conjugate (Santa Cruz Biotechnology Inc: sc-2005) diluted 1:5000 in T-PBS with 5% 
milk for 1 hour at room temperature. The membrane was then washed three times for 
10 min in T-PBS. The immunopositive bands were visualised using luminol-base 
enhanced chemiluminescence (ECL) plus reagents (Thermo Scientific Pierce, 
Rockford, IL, USA). 40:1 solution A and solution B respectively of the ECL plus 
reagents were used to visualise the membrane. Membranes were imaged with the 
LAS-3000 on chemiluminescence increment, standard to ultra at 10-30 sec intervals. 
The ladder was imaged using EPI, precision at 1/100 sec. All western blot exposures 
were in the linear range of detection. To detect that loading was equivalent between 
the wells α-actin antibody was applied. Membrane was then washed for 10 min, three 
times using T-PBS. Before being incubated overnight with agitation in α-Actin 
antibody rabbit IgG (Sigma Aldrich Biotechnology Inc.: sc-A5060) diluted 1:1000 in 
T-PBS with 5% milk. Membranes were then incubated in the secondary antibody, 
goat α-rabbit HRP conjugate (Santa Cruz Biotechnology Inc.: sc-2005) diluted 1:5000 
diluted in T-PBS with 5% milk for 1 hour at room temperature. The membrane was 
then washed 3 times for 10 min in T-PBS. The immunopositive bands were visualised 
using enhanced chemiluminescence (ECL) plus reagents (Thermo Scientific Pierce, 
Rockford, IL, USA) in the manner as previously described. 
2.2.15.1  Densitometry  
Densitometry was used to quantify small changes between samples in the MCF10a 
cell line. Gel files were acquired at minimum exposure and were saved in 16-bit 
grayscale to be analysed by Quantity1 software. Peak intensity of E-cadherin and α-
actin bands of each sample was manually analysed using the Bio-Rad instruction 
manual. The “rolling ball” effect was used to eliminate background. Final ratios were 
calculated by α-actin values being subtracted from E-cadherin. Each of the samples 




2.2.16 Genomic DNA extraction  
Media was aspirated from MCF10a cells after 24 hour drug treatment and cells were 
washed twice in ice-cold PBS. Genomic lysis buffer (Zymo Research, USA) was then 
added and incubated at room temperature for 10 min. Cells were then scraped and 
transferred to a 1.5 mL microfuge tube. To maximise genomic DNA (gDNA) yield 
three wells in each treatment were pooled together. Each tube was vortexed and 
centrifuged at 1000 rpm for 3 min to remove bubbles. The manufacturers (Zymo) 
protocol was followed with minor alterations; pooled gDNA lysate sample was put 
through one column in two loadings due to volume limitations. To increase quality an 
extra wash step was included.  
The gDNA quantification was carried out using Nanodrop as previously described 
(2.2.7). Once quantified, gDNA was stored at -20 ºC. 
2.2.17 Bisulfite conversion 
Bisulfite conversion involves the deamination of unmethylated cytosines to uracil. A 
total of 1.2 mg genomic DNA was bisulfite modified using the EZ DNA Methylation 
Kit (Zymo Research, Irvine, CA, USA) to ensure a high completion of bisulfite 
conversion rate per sample and >30 ng of bisulfite converted gDNA. Manufacturer’s 
instructions were followed with mild alterations to increase yield and bisulfite 
conversion. Alterations were made as follows:  
 The alternate incubation conditions using the Illumina Infinium methylation 
assay PCR conditions were used,  
 After M-wash buffer addition was centrifuged at 13,000 g,  
 M-desulphonation buffer was allowed to stand for 20 min, and centrifuged at 
13,000 g for 1 min,  
 After the second M-wash buffer addition was centrifuged tor 2 min,  
 12 µL of M-elution buffer was added and allowed to stand for 10 min at room 
temperature and centrifuged at 12000 relative centrifugal force (rcf) for 30 sec.  
Bisulfite converted gDNA was quantified using a Nanodrop spectrophotometer set at 




2.2.18 Genome wide methylome profiling in MCF10a cell line 
The Illumina Infinium HumanMethylation450 (450K) BeadChip (Illumina Inc, USA) 
can quantitatively interrogate methylation sites at single nucleotide resolution 
(Bibikova, Barnes et al. 2011, Sandoval, Heyn et al. 2011). A fluorescent signal is 
gathered at each locus by two probes; one designed against the unmethylated site and 
one against the methylated site.   
In total, 200 ng of bisulfite converted gDNA was further processed to run BeadArrays 
according to the manufacturer’s instructions (Appendix F). All 4 samples were within 
a 96-well plate and the Illumina array assay procedure (Illumina, USA) was followed 
until Day 3 in the lab, finishing with re-suspension of the MSA4 plate. The MSA4 
plate was then transferred offsite to AgResearch for hybridisation (Day 3) to produce 
the BeadChip, and the Illumina protocol was continued. The BeadChip was washed, 
stained and then imaged on a HiScan system (Illumina, USA). 
2.2.18.1  Methylome downstream analysis  
Subsequent analysis of the array data file was carried out in R (version 2.10.1) (Team 
2005), and gene annotation with Mar. 2006 (NCBI/36/hg18) assembly at the UCSC 
database (http://genome.ucsc.edu/). The R package made use of Illumina methylation 
annotation for region definition. Probes with no signal were removed and probes in 
each gene CpG island were listed. After background correction of the raw signals, 
beta-values (β-value) were computed from the collection of probes at each location 
and reflected the methylation status of the specific CpG residue site (either being a 
CpG island, north (N.) shore, south (S.) shore, gene body sites or transcription start 
sites (TSS)). The β-value represents the ratio of the intensity of the methylated bead 
type to the combined locus intensity: β=max(M,0)/(max(M,0)+max(U,0)+100). In 
other words, the β-value reflects the methylation status of a specific CpG site. The β-
values were measured as the difference between untreated and 3 mM VPA treated 
MCF10a cells by the Wilcoxon rank test (Wilcoxon 1950, Wilcoxon and Wilcox 
1964). Rankings were classed as significant if the Benjamini-Hochberg (Benjamini 
and Hochberg 1995) adjusted p-values FDR were <0.05. The Wilcoxon test was run 
individually for each gene: CpG islands, N. shores, S. shores, gene bodies and TSS. 
Genes ranked as significant were assessed whether they were hyper or hypo-




The reproducibility of the BeadChips was evaluated using biological (independent 
bisulfite modifications of two independently prepared DNAs) replicates of matched 
VPA exposed vs. negative control normal breast cell lines MCF10a. 
2.2.19 Clinical samples, patients treated for Epilepsy or Migraine 
An in vivo study was undertaken to test whether VPA at therapeutic levels in eleven 
clinical patients had a quantifiable effect on expression of genes relevant to HDGC. 
Eleven patients from the Dunedin Hospital were treated for epilepsy or migraines with 
VPA agreed to participate in the study. Buccal and blood samples were taken before 
and after VPA treatment. The study was approved by the University of Otago Human 
Ethics Committee.  
2.2.19.1 RNA extraction 
Once collected, whole blood samples were stored in RNA lysis buffer and stored at –
80ºC until further RNA processing. RNA was extracted from the whole blood 
samples using the Zymo whole blood RNA miniprep following the recommended 
protocol with minor alterations: step 1 rerun through of the lysate and on the last step 
the elution buffer was heated to 37ºC and 18 µL was loaded onto the column.  
After collection, buccal samples were stored in RNAlater solution at –80ºC so RNA 
quality was not compromised in the batch processing. RNA was extracted from 
buccal samples using the Zymo RNA miniprep following the protocol with minor 
alterations; step one had an extra wash step of 700 µL to ensure removal of RNAlater, 
the last step the elution buffer was heated to 37ºC and 18 µL was loaded onto the 
column.  
After RNA quantification, RNA was stored at – 80ºC for up to 6 months. RNA from 
the buccal and whole blood samples was quantified as previously described Section 
2.2.7.  
2.2.19.2  Real time qPCR  
RNA was converted to cDNA by methods previously mentioned (section 2.2.10.1). 
The cDNA was diluted to reduce inhibition of the qPCR reaction. The target 
primer/probe sets (ADAM23, CDH1 and TGM2) and reference sets (ACTB and 




with ample RNA was used to assess gene reference sets by a four series dilution (200, 
100, 50 and 10 ng total RNA) and Ct were monitored.  
Real-time quantitative PCR (qPCR) was performed in 384 and 96-well optical plates 
using the ABI PRISM 7900HT instrument (Applied Biosystems, Inc., Foster City, 
CA) and CFX connect Real-time system 96-well (Bio Rad) respectively. This was 
similar to section 2.2.10.2 with the following alterations: whole blood samples from 
all patients were assessed for ADAM23, CDH1 and TGM2 gene expression before and 
after VPA administration in singleplex reactions similar to section 2.2.10.2. All 
samples were in technical duplicate with RNA input dilution of 25 ng per reaction. 
Positive controls were lab control cell line RNA (Appendix C); 50 ng was used at 
100, 10, 1, 0.1 and 0.01%. Surrogate markers ADAM23 and TGM2 were validated in 
clinical samples after being identified in the transcriptome data as VPA sensitive, 
refer to Table 5.1. 
Buccal samples from all patients were assessed for CDH1 gene expression before and 
after VPA. Other genes (TGM2 and ADAM23) were not tested due to low template 
availability. The positive controls were lab control cell line RNA (Appendix C); 50 ng 
was used at 100, 10, 1, 0.1 and 0.01%. RT products were added at 100% into the 
qPCR reaction because of low template availability. Magnesium in the ACTB reaction 
was lowered to increase polymerase fidelity of the cDNA in the buccal samples 
(Appendix G), due to an incomplete melting curve completed with SYBRgreen at the 
higher magnesium concentration (data not shown).  
Quantification of expression for buccal and whole blood Ct values were performed as 
per section 2.2.11. According to the Pffafl Equation 2.2, sample was determined as 
the patient after VPA treatment and control as patient prior to VPA treatment. 
Efficiency of the reaction was calculated by LinReg due to singleplex reactions being 
performed so more accuracy to determine inter-well variances was required for each 





Chapter 3: Gene expression analysis of 
CDH1 after VPA and DAC treatment in 
cell lines 
In order for VPA (HDACi) and DAC (demethylating agent) to be used in combination 
as a chemopreventive approach in hereditary diffuse gastric cancer (HDGC) patients, 
it is important to understand their effect on gene expression. Supporting evidence is 
required for VPA and DAC use in the HDGC population. Down-regulation of the 2
nd
 
CDH1 allele by epigenetic silencing has been shown to coincide with early stages of 
the HDGC syndrome (Humar, Blair et al. 2009). It is conceivable that reversal of this 
down regulation by VPA treatment alone or in combination with DAC may prevent or 
delay this “second-hit” and, subsequently, the onset of cancer development. 
Furthermore, it was hypothesised that intermittent DAC activity in conjunction with 
VPA could boost and sustain the effect of VPA on gene expression. 
Work described in this chapter sets out to investigate the impact of VPA on gene 
expression using three cell lines, MCF10a (a non-malignant mammary gland 
epithelial cell line), AGS (a gastric adenocarcinoma epithelial cell line) and NCI-
H460 (a large-cell lung carcinoma epithelial cell line). E-cadherin expression was 
measured post VPA treatment alone and in combination with DAC treatment using 
real-time quantitative PCR (qPCR) and western blotting.  
NCI-H460, a lung cancer cell line was selected as a positive control cell line as it had 
previously been shown, by western blot, to consistently re-express E-cadherin after 24 
hour incubation with 5 mM VPA (Kakihana, Ohira et al. 2009). Acetylation of histone 
3 and 4, the expected mechanisms of action, were observed as little as 3 hours after 
treatment (Kakihana, Ohira et al. 2009). In NCI-H460 cells, CDH1 is silenced via 
methylation, however, a decrease in methylation level after VPA treatment has not 
been examined (Reinhold, Reimers et al. 2007, Kakihana, Ohira et al. 2009). 
AGS has a single base pair heterozygous insertion (1732_1733insC) in the CDH1 
gene (Halling-Brown, Bulusu et al. 2012). Although its mRNA is detectable, these 




MCF10a, a ‘non-tumorigenic’ cell line has heterozygous CDH1 promoter methylation 
and was chosen as a model (in Chapter 3 and 4) to demonstrate that VPA enhances 
CDH1 expression. In other words, MCF10a cells are CDH1+/- due to methylation on 
one allele. MCF10a exhibits functional E-cadherin expression (Lombaerts, Van 
Wezel et al. 2006). The MCF10a cell line is commonly used for studying epithelial 
mesenchymal transition (EMT) in vitro as it exhibits a fibroblast phenotype during its 
sub-culture (Xie, Law et al. 2003, Yang, Mani et al. 2004, Bindels, Mestdagt et al. 
2006, Lombaerts, Van Wezel et al. 2006). VPA may inhibit EMT, a stage that may 
contribute to HDGC metastatic progression (further examined in Chapter 4).  
Physiologically, VPA works in the 0.25-5.5 mM range in cell lines (Catalano, 
Fortunati et al. 2005). This range is comparable to therapeutic levels reached in 
patients treated for epilepsy, typically 100 μg/mL (0.7 mM) (Catalano, Fortunati et al. 
2005). Limited toxicity occurs when the concentration is below 3.1 mM and severe 
side effects develop when the concentration is >5.9 mM (Catalano, Fortunati et al. 
2005). 
It was hypothesised that treatment with either VPA alone or in combination with low 
DAC (nM) would have elevated and sustained effects upon gene expression compared 
with high drug concentrations. If gene effects could be sustained beyond washout, 
lower drug concentrations could be administrated thereby reducing the toxicity 
potential in the cell. MCF10a cells were exposed to low DAC and VPA (nM-μM) 
concentration combinations for 24 hours. Exposure time was then extended to 72 
hours, followed by removal of VPA and renewal of growth media for 24 hours (this 
was the “washout”). It was postulated DAC treatment exposure of 72 hours would be 
the most effective as MCF10a cells have a doubling time of 22 hours therefore this 
time frame would enable passive methylation to occur. Furthermore, this would give a 
reliable indication whether possible synergy could occur when in combination with 
VPA.  
To identify whether there was a synergistic effect of VPA and DAC treatment in 
combination with CDH1 expression, a synergy score was calculated (Equation 3.1) 
(Berenbaum 1978). A synergy score >1 indicated synergy, whereas a synergy score 








Equation 3.1. Synergy score  
Using Pffafl calculated fold change for the CDH1 expression after DAC and VPA 
treatment combination relative to their individual fold changes gave a synergy 
score (Berenbaum 1978). A synergy score (SC) indicated whether the two drug 
combinations have a combined effect on gene expression. SC >1 indicated 
synergy, whereas a synergy score <1 suggested no synergy occurred. Fold change 
(FC) was CDH1 gene expression changes in relation to untreated calculated using 
the Pffafl method. 
3.1 Results 
3.1.1 RNA quality and RNA quantification 
Representative cell line samples treated with and without VPA were chosen to assess 
RNA quality via the RNA Agilent system (Appendix H). All samples tested had a 
RIN value >8.1, indicating a high intact amount of total RNA quality (refer to section 
2.2.8) as (Fleige, Walf et al. 2006).  
RNA quantitation was carried out using two methods spectrophotometric and 
fluorometric by dye binding using wavelength A260nm absorbance based Nanodrop 
(Nanodrop Technologies, USA) and Qubit (Invitrogen, USA) that intercalates dyes. 
Both RNA quantification systems gave similar results with rare exceptions (Appendix 
I).  
Quantitative PCR results met the criteria of ≤0.5 standard deviation of Cts within 
sample replicates, Ct values between 15-35 and R
2 
≤0.98 (data not shown). The 
efficiency calculations overall and individual effiencies also meet the standards set in 
section 2.2.11.1 when using LinReg and the standard curve methods (Appendix J).  
3.1.2 E-cadherin gene expression after 24 hour VPA and DAC treatment 
The cell lines NCI-H460, MCF10a and AGS were treated with VPA and DAC, alone 
and in combination, for 24 hours. A paired sample t-test was conducted to evaluate 
whether VPA and DAC alone and in combination had a significant effect on CDH1 
expression in each cell line. When synergy occurred (SC>1) with a combination 
treatment, one-way ANOVA evaluated the significance of this synergy compared to 




The positive control, NCI-H460 cells, showed the highest increase in CDH1 
expression after VPA treatment compared to AGS and MCF10a cell lines (Figure 3.1 
and Table 3.1). CDH1 expression was induced in NCI-H460 by VPA in a dose 
responsive manner (Figure 3.1 and Table 3.1). Investigation of CDH1 expression after 
5 mM VPA exposure relative to untreated conditions supported the previous finding 
by Kakihana et al that VPA positively induces E-cadherin expression (Kakihana, 
Ohira et al. 2009). Only at the highest tested dosage of 10 µM did DAC have an 
additional effect on CDH1 expression relative to untreated (Figure 3.1 and Table 3.1). 
Synergistic effects were observed in 5 drug combinations including; 3 mM VPA 
exposure with both 500 nM and 10 µM DAC combinations, and 5 mM VPA exposure 
with three 100 nM, 500 nM and 10 µM DAC combination conditions (shown by red 
squares in Table 3.1). The overall highest additive effect and synergistic score was 
observed in 5 mM VPA with 10 µM DAC (FC=50.8, SEM=4.06) treatment; a paired 
sample t-test showed the additive effect was significant relative to untreated; 
p=6.37E-05. Furthermore one-way ANOVA showed the synergistic effect was 
significant relative to no treatment and both 5 mM VPA and 10 µM DAC alone 
conditions; p=1.74E-17 (Figure 3.1 and Table 3.1). 
The AGS cell line CDH1 expression showed a varied response to both VPA and DAC 
conditions. A dose response was observed with both drugs, but no synergy was 
observed (Figure 3.1 and Table 3.1). The highest additive effect of E-cadherin 
expression was observed in 5 mM VPA (FC=1.95, SEM=0.12) relative to no 
treatment (Figure 3.1 and Table 3.1).  
In MCF10a cells, CDH1 showed a dose-responsive increase after 24 hours of VPA 
and DAC exposure (Figure 3.1 and Table 3.1). The VPA effect was, however, 9.3 fold 
lower compared with the same conditions conducted in the positive control NCI-H460 
cells (Figure 3.1 and Table 3.1). However, the higher 10 µM DAC treatment had a 
more comparable CDH1 expression to NCI-H460 cells (FC=2.04, SEM=0.1) relative 
to no treatment at only 1.7 fold lower (Figure 3.1 and Table 3.1). The highest additive 
effect with CDH1 expression in MCF10A cells were observed in the 5 mM VPA and 







Table 3.1. Cell lines CDH1 response after various drug conditions. NCI-H460, 
AGS and MCF10a cells treated with VPA and DAC combinations for 24 hour 
exposure.  
Summary of CDH1 expression of additive (FC>1) and synergistic effects (SC>1) 
were analysed by post drug treatment in each individual cell line. Significance 
tested additive effect by paired t.test, and synergistic effect by one-way ANOVA; 
p<0.05 (significance of CDH1 expression compared to no treatment highlighted by 
green and red respectively).  
 
Cell line Conditions FC SEM T.TEST Significant SC ANOVA
NCI-H460 Untreated 1.00 0.03
0.5 mM VPA 6.24 0.24 1.18E-08 TRUE
3 mM VPA 19.45 0.52 3.65E-10 TRUE
5 mM VPA 21.47 0.36 7.43E-12 TRUE
10 nM DAC 0.94 0.05 3.19E-01 FALSE
100 nM DAC 1.06 0.08 5.17E-01 FALSE
500 nM DAC 1.06 0.05 4.19E-01 FALSE
10 µM DAC 3.45 0.04 4.72E-15 TRUE
0.5 mM VPA + 10 nM DAC 5.13 0.21 2.76E-08 TRUE 0.71
0.5 mM VPA + 100 nM DAC 6.12 0.15 1.65E-10 TRUE 0.84
3 mM VPA + 10 nM DAC 19.04 0.47 2.03E-10 TRUE 0.93
3 mM VPA + 100 nM DAC 19.84 0.47 1.41E-10 TRUE 0.97
3 mM VPA + 500 nM DAC 30.85 1.08 1.29E-03 TRUE 1.5 2.52E-24
3 mM VPA + 10 µM DAC 45.51 0.23 1.88E-05 TRUE 1.99 3.42E-28
5 mM VPA + 10 nM DAC 21.32 0.38 1.27E-11 TRUE 0.95
5 mM VPA + 100 nM DAC 26.89 1.31 4.36E-08 TRUE 1.19 2.14E-25
5 mM VPA + 500 nM DAC 31.09 0.68 1.07E-07 TRUE 1.38 3.85E-30
5 mM VPA + 10 µM DAC 50.82 4.06 6.37E-05 TRUE 2.04 1.74E-17
AGS Untreated 1.03 0.09
0.5 mM VPA 0.74 0.03 1.06E-02 TRUE
3 mM VPA 1.40 0.06 7.92E-03 TRUE
5 mM VPA 1.95 0.12 1.63E-05 TRUE
10 nM DAC 0.78 0.02 2.00E-02 TRUE
100 nM DAC 1.16 0.06 2.46E-01 FALSE
500 nM DAC 1.37 0.06 2.04E-02 TRUE
10 µM DAC 0.73 0.03 8.55E-03 TRUE 0.59
3 mM VPA + 10 nM DAC 1.29 0.06 1.50E-01 FALSE 0.48
3 mM VPA + 100 nM DAC 1.30 0.06 5.43E-02 FALSE 0.35
3 mM VPA + 500 nM DAC 0.99 0.11 7.66E-01 FALSE 0.78
3 mM VPA + 10 µM DAC 1.66 0.09 1.21E-04 TRUE 0.5
5 mM  VPA + 10 nM DAC 1.36 0.06 1.88E-02 TRUE 0.22
5 mM VPA + 100 nM DAC 0.72 0.04 8.14E-03 TRUE 0.21
5 mM VPA + 500 nM DAC 0.70 0.04 4.89E-03 TRUE 0.31
5 mM VPA + 10 µM DAC 0.83 0.05 6.16E-02 FALSE
MCF10a Untreated 1.00 0.04
0.5 mM VPA 1.35 0.08 5.47E-03 TRUE
3 mM VPA 1.76 0.05 3.85E-07 TRUE
5 mM VPA 2.30 0.08 6.57E-07 TRUE
10 nM DAC 1.11 0.05 1.36E-01 FALSE
100 nM DAC 1.29 0.06 3.18E-03 TRUE
500 nM DAC 1.44 0.05 2.25E-04 TRUE
10 µM DAC 2.04 0.10 8.47E-04 TRUE
0.5 mM VPA + 10 nM DAC 1.45 0.05 6.85E-05 TRUE 0.59
0.5 mM VPA + 100 nM DAC 1.65 0.11 1.08E-03 TRUE 0.63
3 mM VPA + 10 nM DAC 2.17 0.06 1.83E-07 TRUE 0.75
3 mM VPA + 100 nM DAC 2.15 0.12 9.07E-05 TRUE 0.7
3 mM VPA + 500 nM DAC 2.34 0.04 1.06E-08 TRUE 0.73
3 mM VPA + 10 µM DAC 2.49 0.08 4.48E-05 TRUE 0.65
5 mM VPA + 10 nM DAC 3.05 0.23 2.57E-04 TRUE 0.89
5 mM VPA + 100 nM DAC 2.67 0.11 3.81E-06 TRUE 0.75
5 mM VPA + 500 nM DAC 2.90 0.16 6.96E-04 TRUE 0.78




A. NCI-H460 mRNA expression 
 











































































































































































































































C. MCF10a mRNA expression 
 
Figure 3.1. VPA and DAC effect on CDH1 expression in in vitro models.  
Two drugs, VPA and DAC, were used individually and in combination in the cell 
lines for 24 hour exposure; NCI-H460 (A), AGS (B) and MCF10a (C). Results 
from A-C are calculated using Pfaffl equation that incorporated primary Ct data of 
CDH1 treated vs untreated relative to the reference genes treated vs untreated. 
CDH1 normalised fold change calculated average ±SEM of qPCR in triplicate. 
Paired sample t-test (*= p<0.05) measured significant difference in comparison to 
the untreated. Synergy (SC>1) was measured as significant (+=p>0.05) by one-
way ANOVA. 
3.1.3 E-cadherin gene expression, 72 hour VPA and DAC treatment followed by 24 
hour washout period 
QPCR was used to assess E-cadherin expression from MCF10a cells treated with low 
drug concentration combinations for an extended exposure of 72 hours, followed by 
removal of VPA upon introduction of fresh media. RNA samples were taken at 72 
hours post drug incubation after cells were split and at 24 hours after drug washout. A 
paired sample t-test was conducted to evaluate whether VPA and DAC alone and in 
combination had an effect on CDH1 expression in the MCF10a cell line. 
The results showed a significant increase in CDH1 expression in MCF10a cells after a 
72 hour exposure to VPA and DAC alone and in combination (Figure 3.2 and Table 
3.2). The greatest effect was observed in 5 mM VPA treated cells (FC=3.49, SEM= 
0.69), compared to untreated. However this VPA effect on CDH1 expression from 5 
mM VPA was not sustained after a 24 hour washout (FC=0.30, SEM=0.12). No 






































































































































































































































72 hour exposure with the minor additive effect previously observed becoming 
insignificant after a 24 hour washout. Conversely, DAC treatment for 72 hours 
following a 24 hour washout resulted in CDH1 expression being sustained and 
amplified (Figure 3.2 and Table 3.2). This supported the proposed hypothesis (Tsai, 
Li et al. 2012) offered that DAC at low concentrations has the ability to 
restore/increase expression in methylated genes after drug cessation.  
 
Table 3.2. MCF10a cells CDH1 expression response after various drug 
conditions.  
Summary of CDH1 expression in MCF10a cells treated with VPA and DAC 
combinations for 72 hours, followed by a 24 hour washout. CDH1 expression fold 
changes (FC) after analysis with the pffafl equation and synergy score (SC) 
equation from post drug treatment in MCF10a cells. Significance tested FCs 
compared to the untreated by paired t.test p<0.05 (significance of CDH1 
expression compared to no treatment highlighted by green). However SCs were not 
required as no values were above the pre-determined threshold of >1. 
 
  
MCF10a Conditions FC SEM T.test Signficant SC
72 hour Exposure Untreated 1.00 0.03
0.5 mM VPA 2.03 0.17 7.51E-03 TRUE
5 mM VPA 3.49 0.69 3.59E-02 TRUE
10 nM DAC 1.38 0.04 5.59E-05 TRUE
0.5 mM VPA + 10 nM DAC 1.38 0.04 1.12E-04 TRUE 0.41
5 mM VPA + 10 nM DAC 1.72 0.16 1.98E-02 TRUE 0.35
24 hour Washout Untreated 1.01 0.07
0.5 mM VPA 0.94 0.08 5.51E-01 FALSE
5 mM VPA 0.30 0.12 4.47E-02 TRUE
10 nM DAC 2.07 0.23 4.82E-03 TRUE
0.5 mM VPA + 10 nM DAC 1.55 0.39 2.09E-01 FALSE 0.51






Figure 3.2. VPA and DAC effect on CDH1 gene expression in MCF10a cells.  
Two drugs, VPA and DAC, were used individually and in combination in the 
MCF10a cell line for 72 hour exposure followed by 24 hour washout. Results are 
calculated using the Pfaffl equation and LinReg method for efficiencies. Results 
show CDH1 average ±SEM of qPCR in triplicate. Paired sample t-test in relation 
to untreated samples were used to measure significant difference (*=p<0.05). 
3.1.4 E-cadherin protein expression, 24 hour VPA and DAC treatment 
To investigate whether the changes in CDH1 expression were reflected at the protein 
level, E-cadherin protein was assessed by a western blot after cells were incubated 
with VPA or DAC alone or in combination for 24 hours. Antibodies specific for E-
cadherin were used on whole cell lysate with expected E-cadherin size of precursor 
135-kDa and mature 120/80-kDa (Figure 3.3 and (Figure 3.4). Each of the cells were 
treated with (0, 0.5, 3 and 5 mM) VPA and the same range of VPA in combination 
with different (10, 100 nM and 10, 20 μM) DAC concentrations had three western 
blots. Representational blots were shown for each cell line treated with VPA and 
DAC.  
The western blot analysis of the NCI-H460 cells showed that the mRNA level was 
indicative of the E-cadherin protein expression. E-cadherin expression was shown to 
increase in a dose-responsive manner to VPA treatment (Figure 3.3). VPA and DAC 
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VPA treatment alone (Figure 3.3). The band visible above 170 kDa in Figure 3.3A 
was perhaps E-cadherin dimer.  
E-cadherin expression was not detected by western blot in the AGS cells (Figure 3.3). 
This is explained by the ins1732 mutation in CDH1 abbrogating the protein from 
amino acids 577, this deleted sequence includes the antibody binding site amino acid 
600-707.  
Unsurprisingly, no dose of VPA or DAC had an obviously visible effect on the level 
of ‘non-tumorigenic’ MCF10a E-cadherin protein expression due to natural high 
endogenous expression in untreated samples (Figure 3.4). To quantify visible effects 
and to detect and quantify any small changes in E-cadherin expression quantitative 
densitometry was performed. VPA treatment alone showed a dose response in E-
cadherin, expression; 5 mM VPA had an E-cadherin fold increase of 1.22 (Figure 
3.4). However, DAC treatment alone appeared to have an inhibitory effect with fold 
change expression as low as 0.80. E-cadherin expression peaked at a fold increase of 
1.3 in MCF10a cells following 5 mM VPA with 10 nM DAC treatment. Densitometry 
and mRNA results were comparable except following 0.5 mM VPA with 10 nM DAC 
treatment as mRNA increased (FC=1.45, p=6.85E-05 paired sample t.test) while 
densitometry showed no change (Figure 3.4).  
All bands that were observed lower than the molecular range expected for α-actin (44 
kDa) in NCI-H460 and MCF10a cells may have been caused from protein degradation 
of the samples. In the future, to prevent possible protein degradation, protease 
inhibitors could be incorporated within the lysis buffer. Bands observed above the E-
cadherin range (precursor 135 kDa/ mature 120/80 kDa) in NCI-H460 cells most 
likely may have been from either the primary antibody concentration being too high, 
or the passage number (at passage 15) was too high and the protein accumulated 
differences or the secondary antibody could be binding non-specifically. It was 
considered the PVDF membrane can have higher background than nitrocellulose 
membrane, which could be used instead in future experiments. The band observed in 
the MCF10a CDH1-/- cells in Figure 3.3A may be an E-cadherin precursor band, 















Figure 3.3. E-cadherin protein expression in NCI-H460 and AGS cell lines.  
(A) E-cadherin protein expression is increased in the large cell lung cancer (NCI-
H460) cell line after a 24 treatment with VPA (mM) and DAC (nM) alone and in 
combination. Western blot analyses of 5 µg cell lysates from cultured cells. (B) E-
cadherin is not present in the gastric adenocarcinoma (AGS) cell line following a 
24 hour treatment with VPA (mM) and DAC (nM-µM) alone and in combination. 
Western blot analyses of 10µg cell lysates from cultured cells. All cells were 
exposed to DAC and VPA for 24 hours and detected using E-cadherin and α-actin 
antibodies. E-cadherin: precursor 135-kDa/ mature 120/80 kDa. α-actin (44 kDa) 
served as a loading control. MCF10a CDH1-/- and MCF10a are negative and 






Figure 3.4. E-cadherin protein expression in MCF10a cell 
line.  
Western blot analyses of 10 (A) and 5 µg (B) lysates 
(respectively) from the breast MCF10a cell line were analysed 
for their E-cadherin accumulation by western blotting after 
exposure to VPA and DAC at indicated concentrations for 24 
hours. E-cadherin: precursor 135-kDa/ mature 120/80 kDa. α-
actin (44 kDa) served as a loading control. The amount of E-
cadherin increased, with some treatment combinations. The 
images were analysed with Quantity1 software. (C) Graphical 
presentation of the E-cadherin levels determined by 
quantitative densitometry are after 24 hour exposure data 
points obtained after normalisation to α-actin relative to 














3.2.1 VPA and DAC exposure can increase E-cadherin expression in vitro 
VPA, a HDACi, can increase CDH1 expression in the breast cell line MCF10a and 
the large-cell lung carcinoma line NCI-H460 (Kakihana, Ohira et al. 2009), in the 
presence and absence of the de-methylating agent DAC. Re-expression of CDH1 
expression by VPA in the MCF10a cell line had not been previously reported. This 
induction was maintained to the protein level. However, no consistent E-cadherin 
induction after VPA and DAC exposure was found in the gastric adenocarcinoma 
AGS cell line. Instead, after VPA and DAC exposure, the AGS cell line can both 
induce E-cadherin expression and reduce it at the mRNA level. This trend may be 
caused by DNMT3A spontaneous expression in AGS cells (Ushijima, Watanabe et al. 
2005) that may work against VPA effect on CDH1 expression, by re-methylating 
DNA.  
Importantly the VPA concentrations examined were clinically achievable. Low 
therapeutic doses of VPA were able to induce E-cadherin expression after an extended 
period of exposure in the MCF10a cell line, which has heterozygous CDH1 promoter 
methylation. CDH1 expression after 0.5 mM VPA was 25% more effective after 72 
hour exposure than after 24 hour exposure. Furthermore, E-cadherin expression 
following a 72 hour exposure of 0.5 mM VPA was comparable to the 24 hour 
exposure of 3 mM VPA, indicating a lower dose over a longer period of time 
enhanced gene expression levels. However, this increase in gene expression was not 
sustained after a 24 hour treatment withdrawal. Moreover, E-cadherin induction after 
VPA exposure in MCF10a cells was not as clear as the NCI-H460 cell line, perhaps 
indicating the difference in tumorigenic potential. 
DAC activity in conjunction with VPA was hypothesised to boost and sustain the 
effect of CDH1 expression. First, DAC treatment alone was assessed in three cell 
lines for background level of E-cadherin expression after a 24 hour exposure. DAC 
treatment was seen to cause an increase in CDH1 endogenous expression in MCF10a 
cells at 10, 100 nM and 10 µM exposure. However, DAC treatment of 10 µM in 
MCF10a cells had an observed lower CDH1 FC than in NCI-H460 cells by 1.41 FC. 




significant in MCF10a cells. CDH1 expression was induced by 29% compared with 
the 24 hour DAC exposure. Interestingly, CDH1 gene expression was sustained and 
increased after a 24 hour drug washout by 67.6%. This supports previous findings by 
Tsai et al. of DACs ability of transient low doses to sustain long-term antitumor 
effects by retaining the ability to target DNA methylation processes and alter gene 
expression after cessation of drug administration (Tsai, Li et al. 2012).  
A synergistic effect was observed only in the positive cell line NCI-H460 after 24 
hour exposure of VPA and DAC. A dose-response effect occurred with high DAC 
concentrations when in combination with increasing VPA, suggested that the drug 
combination effect was cell line specific as it was not observed in MCF10a cell-line 
after 24 hour, or 72 hour exposure or following a 24 hour washout. 
3.3 Conclusion 
Overall, the MCF10a cell data after VPA treatment was of great importance, because 
of its relevance to HDGC chemoprevention. CDH1 induction was observed in a 
physiologically achievable range, however it was not sustained following drug 
washout. It is likely that the transience of CDH1 upregulation would prohibit on-
going VPA use in HDGC patients, although it may be able to be maintained with 




Chapter 4: Transcriptome and DNA 
methylation profiling of MCF10a cells 
after treatment with VPA 
To assess global genetic and epigenetic changes induced by VPA, RNA was extracted 
from MCF10a cells at passage 6 after a 24 hour VPA treatment and RNA-Seq 
performed (by New Zealand Genomics Limited; NZGL). To investigate epigenetic 
changes induced by VPA, genomic DNA was extracted from MCF10a cells after a 24 
hour VPA treatment at passage 5 and 6, bisulphite converted and DNA methylation 
array performed (by AgResearch). MCF10a cells, as previously described, were 
selected because of their relatively normal, non-tumorigenic phenotype- increasing 
the relevance of subsequent data to the chemoprevention setting.  
4.1 Results 
4.1.1 RNA quality and RNA quantification 
Two identical experiments were performed on independent days and each had two 
biological replicates. RNA was quantified by a spectrophotometer (Nanodrop) and by 
a fluorometer using picogreen dye (Qubit). The RNA integrity was assessed by 
electrophoretically driving denatured RNA by a voltage gradient and separating the 
molecules by size which were subsequently detected by laser-induced fluorescence 
(Agilent bioanalyzer system, Appendix K). From these results, the best quality RNA 
from each biological replicate was selected for RNA-Seq.  
RNA from the second biological replicate was DNase1 treated to remove any DNA 
contamination. The DNase1 treated samples (Appendix L) had a multitude of 
fragments with different lengths as reflected in a poor-quality bioanalyzer trace with 
obscured peaks and a diminished peak for 28S rRNA, and thus by low RIN values 
<7.0 (Appendix L). The samples that had not been DNase1 treated had exemplary 
quality traces and resulted with a flat base line that was scattered with narrow peaks 
and distinct 18S and 28S rRNA peaks, followed with excellent RIN values >9.0 




Due to the apparent degradation of the RNA by the DNase1 treatment, every RNA 
sample used for sequencing came from the first biological set. Each sample gave 
consistently high quality of RNA and a high amount of total RNA. 
4.1.2 Transcriptome quality control 
The quality and quantity of the cDNA library generated was verified by NZGL. The 
Illumina HiSeq was used to perform 100bp single end sequencing. Samples were 
demultiplexed based on barcode sequences inserted specifically into the flanking 
Illumina adapter sequence.  
The raw reads were trimmed to remove read through (i.e. remove adapter sequence), 
this also removed any adapter oligonucleotides that were sequenced. Quality control 
trimming was performed based on reads having >Q30 (the probability of a correct 
base call >99.9%) to be kept, 79-80% of reads passed this filter (Table 4.1).  
 















% > = 
Q30 
MCF10a WT (1) 426 1 17.4 332 7.97E+07 79 
MCF10a WT (2) 556 1 27.8 339 6.49E+07 80 
MCF10a 3 mM 
VPA (1) 
197 1 18.3 344 8.28E+07 79 
MCF10a 3 mM 
VPA (2) 
238 1 27.4 342 5.36E+07 79 






4.1.3 Differentially Expressed Genes 
The volcano plot is a representation of the significant differentially expressed (DE) 
results. This showed the magnitude (effect, x-axis) and significance (log odds, 
inverted y-axis) of all drug-gene associations (Figure 4.1). The Limma package was 
used in R to create this plot using data adjusted for multiple comparisons. Differential 
expression was considered if there was a log2 fold change (FC) ≥1.0 or ≤-1 and genes 
were considered significant if the log odds were ≥3.0 (Figure 4.1, horizontal line). 
Genes of interest were defined as the genes that meet both these criteria, i.e. the genes 
that fall into the top left and top right squares of the volcano plot (Figure 4.1, green 
and red respectively). 
 
Figure 4.1. A volcano plot of expression changes in MCF10a cells following 
VPA treatment.  
1,889 genes are significantly differentially expressed between MCF10a VPA 
treated and untreated cells. Gene counts were normalised according to the Limma 
manual as explained in the methods section. The graph was created using R (Team 
2005). Dashed lines indicate the significance criterion of log2 fold change (FC) ≥1 
or ≤-1. 
Of the 29,172 mapped genes, 6.5% were significantly differentially expressed after 
VPA exposure (Figure 4.1). There were 621 genes with decreased expression and 




To identify chromosomal bias, VPA effect was assessed across all differentially 
expressed genes and a percentage was calculated according to the number of genes 
estimated on each chromosome (Information 1998). The highest percentage of 
differentially expressed genes was found on chromosome 19 (9.0%), the chromosome 
with the highest gene-density in all human chromosomes (Grimwood, Gordon et al. 
2004) (Figure 4.2). The lowest percentages of differentially expressed genes were 
found on chromosome 7 and 18, both at 3.8%.  
Interestingly the X-chromosome had 80.5% genes (62 genes of the 77 X-chromosome 
genes that passed the significance criteria) differentially up regulated. This is notably 
higher than the other chromosomes, which exhibited an average gene up regulation 
percentage of 65.7% (compared to down regulation). After VPA exposure in MCF10a 
cells there is evidence of X-chromosome gene up regulation that could be an 
indication of removal of X- chromosome inactivation.  
Another type of epigenetic effect, genomic imprinting (also referred to as gamete or 
parental imprinting) was examined after VPA treatment. Nine imprinted genes were 
identified from the 126 total identified from (Morison IM 2005) to be differentially 
expressed after VPA treatment. Of these, six were up regulated, CPA4, SLS22A18, 
BDNF, NAP1L5, GNAL and L3MBTL. The remaining three were down regulated, 
CDKN1C, TCOF1 and PHF11.  
 




Percentage of differentially expressed genes corrected for approximate gene 
number (estimated from (Information 1998)) per chromosome.   
4.1.3.1 DNA methyl transferase inhibition  
DNA methyl transferase (DNMT) was examined in the gene expression data to see 
whether the maintenance machinery in DNA methylation in differentiated cells was 
affected by VPA exposure. Specifically, DNMT1 is involved in maintenance of 
methylation and DNMT3a and DNMT3b are involved in de novo methylation (Jones 
and Liang 2009). DNMTs gene expression after VPA treatment in MCF10a cells 
resulted in DNMT1 down regulation by 56% and no significant change in DNMT3a/b 
gene expression compared to untreated cells (Table 4.2). 
Gene  Fold Change Average Expression Adjusted p-value Log Odds 
DNMT1* 0.44 7.53 2.18E-05 6.38 
DNMT3A 1.31 2.62 3.70E-02 -3.21 
DNMT3B 0.75 2.41 2.36E-02 -1.85 
Table 4.2. DNA methyl transferase inhibition after VPA treatment.  
Gene expression from RNA-Seq data with MCF10a cells treated with VPA. Genes 
marked with* meet the significance criteria. 
4.1.4 Most differentially expressed genes 
To detect genes of biological interest and possible trends of VPA effects, RNA-Seq 
data were ranked to identify differentially expressed genes. The criteria were log2 
fold changes (FC) ≥1or ≤-1, highest adjusted p-value and then highest log odds of 
gene expression. The top positive and negative 30 genes are listed in Table 5 and 6, 
respectively. It was observed that genes from all the chromosomes made the top 30 
lists except those from the X-chromosome. 
The gene with the most significant positive FC was carboxypeptidase (CPA4) on 
chromosome 7, an imprinted gene (FC=8.98, adj. p-value=4.99E-07, log odds=15.73) 
(Table 4.3) (Morison IM 2005). The gene with the most significant negative FC was 
serine/threonine-protein kinase (PLK1) on chromosome 17 (FC=0.24, adj. p-
value=4.99E-07, log odds =16.31) (Table 4.4). Interestingly, SMYD2 (SET domain-
containing proteins), a gene that catalyses lysine methylation on histones and non-
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CPA4 7 8.98 5.298 4.99E-07 15.726 
GSN 9 4.87 6.237 4.99E-07 16.093 
ANGPTL4 19 4.40 8.035 4.99E-07 17.297 
TGM2 20 7.95 4.839 6.16E-07 15.302 
NDRG1 8 3.35 7.802 8.05E-07 15.358 
MRC2 17 4.49 4.879 1.06E-06 14.76 
STMN3 20 9.28 3.542 1.10E-06 13.75 
UBE2L6 11 5.70 3.275 1.10E-06 13.697 
BAI2 1 13.09 3.29 1.14E-06 13.133 
GJB2 13 3.27 5.834 1.14E-06 14.081 
AKR1B1 7 2.90 8.192 1.14E-06 14.138 
APLP1 19 20.32 3.046 1.15E-06 12.308 
ABAT 16 10.26 3.085 1.19E-06 12.46 
ST3GAL5 2 8.76 3.208 1.19E-06 12.356 
ANXA6 5 8.22 2.588 1.19E-06 12.735 
TMOD2 15 7.65 2.946 1.19E-06 12.819 
EPHB2 1 6.58 3.478 1.19E-06 12.696 
TUBA1A 12 6.30 5.848 1.19E-06 13.49 
GBP2 1 5.42 3.684 1.19E-06 12.564 
MCAM 11 4.87 5.206 1.19E-06 13.476 
FGFR1 8 3.80 4.105 1.19E-06 13.16 
LAMB3 1 3.76 9.763 1.19E-06 13.017 
TMEM132A 11 3.12 6.007 1.19E-06 13.149 
CADM3 1 2.97 3.634 1.19E-06 13.009 
FADS3 11 2.92 6.02 1.19E-06 13.234 
TIMP2 17 2.76 7.35 1.19E-06 13.263 
DBN1 5 2.09 7.26 1.19E-06 13.197 
ARRDC4 15 4.21 4.129 1.24E-06 12.558 
PBXIP1 1 4.14 5.34 1.24E-06 12.788 
SPOCK1 5 3.87 4.864 1.24E-06 12.71 
Table 4.3. Top 30 positive gene fold changes in MCF10a cells after VPA 
treatment.  















ATF5 19 -7.77 5.208 4.99E-07 14.953 
LMNB1 5 -4.72 6.905 4.99E-07 15.9 
KIF20A 5 -4.65 7.153 4.99E-07 16.008 
PLK1 16 -4.23 7.16 4.99E-07 16.305 
CCNA2 4 -3.85 7.046 1.08E-06 14.845 
TPX2 20 -2.78 7.974 1.08E-06 14.839 
SYT8 11 -4.17 7.034 1.10E-06 14.461 
TRIP13 5 -3.53 5.874 1.10E-06 14.314 
U2AF2 19 -2.44 7.846 1.10E-06 14.487 
KIF2C 1 -3.60 6.292 1.14E-06 13.997 
KRT10 17 -3.52 5.963 1.14E-06 14.187 
KIF22 16 -3.10 6.281 1.14E-06 14.138 
MCM4 8 -2.65 8.169 1.14E-06 14.173 
NOP56 20 -2.20 8.332 1.14E-06 14.147 
PHF19 9 -5.42 5.796 1.19E-06 13.085 
ADI1 2 -4.74 6.503 1.19E-06 13.794 
TIMELESS 12 -4.73 6.118 1.19E-06 13.593 
SCNN1G 16 -4.41 6.473 1.19E-06 13.016 
TYMS 18 -4.22 6.516 1.19E-06 13.299 
ALDH16A1 19 -3.67 5.447 1.19E-06 13.108 
SLC5A6 2 -3.58 5.684 1.19E-06 13.093 
KEAP1 19 -3.55 5.893 1.19E-06 13.057 
RCC1 1 -3.45 7.263 1.19E-06 13.462 
DLGAP5 14 -3.13 6.603 1.19E-06 13.62 
FAM83D 20 -3.09 6.769 1.19E-06 13.86 
CCNB1 5 -3.06 7.945 1.19E-06 13.09 
TAX1BP3 17 -2.85 6.438 1.19E-06 13.13 
PKP3 11 -2.84 7.258 1.19E-06 13.495 
SMYD2 1 -2.82 6.59 1.19E-06 13.207 
MCM7 7 -2.76 7.791 1.19E-06 13.785 
Table 4.4. Top 30 negative gene fold changes in MCF10a cells after VPA 
treatment.  
DE genes are sorted by highest adjusted p-value. 
4.1.5 GATHER and KEGG analysis 
To study the effect of VPA at the biological process level, differentially expressed 
genes were subjected to analysis of their functional profiles. GATHER, an online tool, 
extracted information from the differentially expressed gene list and compared the 
frequencies of functional terms and pathways. Gene Ontology (GO) finds terms over-




important. Kyoto encyclopedia of genes and genomes (KEGG), maps molecular 
datasets, especially large-scale datasets and shows biological interpretation of higher-
level systemic functions. A Bayes factor of ≥6 is the recommended significance 
criteria for GATHER as it signifies strong evidence, implies an association and also 
balances false negatives with false positives (Chang and Nevins 2006). GO terms and 
KEGG pathways associated with the differentially expressed genes were identified. 
The analysis was performed separately for all differentially expressed genes and the 
up and down regulated gene groups alone (Appendix M). 
Gene ontology analysis of the core subset of candidate genes (all differentially 
expressed) revealed that 21 GO biological processes were significantly enriched 
(Bayes factor >6). Over-representation of the gene ontology groups included cell 
proliferation, cell cycle, M phase, DNA replication and chromosome cycle, nuclear 
division, organogenesis and morphogenesis (Table 4.5).  
Interestingly, the top GO process were formed with the down regulated differentially 
expressed gene group after VPA exposure was cell proliferation with an exceptionally 
high Bayes factor of 75 (Appendix M). This was closely followed by M phase, DNA 
replication and chromosome cycle, DNA metabolism mitotic cell cycle and nuclear 
division (Appendix M). Other interesting GO analyses revealed from the down 
regulated differentially expressed gene group after VPA treatment were DNA damage 
stimulus, DNA repair, DNA recombination, spindle organisation and biogenesis, 
DNA packaging, G2/M transition of mitotic cell cycle, response to external stimulus 
and establishment and/or maintenance of chromatin architecture (Appendix M).  
The top GO processes formed from the up regulated differentially expressed gene 
group after VPA exposure were cell communication, organogenesis, organ 
development, morphogenesis and transcription (Appendix M). Other interesting GO 
analyses shown from the up regulated differentially expressed gene group after VPA 











Cell proliferation 167 25 
Cell cycle 123 22 
M phase 44 16 
M phase of mitotic cell cycle 36 15 
Mitosis 35 14 
Mitotic cell cycle 45 13 
DNA replication and chromosome cycle 43 13 
Nuclear division 40 13 
Regulation of cell cycle 70 11 
Organogenesis 129 10 
Organ development 129 10 
DNA replication 34 10 
Morphogenesis 150 8 
Protein biosynthesis 20 7 
Transcription 126 6 
DNA metabolism 80 6 
Macromolecule biosynthesis 25 6 
Regulation of transcription 120 6 
Regulation of transcription, DNA-dependent 115 6 
Cell-cell signalling 79 6 
Transcription, DNA-dependent 120 6 
Table 4.5. Gene ontology results analysis using GATHER. 
Genes were chosen from the RNA sequencing results using significance criteria.  
All Gene Ontology results have a p-value of <0.001.  
KEGG pathway analysis showed the cell cycle (with a Bayes factor of 10) was the 
only high level systemic function affected by VPA in MCF10a cells when examining 
all the differentially expressed genes (Table 4.6). When the KEGG pathway was used 
to examine the up regulated group of differentially expressed genes after VPA 
treatment, analysis showed involvement in the extracellular matrix-receptor 
(Appendix M). Whereas KEGG analysis of the down regulated group of differentially 
expressed genes after VPA showed involvement in the cell cycle and pyrimidine 
metabolism (Appendix M). 









 Cell cycle 30 10 
Table 4.6. Kyoto encyclopaedia of genes and genomes (KEGG) analysis on 
1889 differentially expressed genes.  
KEGG analysis was performed using GATHER (Chang and Nevins 2006). Genes 
were chosen from the RNA sequencing results using the significance criteria. The 
KEGG result has a p-value of <0.001.  
4.1.6 Epithelial mesenchymal transition biomarkers 
It was hypothesised that E-cadherin methylation in HDGC individuals increases the 
likelihood of the epithelial mesenchymal transition (EMT) occurring in pre-malignant 
cells. An EMT is thought to promote HDGC invasion (Humar, Fukuzawa et al. 2007), 
evidence that VPA decreased the likelihood of an EMT would support its use in 
HDGC chemoprevention.  
After VPA exposure, E-cadherin was up regulated 1.23 fold (significant adj. p-
value=3.86E-03, but not log odds=-1.236); this was comparable to the qPCR result of 
1.75 fold (Figure 3.1). However, the tight junction gene marker (TJP1), a negative 
EMT marker, had undergone no change, while a cytoskeletal marker ANLN, a positive 
EMT marker, had been significantly down regulated (Table 4.7). There was up-
regulation of a number of positive EMT markers including: cell surface markers (N-
cadherin (CDH2), ITGB6 and SPOCK1), cytoskeletal marker (S100A4), ECM 
markers (Fibronectin (FN1) and collagen type 1/3 alpha 1 (COL1A1)) and 
transcription factors (TP53 and SPARC) (Table 4.7). 
This evidence suggests that VPA does not strongly inhibit the EMT, although a firm 

















Cell surface proteins   
CDH1 Down 1.23 6.59 3.86E-03 -1.24 
(Thiery, Acloque et al. 2009, Tomaskovic-Crook, 
Thompson et al. 2009, Zeisberg and Neilson 2009) 
TJP1 Down 0.66 7.14 Ns -8.2 
 (Thiery, Acloque et al. 2009, Tomaskovic-Crook, 
Thompson et al. 2009, Zeisberg and Neilson 2009) 
KRT8 Down 1.91 8.52 8.68E-06 7.94  (Tomaskovic-Crook, Thompson et al. 2009) 
KRT18 Down 1.13 8.6 9.95E-03 -2.6  (Tomaskovic-Crook, Thompson et al. 2009) 
KRT19 Down 1.33 -1.23 Ns -6.01  (Tomaskovic-Crook, Thompson et al. 2009) 
OCLN Down 0.85 5.19 2.99E-02 -3.38  (Tomaskovic-Crook, Thompson et al. 2009) 
DSP Down 0.65 9.64 1.90E-02 -3.59  (Tomaskovic-Crook, Thompson et al. 2009) 
CDH2* Up 2.32 4.43 8.09E-06 8.5 
 (Tomaskovic-Crook, Thompson et al. 2009, 
Zeisberg and Neilson 2009) 
ITGA5 Up 1.98 7.81 3.87E-06 9.86  (Zeisberg and Neilson 2009) 
ITGB1 Up 1.39 10.07 3.65E-05 5.1  (Zeisberg and Neilson 2009) 
ITGB6* Up 2.16 6.14 2.26E-05 6.48  (Zeisberg and Neilson 2009) 
MUC1 Up 0.68 7.53 9.88E-05 3.98  (Kufe 2009) 
SPOCK1*  Up 3.87 4.86 1.24E-06 12.71 
 (Gröger, Grubinger et al. 2012, Miao, Wang et al. 
2013) 
Cytoskeletal markers           
ANLN* Up 0.32 8.35 3.38E-06 10.25  (Tomaskovic-Crook, Thompson et al. 2009) 
CTNNB1 Up 0.95 8.22 Ns -5.67 
 (Thiery, Acloque et al. 2009, Zeisberg and Neilson 
2009, Sánchez-Tilló, de Barrios et al. 2011) 
S100A4* Up 2.42 6.54 1.28E-05 7.4 
 (Thiery, Acloque et al. 2009, Tomaskovic-Crook, 
Thompson et al. 2009) 
VIM Up 1.14 9.27 4.41E-03 -1.66 
 (Thiery, Acloque et al. 2009, Tomaskovic-Crook, 
Thompson et al. 2009, Zeisberg and Neilson 2009) 
Extracellular matrix proteins  
COL1A1* Up 4.54 3.94 1.60E-05 7.32  (Zeisberg and Neilson 2009) 
COL3A1 Up 2.21 -4.38 Ns -3.71  (Zeisberg and Neilson 2009) 
FN1* Up 5.49 8.15 8.61E-06 7.85  (Yang, Zhang et al. 2007) 
Transcription factors   
 
      
TP53* Down 0.38 6.27 2.34E-06 11.34  (Chang, Chao et al. 2011) 
ETS1 Up 1.36 6.06 Ns -2.78  (Tomaskovic-Crook, Thompson et al. 2009) 
FOXC1 Up 0.72 4.96 2.34E-03 -0.07  (Tomaskovic-Crook, Thompson et al. 2009) 
FOXC2 Up 1.27 3.25 4.29E-03 -0.58 
 (Tomaskovic-Crook, Thompson et al. 2009, 
Zeisberg and Neilson 2009, Dave, Mittal et al. 
2012) 
LEF1 Up 0.97 1.43 Ns -7.1 
 (Zeisberg and Neilson 2009, Dave, Mittal et al. 
2012) 
SNAI1 Up 1.84 0.75 5.82E-03 -0.43 
  (Thiery, Acloque et al. 2009, Tomaskovic-Crook, 
Thompson et al. 2009, Zeisberg and Neilson 2009, 
Dave, Mittal et al. 2012) 
SNAI2 Up 1.76 6.48 1.69E-05 6.93 
 (Thiery, Acloque et al. 2009, Tomaskovic-Crook, 
Thompson et al. 2009, Zeisberg and Neilson 2009, 
Dave, Mittal et al. 2012) 
SRC Up 0.79 5.79 8.53E-03 -1.98  (Galliher and Schiemann 2006) 
SPARC* Up 2.56 5.3 4.45E-06 9.7  (Tomaskovic-Crook, Thompson et al. 2009) 
TCF3 Up 0.66 7.14 9.78E-06 7.89  (Tomaskovic-Crook, Thompson et al. 2009) 
TCF4 Up 1.21 4.24 Ns -6.15  (Sánchez-Tilló, de Barrios et al. 2011) 
TWIST1 Up 0.82 3.82 6.37E-02 -4.12 
 (Thiery, Acloque et al. 2009, Tomaskovic-Crook, 
Thompson et al. 2009, Zeisberg and Neilson 2009, 
Dave, Mittal et al. 2012) 
TWIST2 Up 0.78 3.41 4.46E-02 -3.57 
 (Thiery, Acloque et al. 2009, Tomaskovic-Crook, 
Thompson et al. 2009, Zeisberg and Neilson 2009, 
Dave, Mittal et al. 2012) 
ZEB1 Up 1.64 2.92 1.44E-03 0.91 
 (Tomaskovic-Crook, Thompson et al. 2009, 
Zeisberg and Neilson 2009, Sánchez-Tilló, de 
Barrios et al. 2011, Dave, Mittal et al. 2012) 
ZEB2 Up 0.79 3.16 1.16E-02 -2.03 
 (Tomaskovic-Crook, Thompson et al. 2009, 
Zeisberg and Neilson 2009, Dave, Mittal et al. 
2012) 
Table 4.7. Epithelial mesenchymal transitional biomarkers. 
Genes associated with EMT were examined from the RNA-Seq experiment data. 
Gene names with * meet the significance criteria. The significant criteria was  




4.1.7 MCF10a methylome analysis after 24 hour VPA treatment  
To investigate whether VPA had an effect on global DNA methylation a methyl array 
was performed with MCF10a cells after a 24 hour VPA treatment similar to the 
conditions of the RNA-Seq cell experiment. 
Methylation assessment is based on highly multiplexed genotyping of bisulfite-
converted genomic DNA. The bisulfite conversion results in unmethylated cytosines 
being converted to uracil, while methylated cytosines remain unchanged. This 
differentially converted DNA is interrogated simultaneously at each locus using 
fluorescently labelled probes designed to either the methylated or unmethylated site. 
Consequently, VPA treatment was investigated to assess whether or not it was 
associated with specific methylation changes. VPA is hypothesised to increase the 
expression of multiple genes, including CDH1 through passive de-methylation of the 
promoter CpG islands and by more direct effects on histone acetylation.  
In this experiment two biological replicates were performed on independent days each 
with three replicates that were then pooled. Genomic DNA was quantified with the 
Nanodrop and then underwent bisulfite conversion in preparation for the methyl array 
assay. Experiments 1 and 2 were performed with MCF10a cells at passage 5 and 6 
respectively with and without VPA exposure for 24 hours. From these results bisulfite 
converted gDNA of >30 ng/µL was used for methylome profiling to ensure 
reproducibility (Appendix M).  
The bisulfite converted gDNA samples underwent the Illumina Infinium 
HumanMethylation450 (450K) BeadChip (Illumina Inc., USA) array assay procedure. 
The BeadChip was initiated in the lab and continued at AgResearch for hybridisation 
from Day 3. The BeadChip was washed, stained and then imaged on a HiScan system 
(Illumina, USA).  
Differential methylation was assessed using β-values as calculated from the collection 
of probes at its specific location; CpG Island, N. shore, S. shore, gene body sites or 
transcription start site. The β-values are continuous variables between 0 and 1, 
representing the ratio of the intensity of the methylated bead type to the combined 
locus intensity. The β-values between the VPA treated and untreated MCF10a cells 




Hochberg adjusted p-values >0.05 determined by the Wilcoxon rank test were 
excluded and gene average β-values where then ranked.  
4.1.7.1 Methylation analysis  
The average methylation β-values of these genes were investigated to gauge the level 
of biological significance. Interestingly, the genes identified from the Wilcoxon test 
only had minimal changes in methylation (Appendix N). A minimum threshold of 
methylation changes is usually set at β-value average of ±0.2 (Cahill, Bergh et al. 
2012). The β-value gained in this experiment was a tenth smaller (at ±0.01-0.4). At 
this low β-value range there were 321 significant differentially methylated associated 
genes that were situated in the gene bodies. The highest β-value difference was 
observed in the gene body of GNAQ (β-value=+0.0353) with ‘hypomethylation’ 
occurring after VPA exposure (Appendix N).  
It was explored in the methyl array data whether β-values in the highest range of 0.02-
0.04 had an association with gene expression; this was identified by the RNA-Seq 
data. However, methylation occurring in gene bodies is known to have a unique effect 
on gene expression. In the literature, the relationship between gene-body methylation 
and expression is bell-shaped, meaning mid-level expressed genes have the highest 
levels of gene-body methylation (Jjingo, Conley et al. 2012). Forty-eight genes were 
identified in this range and their individual gene expression was scrutinised by the 
RNA-Seq filtering significant criteria; only four genes had an increase in expression. 
These genes were BICC1 (negative regulator of WNT pathway), CAMK4 
(calcium/calmodulin-dependent protein kinase), FAM190A (cell division regulator) 
and PAD14 (peptidyl arginine deiminase) with FC 4.25, 36.75, 3.82 and 11.17 
respectively (Appendix N). However, these results are perhaps unreliable due to the 
low β-value (<0.02) gathered after VPA treatment. Overall, these data strongly 
suggests that VPA does not demethylate gene promoters in MCF10a cells. 
4.2 Discussion 
4.2.1 Cellular impact of VPA exposure on MCF10a cell line 
Understanding the function of genes differentially expressed after VPA exposure will 




Generally, VPA exposure has an effect on cell proliferation, cell cycle and organ 
development.  
The up regulation of developmental genes was expected as VPA is recommended not 
to be administered to pregnant women as a consequence of its toxic effects on the 
developing foetus (DiLiberti, Farndon et al. 1984). In total, 56 genes involved in 
neurogenesis pathways were increased after VPA treatment, this effect had been 
reported in vitro studies with mice (Laeng, Pitts et al. 2004, Liu, Chopp et al. 2012). 
VPA antitumor effects of reducing cell proliferation and cell cycle has also been 
described, previously (Strey, Schamell et al. 2011).  
The imprinted gene CPA4 identified to be the most significant with positive fold 
change had been previously shown to be up regulated by the HDACi sodium butyrate 
and be involved in histone hyper-acetylation (Huang, Reed et al. 1999). The most 
significant negative fold change in expression was observed with the PLK1 gene, and 
commonly associated BIRC5 gene was also significantly reduced in expression 
(FC=0.36, adj. p-value=1.24E-06, log odds=12.74). These two genes when over 
expressed have been previously shown to contribute to the formation of misaligned 
chromosomes and defective spindles that lead to interfering with G2/M transition in 
mitosis (Noh, Lim et al. 2009, Wissing, Mendonca et al. 2013).  
This analysis has provided some support for the use of VPA in HDGC 
chemoprevention. It confirmed the increased expression of CDH1 and the reduced 
proliferation capability after VPA treatment in vitro. Rajendran, Ho et al. (2011) 
described how normal cells circumvent VPA effects by checkpoint activation leading 
to cell cycle arrest and effective DNA repair (Rajendran, Ho et al. 2011). In MCF10a 
cells after VPA treatment, GO analysis results exhibited reduced cell proliferation and 
cell cycle. Whereas cancer cells, known to be defective in some of these mechanisms 
for example check point kinases and repair genes, failed to repair the DNA damage 
which led to cell death by apoptosis (Rajendran, Ho et al. 2011). After VPA exposure, 
a reduction in DNA repair gene expression from the RNA-Seq data set was observed 
in MCF10a cells examined by the GO analysis. These results are similar to the 
expected response of transformed cells, however no apoptosis was visually observed 




HDACi are known to cause DNA strand breaks through chromatin remodelling. The 
CPA4 gene being most significantly up regulated supported VPA effect on chromatin 
remodelling and additionally so did the GO functional group analyses which 
identified down-regulation of DNA packaging and establishment and/or maintenance 
of chromosome (Table 4.5). VPA relaxes heterochromatin (condensed DNA) to 
euchromatin that may be a consequence of hyperacetylation, which facilitates 
chromatin remodelling. This was indicated by the increase in transcription, which was 
observed in the gene ontology results (Table 4.5), and also by the 4.3% increase of 
gene expression (RNA-Seq data after meeting the significant criteria).  
RNA-Seq GO analysis results imply that cell cycle, specifically at M phase was 
decreased. The M phase is usually the spindle assembly checkpoint, to check for 
chromosome attachment to spindles. Unsurprisingly, the GO analysis also identified 
spindle organisation and biogenesis gene groups as reduced along with other factors 
associated with the cell cycle such as DNA replication and chromosome cycle, DNA 
metabolism, mitotic cell cycle and nuclear division. Furthermore, as the cell cycle was 
inhibited by VPA, perhaps it was foreseeable that cell proliferation was reduced. VPA 
effect may be cell line specific to the MCF10a cells at sub-culture.  
The VPA effect may be more amplified with cells increasing in carcinogenic 
potential. Only MCF10a cells expressing oncogenic Ras have resulted in apoptotic 
effects after VPA treatment from increasing DNA damage response (DDR) signalling 
(Di Micco, Sulli et al. 2011). Moreover, if MCF10a cells were tumorigenic they could 
yield more striking antitumor effects after VPA treatment such as an increase of 
tumor suppressor gene expression demonstrating its chemopreventive potential. 
However as stated VPA did have some antitumor affects in MCF10a cells, this could 
be perhaps attributed to being an immortal cell line. 
The inhibition of cell proliferation and decrease in DNA repair gene expression from 
VPA treatment could be a mechanism exploited in MC10a cells with increasing 
carcinogenic potential. For example, VPA used in synergy with another drug could 
create vulnerabilities in cells with a higher tumorigenic potential. This has been 
identified previously with chromatin decondensation and increased DNA damage 
after pre-treatment with VPA for 48 hours that sensitised cells to death induced by the 
topoisomerase II inhibitor epirubicin in a mouse model implanted with breast cancer 




4.2.2 MCF10a had no methylation changes after VPA exposure of 24 hours  
A 450K Illumina methyl array on MCF10a cells exposed to VPA found no significant 
average β-value changes that were in the commonly reported reproducible range of 
>0.2 in the methylation of CpG sites tested. This was interesting as a reduction in 
gene expression regulating passive methylation (DNMT1 and SMYD2) were identified 
in the transcriptome analysis. Reduced stability of DNMT1 has been identified 
previously as a chemopreventive mechanism with VPA in reducing smoke induced 
lung carcinoma (Brodie, Li et al. 2014). Here, observations contrast with published 
data with neuroblastoma, NBL-W-N and LA1-55n cell lines which suggested VPA 
can induce de-methylation in tumor suppressor genes and reduce overall methylation 
levels (Gu, Tian et al. 2012). One explanation for this discrepancy may be that 
MCF10a cells doubling time of 22 hours and a 24 hour VPA treatment time may be 
not enough for passive methylation to occur. Therefore a longer time period of VPA 
exposure could have an effect on methylation. This indicates gene expression changes 
identified in the RNA-Seq data were not caused by methylation changes but instead 
caused by other mechanisms. The lack of methylation changes does not indicate that 
gene expression changes detected by RNA-Seq are not sustainable changes. This 
would need to be investigated further by assessing MCF10a cells methylation changes 
after a longer exposure from VPA treatment such as 48-72 hours.  
4.2.3 Epithelial mesenchymal transition was not inhibited 
VPA treatment was hypothesised to have the ability to inhibit EMT in MCF10a cells. 
In this study, biomarkers were used to identify the occurrence of an inhibitory effect 
on EMT after VPA treatment. The expression profiles of the majority of EMT 
biomarkers were not consistent with the inhibition of an EMT. MCF10a sub-culture 
has previously been shown to be an EMT model (Xie, Law et al. 2003, Yang, Mani et 
al. 2004, Bindels, Mestdagt et al. 2006, Lombaerts, Van Wezel et al. 2006). Further 
investigation to characterise VPA by conducting an invasion or migration assay with 





Transcriptome sequencing of the MCF10a cell line post VPA treatment has provided 
an insight into VPA-induced gene expression changes in a relatively normal genetic 
background.  
These results demonstrate that VPA causes transcriptional changes that reduce 
proliferation by controlling cell cycle progression. It was hypothesised VPAs negative 
effect on cell cycle progression because this was only measured by RNA-Seq with 
one biological replicate. For future work MCF10a cells with and with-out VPA 
treatment could have their cell cycle progression and specifically down regulation of 
G2/M phases confirmed by flow cytometry using DNA staining dyes such as 
propidium iodide.  
No de-methylation occurred after a 24 hour VPA treatment in MCF10a cells as no 
average β-values were concluded as significantly different (threshold >0.2). The 
limitation of this experiment was that this was measured by only one biological 
replicate in the methyl array. In a future experiment VPA time exposure could be 





Chapter 5: Analysis of in vivo models of 
VPA action  
Work described in previous chapters has shown that VPA can increase the expression 
of the CDH1 gene in the non-tumorigenic cell line MCF10a. In this chapter, it has 
been explored whether CDH1 expression is increased in the blood and buccal cells of 
patients receiving VPA for neurological disease.  
 
5.1 Results 
Eleven patients treated with epilepsy and migraines from the Dunedin hospital gave 
buccal and blood samples prior to and after VPA treatment. Varying amounts of time 
elapsed between the pre and post VPA treatments samples ranging from 3-266 days. 
Of the patients recruited the average age was 51.5 years (range, 17-75 years), with 
samples taken on average 74 days into VPA treatment and 82% being male (Table 
5.2).  
Quantification of DNA and RNA was performed using either a spectrophotometer 
(Nanodrop) or picogreen fluorescence assays (Qubit) (refer to methods section 
2.2.18). Whole blood sample qPCR amplifications were performed using 25 ng of 
total RNA, while buccal samples amplifications were used undiluted due to the 
limited RNA concentration. Although buccal RNA was successfully extracted, it was 
of consistently poor quality as determined by Qubit/Nanodrop (data not shown). 
Because of the low expression of CDH1 in blood, markers of VPAs effect on gene 
transcription were identified, which could be used as surrogates for an increase in 
CDH1. Surrogate markers were required to ensure VPA is being administered at a 
level that impacts gene expression using the RNA-Seq data (Chapter 4). VPA 
sensitive genes were selected to determine if they had value as markers of VPA intake 
in samples of whole blood and buccal cells from patients being treated for epilepsy or 
migraines. Tissue-specific Gene Expression and Regulation (TiGER), an online 
database containing tissue-specific gene expression profiles or expressed sequence tag 




were used to test potential surrogate markers suitability in the buccal and whole blood 
samples gathered (Liu, Yu et al. 2008). Two cell adhesion genes were chosen as 
potential biomarkers of VPA exposure. ADAM23 was highly up regulated while 
TGM2 was highly statistically significant (Table 5.1). TGM2 was especially 













(Liu, Yu et al. 
2008) 
ADAM23 14.48 0.00 2.46E-04 3.61 High 
TGM2 7.95 4.84 6.16E-07 15.30 Low 
Table 5.1. Surrogate VPA markers.  
Genes assessed as being viable candidates from the RNA-Seq data of MCF10a 
cells treated with VPA. 
QPCR was used to assess E-cadherin expression in patients' buccal and whole blood 
samples following VPA exposure. Surrogate gene markers that were chosen from the 
transcriptome data, ADAM23 and TGM2, were assessed by qPCR in whole blood 
RNA following VPA exposure. Both genes were assessed for their expression profile 
in blood by TiGER (Liu, Yu et al. 2008); ADAM23 was predicted to have a high 
expression in blood while TGM2 was predicted to have a low expression, however, 
TGM2 expression had a very high significance (both adjusted p-value and log odds 
values) after VPA treatment in the MCF10a transcriptome data analysis. 
Patients’ quantitative PCR results met the criteria set in section 2.2.11.1 of ≤0.5 
standard deviation of Cts within sample replicates, Ct values between 15-35 and R
2  
≤0.98 (data not shown). The efficiency calculations overall and individual effiencies 
also meet the standards set in section 2.2.11.1 when using the LinReg method to 






Table 5.2. Patient clinical data.  
Patient details of RNA samples. RNA concentrations from each sample before 
treatment and post treatment measured with Nanodrop (buccal sample) and Qubit 
(whole blood samples) in a total volume of 15 μl. Note patient 2a and 2b is the 
same patient, with VPA dose increasing to 800 mg from 400 mg after 87 days.   
A simple graph showing patient number vs. normalised fold change (FC) of gene 
expression was used to display the patient gene expression (Table 5.3, Figure 5.1A, 
Figure 5.2A, and Figure 5.3A). A non-compartmental analysis was included in this 
work for assessing how gender, VPA dosage over varying durations (days) affected 
gene expression (Table 5.3, Figure 5.1B, Figure 5.2B, Figure 5.3B). 
The non-compartmental analysis included an estimation of area under plasma 
concentration time curve (AUC) being calculated by the linear trapezoidal rule. AUC 
total was calculated from t0 to t24 hours (AUC0-24), multiplied by number of days 
patient received specified VPA dosage plus extrapolation to infinity (AUC24-∞), refer 
to Equation 5.1. AUC24-∞ calculation used elimination rate constant obtained from the 
Iberra et al. study that had obtained the value by log linear regression of post-12 h 
data from patients given VPA once over a 48 hours’ time period (Ibarra, Vázquez et 
al. 2013).  
 
Equation 5.1. Total plasma concentration under the curve. 
To estimate a total plasma concentration area under the curve (AUC) calculation, the 














1 F 61 400 3 19 12 54 49
2a F 42 400 87 8 7 10 20
2b F 42 800 32 8 3 10 182
3 F ? 400 77 14 9 58 152
4 M 73 800 60 9 53 179 160
5 M 23 800 39 4 3 47 182
6 M 51 400 25 145 64 49 48
7 M 57 800 60 9 5 40 38
8 M 17 800 88 9 35 5 56
9 M 24 800 44 8 4 101 53
10 M 70 400 266 18 35 27 47












to Equation 5.2. Volume of distribution and elimination rate constant from the Ibarra 
et al. study using the non-compartmental values specific to gender (with average 
gender body weights; 59 kg female and 79 kg male) values used in Equation 5.2. VPA 
half-life assumption of 12.0 hours was used which was a median value attained from 
literature (Chateauvieux, Morceau et al. 2010).  
𝐶 =  (
𝐷𝑜𝑠𝑒
𝑉
 ) 𝑒−𝑘𝑡  
Equation 5.2. The plasma concentration calculation to quantify VPA at a 
specific time point.  
Assumptions made in calculating total AUC did not detract from the main aim of 
estimating overall exposure to VPA for each patient. The following parameters were 
not accounted for; VPA residual from the previous days medication was not 
incorporated, neither at time point 0 the initial bioavailability of VPA was 100% 
bioavailable, instead patients receiving VPA orally would have experienced a lag 
period of peak absorption (distribution phase) approximately 2 hours after intake 






Table 5.3. Patient data showing VPA (g/day/L) and normalised fold changes (Pffafl analysis) for the respective gene expression; 
CDH1, TGM2 and ADAM23 in buccal and whole blood tissues.  
Note patient 2a and 2b is the same patient, with VPA dose increasing to 800 mg from 400 mg after 87 days.   
 
 
CDH1 T.test CDH1 T.test TGM2 T.test ADAM23 T.test
1 1 1.0 7.68E-01 1.0 8.70E-01 1.0 7.06E-01 1.9 1.79E-02
2a 41 2.7 1.90E-01 1.1 5.93E-01 0.6 5.78E-03 2.1 9.40E-03
2b 72 3.3 7.17E-03 1.0 7.97E-01 0.3 1.79E-02 0.5 1.07E-02
3 37 1.6 4.72E-04 1.5 2.27E-01 1.1 7.06E-01
4 44 0.5 3.29E-02
5 28 1.2 3.87E-01 0.4 6.20E-03 1.1 1.81E-01
6 9 0.5 2.24E-02 0.7 3.11E-02 0.7 2.37E-02 1.1 4.15E-01
7 44 0.7 1.16E-02 0.8 5.90E-01 0.6 1.30E-04
8 64 0.5 1.17E-02 0.8 2.65E-01 0.5 8.40E-04 0.5 7.72E-02
9 32 2.0 1.38E-02 2.2 1.88E-02 0.8 1.25E-01
10 97 0.6 6.60E-03 1.0 1.69E-01






5.1.1 Expression analysis of CDH1 in patients 
A one-way ANOVA followed by Bonferroni correction post threshold was conducted 
to evaluate whether VPA had a reliable effect on CDH1 expression in the patient 
population. The buccal samples results indicated no significant difference in the 
scores for VPA effect on CDH1 expression in the overall population (FC=1.61, 
SEM=0.58), compared to untreated (FC=1.04, SEM=0.04) conditions; p=0.39 (Figure 
5.2). Additionally, no significant difference occurred in whole blood samples in the 
scores for VPA effect on CDH1 expression in the overall population examined 
(FC=1.08, SEM 0.1346) compared to untreated (FC=1.00, SEM=0.01) conditions; 
p=0.58 (Figure 5.2). 
Buccal tissue 
A paired sample t-test was conducted to evaluate whether VPA had a reliable effect 
on CDH1 expression comparing individual patients. Specifically, in individuals there 
was one significant increase and two significant decreases in the fold changes for 
VPA, patient 2b, patient 6 and patient 8 respectively when compared to untreated 
(Figure 5.2 and Table 5.4). No trend was detectable between overall VPA exposure 
and CDH1 response in buccal tissue sample (Figure 5.2).  
The buccal samples may have been of too poor quality and low quantity to be 
accurately measured in qPCR. This in indicated by the inability to measure RNA 
concentration via Qubit and the inconsistent qPCR data gathered for the reference 
genes in comparison to the high quality lab control RNA that made up the positive 
control standard curve had low Ct variation. Reference genes as explained in section 






Table 5.4. Patient CDH1 gene response after VPA treatment.  
Significance tested VPA effect by paired t-test followed by Bonferroni correction 
post threshold (Significant threshold, p<0.05). Note patient 2a and 2b is the same 
patient, with VPA dose increasing to 800 mg from 400 mg after 87 days.   
 
  
Before VPA- FC Before VPA-SEM After VPA- FC After VPA-SEM T.test
Patient 1 1.18 0.44 1.02 0.23 7.68E-01
Patient 2a 1.00 0.02 2.67 0.99 1.90E-01
Patient 2b 1.00 0.02 3.34 0.36 7.17E-03
Patient 6 1.00 0.04 0.49 0.13 2.24E-02
Patient 8 1.00 0.07 0.51 0.11 1.17E-02
Patient 1 0.99 0.01 1.00 0.08 8.70E-01
Patient 2a 1.01 0.10 1.10 0.13 5.93E-01
Patient 2b 1.01 0.10 0.97 0.23 7.97E-01
Patient 3 0.98 0.05 1.56 0.02 4.72E-04
Patient 5 0.98 0.01 1.20 0.22 3.87E-01
Patient 6 0.98 0.02 0.71 0.07 3.11E-02
Patient 7 0.97 0.05 0.71 0.06 1.16E-02
Patient 8 1.08 0.22 0.77 0.06 2.65E-01
Patient 9 1.01 0.12 2.01 0.19 1.38E-02










    VPA (g/day/L) 
Figure 5.1. CDH1 gene expression taken from patients’ buccal tissue after 
VPA treatment.  
(A) Individual patients CDH1 expression was measured after VPA treatment. (B) 
Overall VPA quantity and exposure was compared to CDH1 expression. Fold 
changes were calculated using the Pfaffl equation and Linreg method for 
efficiencies. Results show CDH1 average ±SEM of qPCR in duplicate. Two-tailed 
paired sample t-test (*=p<0.05) measured significant difference. Overall VPA 
quantity and exposure was calculated using the trapezoidal rule for plasma 
concentration under a time-curve. Patients 3, 4, 5, 7, 9, 10 and 11 were excluded 
from analysis as, for unknown reasons the qPCR failed and could not be repeated 
due to the limited samples available. Note patient 2a and 2b is the same patient, 


































































Whole blood tissue 
A paired sample t-test was conducted on duplicate qPCR reactions to evaluate 
whether VPA had a reliable effect on CDH1 expression comparing individual patients 
in whole blood tissue. Specifically, there were two significant increases in the CDH1 
fold changes after VPA treatment; patient 3, patient 9 compared to untreated. 
However, there were three individuals with a significant decrease in the FC for VPA, 
patient 6, patient 7 and patient 11 compared to untreated (Figure 5.2 and Table 5.4). 
Patients treated with 32 and 37 g/day/L of VPA had the only significant CDH1 gene 
expression over 1.60, outside <32 and >37 g/day/L CDH1 expression did not have an 
additive effect Figure 5.2. 
CDH1 expression was undetectable in patients 4 and 10 either before or after VPA 
treatment. RNA initial concentrations measured by Qubit were adequate, however, the 










    VPA (g/day/L) 
Figure 5.2. CDH1 gene expression taken from patients’ whole blood after VPA 
treatment.  
(A) Individual patients CDH1 expression was measured after VPA treatment. (B) 
Overall VPA quantity and exposure was compared to CDH1 expression. Fold 
change were calculated using the Pfaffl equation and Linreg method for 
efficiencies. Results show CDH1 average ±SEM of qPCR in duplicate. Two-tailed 
paired sample t-test (*=p<0.05) measured significant difference. Overall VPA 
quantity and exposure was calculated using the trapezoidal rule for plasma 
concentration under a time-curve. Patients 4 and 10 were excluded from analysis 
as, for unknown reasons the qPCR failed and could not be repeated due to the 
limited samples available. Note patient 2a and 2b is the same patient, with VPA 






























5.1.2 Expression analysis of TGM2 in patients 
VPA effect on TGM2 expression in the patient population was tested for 
reproducibility by a one-way ANOVA followed by Bonferroni correction post 
threshold. The results indicated no significant difference in the scores for VPA effect 
on TGM2 expression in the overall population (FC=0.79, SEM=0.16), compared to 
untreated (FC=1.01, SEM=2.26E-03) conditions; p=0.20 (Figure 5.3).  
TGM2 gene expression was highly significantly increased after VPA treatment in 
MCF10a cells transcriptome data, in the patients however, only one patient’s TGM2 
levels was significantly increased (patient 9) and 7 of the 11 were significantly 
decreased (patient 2a, 2b, 4, 5, 6, 8, 10 and 11) (Figure 5.3). The highest increase in 
patient 9 and highest decrease in patient 2b of TGM2 expression after VPA treatment 
had no identifiable causative descriptive characteristics between them. Patient 2b was 
a 42-year-old female, who was treated with 400 mg VPA for 87 days, then 800 mg for 
the next 32 days. Whereas patient 9 was a 24-year-old male treated with 800 mg VPA 
for 44 days. Patients treated with 32 and 37 g./day/L of VPA had the only significant 
increase in TGM2 gene expression over 1.40, <32 and >37 g/day/L (Figure 5.3), the 
same observation was observed in whole blood CDH1 expression, refer to Figure 5.2. 
 
Table 5.5. Patient TGM2 gene response after VPA conditions.  
Significance tested effect by paired t-test followed by Bonferroni correction post 
threshold (Significant=p<0.05). Note patient 2a and 2b is the same patient, with 
VPA dose increasing to 800 mg from 400 mg after 87 days.   
  
Before VPA-FC Before VPA- SEM After VPA-FC After VPA- SEM T.test
Patient 1 1.00 0.05 1.05 0.11 7.06E-01
Patient 2a 1.00 0.03 0.56 0.07 5.78E-03
Patient 2b 1.00 0.03 0.26 0.04 1.79E-02
Patient 3 1.02 0.03 1.47 0.30 2.27E-01
Patient 4 1.01 0.11 0.52 0.12 3.29E-02
Patient 5 1.01 0.10 0.36 0.03 6.20E-03
Patient 6 1.00 0.09 0.67 0.05 2.37E-02
Patient 7 1.03 0.10 0.82 0.34 5.90E-01
Patient 8 1.00 0.02 0.50 0.05 8.40E-04
Patient 9 1.00 0.05 2.22 0.27 1.88E-02
Patient 10 1.00 0.07 0.62 0.05 6.60E-03








    VPA (g/day/L) 
Figure 5.3. TGM2 gene expression taken from patients’ whole blood after 
VPA treatment.  
(A) Individual patients TGM2 expression was measured after VPA treatment. (B) 
Overall VPA quantity and exposure was compared to TGM2 expression. Fold 
changes were calculated using the Pfaffl equation and Linreg method for 
efficiencies. Results show TGM2 average ±SEM of qPCR in duplicate. Two-tailed 
paired sample t-test (*=p<0.05) measured significant difference. Overall VPA 
quantity and exposure was calculated using the trapezoidal rule for plasma 
concentration under a time-curve. Note patient 2a and 2b is the same patient, with 
VPA dose increasing to 800 mg from 400 mg after 87 days.   
These results suggest that VPA had an unpredictable effect on TGM2 expression in 
whole blood. TiGER predicted this gene to be expressed at a low level in whole blood 


























































































































5.1.3 Expression analysis of ADAM23 in patients 
VPA effect on ADAM23 expression was evaluated in the patient population overall by 
a one-way ANOVA followed by Bonferroni correction post threshold. The results 
indicated no significant difference in the scores for VPA effect on ADAM23 
expression in the overall population (FC=1.02, SEM=0.16), compared to untreated 
(FC=1.00, SEM=9.79-E03) conditions; p=0.90 (Figure 5.4).  
VPA had a significant effect on ADAM23 expression in individual patients when 
determined by a paired sample t-test. The potential surrogate ADAM23 gene was 
predicted to be greatly increased following VPA treatment based upon results from 
MCF10a cells transcriptome data whereas here, 2 of the 11 patients’ ADAM23 levels 
were increased (patient 1 and 2a) with 3 patients decreased (patient 2b, 7 and 10) after 
qPCR analysis (Figure 5.4 and Table 5.6). Interestingly, patient 2 ADAM23 fold 
changes were additive after 87 days of 400 mg VPA, but this became inhibitory when 
VPA was increased to 800 mg for a further 32 days. Overall VPA exposure had an 
unidentifiable effect on ADAM23 expression in whole blood tissue (Figure 5.4). 
 
Table 5.6. Patient ADAM23 gene response after VPA conditions.  
Significance tested effect by paired t-test followed by Bonferroni correction post 
threshold (Significant threshold, p<0.05). Note patient 2a and 2b is the same 
patient, with VPA dose increasing to 800 mg from 400 mg after 87 days.   
  
Before VPA- FC Before VPA-SEM After VPA- FC After VPA-SEMT.test
Patient 1 0.99 0.01 1.85 0.19 1.79E-02
Patient 2a 1.01 0.10 2.07 0.21 9.40E-03
Patient 2b 1.01 0.10 0.55 0.09 1.07E-02
Patient 3 1.03 0.16 1.10 0.06 7.06E-01
Patient 5 0.98 0.05 1.13 0.08 1.81E-01
Patient 6 0.98 0.02 1.08 0.11 4.15E-01
Patient 7 0.97 0.03 0.57 0.02 1.30E-04
Patient 8 1.08 0.23 0.49 0.04 7.72E-02
Patient 9 1.00 0.01 0.81 0.09 1.25E-01
Patient 10 0.98 0.02 1.01 0.15 1.69E-01








    VPA (g/day/L) 
Figure 5.4. ADAM23 gene expression taken from patients’ whole blood after 
VPA treatment.  
(A) Individual patients ADAM23 expression was measured after VPA treatment. 
(B) Overall VPA quantity and exposure was compared to ADAM23 expression. 
Fold changes were calculated using the Pfaffl equation and Linreg method for 
efficiencies. Results show ADAM23 expression average ±SEM of qPCR in 
duplicate. Two-tailed paired sample t-test (*=p<0.05) measured significant 
difference. Overall VPA quantity and exposure was calculated using the 
trapezoidal rule for plasma concentration under a time-curve. Patient 4 was 
excluded from analysis as, for unknown reasons the qPCR failed and could not be 
repeated due to the limited sample field. Note patient 2a and 2b is the same patient, 





















































































































5.2.1 In vivo analysis of VPA sensitive biomarkers 
Neither CDH1 nor the two putative surrogate markers showed significant differences 
between the before and after VPA samples in the pilot study. Blood and buccal 
samples taken from patients treated with VPA may not have been effective at 
measuring changes experienced by the tested genes for various reasons such as 
insufficient drug concentration and differences in expression patterns of these genes 
in these surrogate tissues compared to MCF10a cells.  
In the buccal and whole blood samples, RNase introduction may have caused poor 
RNA quality. However, the buccal cells did have RNAlater reagent added to stabilise 
the RNA and to avoid RNA degradation. Also, to ensure RNAlater was removed, an 
extra wash step was included after the lysis solution to ensure tissue disruption in the 
methodology (2.2.19.1).  
All samples were performed in technical duplicate but not biological replicates due to 
insufficient material and this may have contributed to the inconsistent changes in gene 
expression. Ideally there would have been biological replicates performed in technical 
triplicate. CDH1, TGM2 and ADAM23 graphed gene expression changes upon VPA 
treatment using the SEM (significance values calculated by a paired t-test) of the 
qPCR technical duplicates as a measure of the reliability of these measurements may 
have underestimated the true variance. Given that plate variation, reverse 
transcription, biological sampling and variations in blood handling are all likely to be 
contributing to these measurements.  
VPA exposure in the samples collected may not be able to show E-cadherin up-
regulation in cells that have had no methylation or mutation changes to its CDH1 






Chapter 6: Overall Discussion 
The research in this thesis set out to characterise VPA as an epigenetic therapy for the 
chemoprevention of cancer in HDGC families. The thesis also set out to assess CDH1 
expression regulation after VPA treatment in vitro and in vivo. As CDH1 expression 
is low in blood, alternative surrogate VPA marker genes, TGM2 and ADAM23 
identified from the transcriptome data were also tested in vivo. The thesis also detailed 
overall gene expression changes and methylation changes after VPA treatment in the 
non-malignant mammary MCF10a cell line.  
6.1  Empirical findings 
E-cadherin down regulation, as described in section 1.2.3 is the HDGC mechanism 
proposed by Humar et al to occur in the gastric mucosa before development of stage 
T1a signet ring cell carcinoma (Humar, Blair et al. 2009). It is hypothesised at least 
50% of these T1a lesions have CDH1 promoter hypermethylation. Interestingly, VPA 
increased CDH1 expression at the mRNA and protein levels in the cell lines tested 
(MCF10a and NCI-H460) although the effect was short lived.  
Transcriptome sequencing was used to investigate expression patterns in the non-
malignant cell line MCF10a. This supported previously published VPA antitumor 
mechanisms such as down-regulation of cell proliferation, the cell cycle, DNA repair 
and DNA packaging. VPA was hypothesised to cause acetylation and gene expression 
changes, where methylation marks were hypothesised to occur to increase long term 
effects. Interestingly, VPA had no effect on methylation levels of MCF10a cells after 
a 24 hour exposure. 
Samples from patients who were treated with VPA for migraines and epilepsy did not 
show any trends in the expression of CDH1 or the potential surrogate gene markers 
identified from the transcriptome data, ADAM23 and TGM2.  
6.2 Recommendations for future research  
To support findings found in this thesis, evidence to further characterise VPA effects 
in pre-clinical studies is required. The following experiments would add value to the 




methylation occurs in a methyl array by increasing VPA exposure to a 48 hour period. 
This could allow adequate time for passive methylation to occur in the MCF10a cell 
line which has a doubling time of 22 hours. Secondly, assess whether EMT inhibition 
occurs after VPA treatment by immunocytochemistry of the mesenchymal markers; 
fibronectin, vimentin and collagen 1. Thirdly, VPA could be tested at nM-μM 
concentrations, similar to how DAC at lower concentrations had the ability to 
increase/restore gene expression and also sustain gene expression after cessation of 
the drug. Fourthly, the transcriptome analysis by RNA-Seq in MCF10a cells of gene 
expression changes after VPA exposure would need to be further validated by either 
RT-qPCR or western blots. ADAM23 and TGM2 gene expression were validated in 
MCF10a cells as being increased after VPA exposure by RT-qPCR. However, this 
was with 0.5 mM and 5 mM VPA concentrations after 72 hour exposure instead of 3 
mM VPA after 24 hours exposure that the transcriptome samples were (data not 
shown). 
The following recommendations for future experiments using RNA samples from 
patients treated with VPA for neurological disease would help support VPA use in 
meeting the FDA chemopreventive criteria. FDA criteria requires surrogate markers 
to measure chemopreventive effect, new markers could be identified from 
transcriptome gastric cell line data or whole blood cells after VPA exposure and re-
assessed in the patients treated with VPA for epilepsy and migraines. Further 
characterisation of VPA effects in vivo gene expression changes could be examined 
by whole transcriptome sequencing in patients before and after VPA treatment using 
either stomach tissue or whole blood samples.  
The clinical patient population used to test for VPA effects had its limitations of being 
firstly a small sample size, and secondly, having varying drug concentrations and 
variable exposures. Attempts were made to mitigate this second limitation by 
conducting non-compartment analyses, however when characterising VPA in vivo an 
accurate estimate of VPA exposure is required. For the AUC calculation, it is 
recommended VPA (unbound) concentrations in plasma need to be assessed regularly 
in patients treated for neurological disease because of the individuals’ unique 
clearance times. It cannot be overstated however this in vivo model had many benefits 





A murine study similar to that described in (Humar, Blair et al. 2009) could be an 
invaluable source of VPA characterisation to model eHDGC. Using CDH1+/- mice to 
model HDGC used to initiate SRCC but instead be alongside VPA exposure plus 
minus treatment. The first stage would be assessing if the mouse model develops 
fewer cancers then mice given VPA. After confirmation of this, transcriptome 
sequencing could be performed on the mice stomach tissues with and without VPA 
treatment to assess VPA effects. Subsequent sampling of the mice stomachs to assess 
CDH1 could support VPA use for inhibiting HDGC and provide biomarkers 
correlating with HDGC incidence.  
In conclusion further support is required for VPA treatment in the HDGC syndrome. 
As it stands the transient effect on CDH1 expression exhibited after VPA treatment 
and subsequent drug withdrawal in MCF10a cells and the inability to detect CDH1 
expression in neurological patients, prohibits ongoing use of VPA as a 
chemopreventive agent in HDGC patients. VPA’s significant effect on cell 
proliferation and cell cycle is promising, however, as suggested a murine model of 
HDGC to show VPA inhibits growth, along with using VPA at least 1000 fold lower 
concentrations to potentially increase/restore CDH1 expression that is able to be 
sustained after drug withdrawal. Additionally in vivo studies of patients would need to 
complement data gained from the murine studies and this would provide substantial 
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  Appendix A.
MCF10a Additive methods 
a= Actrapid Penfil Neutral Insulin- Stock solutions (10 mg/mL) were prepared in 
acidified-water (100 µl or glacial acetic acid in 10 mL of sterile water). Then filter 
sterilised and aliquots stored at -20ºC. 
b= Hydrocortisone (1 mg/mL stock): 50 mg hydrocortisone powder was weighed, 
dissolved in 25 mL 100% analytical grade Ethanol, then 25 mL ultra-pure distilled 
water (Invitrogen No. 10977-023) was added. Aliquots stored at -20ºC. 
c= EGF (100µg/mL stock): Resuspend at 100 µg/mL in sterile distilled water, aliquots 
were then stored at -20ºC. 





  Appendix B.
RNA Clean and Concentrate Protocol 
10 x DNAase 1 buffer 1 µL 
RNA α µL 
DNase 1 µL 
DEPC H2O 8 µL –α µL 






  Appendix C.
The lab control cell line RNA sources. 
Cells were from a range of origins including: leukemia, melanoma, 
rhabdomyosarcoma, gastric, colorectal, ovarian, kidney, urinary, cervix, lung, 
glioblastoma and breast carcinomas.   
 
  
CCRF2-CEM (2) KATO III AGS NCI-H460
Gastric tissue HL60 J82 U251
CCRF-CEM CACO2 COLO PC3
M14 ovcar 3 c33a ovcar 8




  Appendix D.
Master Mix components for RT-qPCR (Sullivan, personal communication). 
Stock Solution Units 
Volume 
(µl) 
Rox Reference dye 50 X 0.26 
RNase-Out 10 U/ µl 0.08 
SuperScript III 6.25 U/ µl 0.16 
CDH1 Taqman assay 50 X 0.22 
Probe 20 mM 0.14 
Primer Forward 10 mM 0.18 
Primer Reverse 10 mM 0.18 
FastStart Taq 5 U/ µl 0.41 
DTT 0.1 M 0.41 
dNTPs 10 mM 0.49 
MgSO4 50 mM 1.17 
PCR buffer 10 X 1.3 
GC Rich 5 X 2.15 
RNA 25 ng 4 
DNase/RNase free water   1.85 






  Appendix E.
Master Mix components for qPCR adapted protocol with-out RT components 
(Sullivan, personal communication).  
A. Taqman assays.  
Stock Solution Units 
Volume 
(µl) 
Rox Reference dye 50 X 0.26 









MgSO4 50 mM 1.17 
PCR buffer 10 X 1.3 
GC Rich 5 X 2.15 
cDNA (input)  4 
DNase/RNase free water   3 
Sum   13 
B. Primer and Probe 
Stock Solution Units 
Volume 
(µl) 
Rox Reference dye 50 X 0.26 
Probe 20 mM 0.14 
Primer Forward 10 mM 0.18 
Primer Reverse 10 mM 0.18 
FastStart Taq 
dNTPS 




MgSO4 50 mM 1.17 
PCR buffer 10 X 1.3 




DNase/RNase free water  2.72 






  Appendix F.
Methyl array bisulfite converted details of MCF10a gDNA with 3 mM VPA 
exposure for 24 hours and control 
Plate position Condition Experiment 
Bisulfite Converted gDNA 
concentration (ng/ µl) 
C3 Untreated 1 78 
C4 Untreated 2 100 
C5 Treated 1 31.8 






  Appendix G.
Master mix reagent components used in the qPCR to assess patients’ buccal 
samples.  
Primer and Probe adapted without RT components and with lower magnesium 
concentration (Sullivan, personal communication). 
Stock Solution Units 
Volume 
(µl) 
Rox Reference dye 50 X 0.26 
Probe 20 mM 0.14 
Primer Forward 10 mM 0.18 
Primer Reverse 10 mM 0.18 
FastStart Taq 5 U/ µl 0.41 
MgSO4 33.3 mM 0.78 
PCR buffer 10 X 1.3 




DNase/RNase free water  3.60 






  Appendix H.
Cell line BA traces 
NCI-H460: RNA 2100 bioanalyzer analysis was performed as described in the 
methods section.  
Each electropherogram is a representative graph RNA extracted from the NCI-H460 
cell line. (A) NCI-H460 alone. (B) NCI-H460 exposed to 5 mM VPA. The marker 
peak is at 25 nt. 18S rRNA and 28S rRNA are also shown in the figure as the first and 
second primary peaks from left to right respectively. Fluorescence units absorbed 
=FU. 
A. NCI-H460 RIN 8.7 
 
    RNA Length 
 
B. NCI-H460 5mM VPA treated RIN 8.1 
 





AGS: RNA 2100 bioanalyzer analysis was performed as described in the 
methods section.  
Each electropherogram is a representative graph of RNA extracted from the AGS cell 
line. (A) AGS alone. (B) AGS exposed to 5 mM VPA. The marker peak is at 25 nt. 
18S rRNA and 28S rRNA are also shown in the figure as the first and second primary 
peaks from left to right respectively. Fluorescence units absorbed =FU. 
A. AGS RIN 9 
 
    RNA Length 
 
B. AGS 5 mM VPA treated RIN 8.6 
 





  Appendix I.
Cell line Quantification Systems  
NCI-H460: Spectrophotometer and fluroscence asays (Nanodrop and Qubit, 
respectively) were used to quantify total RNA. Numbers of technical replicates 
were indicated in brackets. 
 
AGS: Spectrophotometer and fluroscence asays (Nanodrop and Qubit, 
respectively) were used to quantify total RNA.  





MCF10a: Spectrophotometer and fluroscence asays (Nanodrop and Qubit, 
respectively) were used to quantify total RNA.  






  Appendix J.
Raw Ct results for qPCR 
Efficiencies for each amplicon and the average Ct averages for untreated cells are 
listed.  
# Average Ct of cell lines had the same amount of RNA input within each treatment 
exposure time. Ct averages of overall untreated cells in patient data were not 
published as each patient had a different amount of cDNA input into each reaction.  
*Experiments efficiencies were performed by Linreg to reduce inter-well variation as 
genes were measured in singleplex. These experiments were also performed in two-









Ct average of 
untreated cells#
AGS cell line CDH1 1.93 27.83
ACTB 2.00 16.81
NCI-H460 cell line CDH1 1.99 34.43
ACTB 1.97 18.49
MCF10a cell line CDH1 2.03 25.92
ACTB 2.00 18.18
MCF10a cell line CDH1 1.96 26.49
ACTB 2.09 19.459
GUSB 2.00 24.91
MCF10a cell line CDH1 1.86 24.77
ACTB 1.86 17.73
GUSB 1.88 23.77
Patient data overall- Buccal CDH1 1.83
ACTB 1.87
GUSB 1.82





After 24 hour with and with out VPA/DAC exposure
After 72 hour with and with out VPA/DAC exposure*
After 72 hour with and with out VPA/DAC exposure, and 24 hour washout*




  Appendix K.
RNA-Seq 
Nanodrop, Qubit and Agilent 6000 bioanalyzer assays were used to quantify total 
RNA in MCF10a cells prior to RNA-Seq. (A) RNA extraction Experiment 1 and (B) 
Experiment II are biological replicated. Each experiment had two technical replicated 
shown by (1) and (2).  
A   RNA Extraction Experiment 1 
 







  Appendix L.
MCF10a RNA concentration values of samples untreated and VPA exposed 
gathered from the Nanodrop and Qubit with total volume.  
Both technical replicates from both biological replicates were tested. 
Sample Names 
Nanodrop 
(ng/µL) Qubit (ng/µL) Volume (µL)  
Experiment I 
MCF10a WT (1) 576 367.5 20 
MCF10a WT (2) 545 356 20 
MCF10a 3mM (1) 391 138 20 
MCF10a 3mM (2) 406 156 20 
Experiment II 
MCF10a WT (1) 70.1 42 20 
MCF10a WT (2) 114 57.5 20 
MCF10a 3mM (1) 109 62.5 20 






MCF10a cells DNase treated samples have insufficient RNA quality.  
Samples from RNA extracted from Experiment II were analysed by Agilent RNA 
2100 bioanalyzer as described in the methods section. (A) DNase treated MCF10a 
WT (1). (B) DNase treated MCF10a WT (2). (C) DNase treated MCF10a 3 mM VPA 
(1). (D) DNase treated MCF10a 3 mM VPA (2). (E) Untreated MCF10a (1). (F) 
Untreated MCF10a 3 mM VPA (1). The marker peak is at 25 nt. 18 S rRNA and 28S 






MCF10a RNA extraction Experiment I RNA is of excellent quality.  
Agilent RNA 2100 bioanalyzer analysis was performed as described in the methods 
section. (A) MCF10a WT (1). (B) MCF10a WT (2). (C) MCF10a 3 mM VPA (1). (D) 
MCF10a 3 mM VPA (2). Experiments 1 technical replicates are indicated by number 
in brackets. Each electropherogram is a representative graph of a technical replicate. 
The marker peak is at 25 nt. 18S rRNA and 28S rRNA are indicated in the figure. 






Appendix L.  
Gene ontology results analysis using GATHER. 
Genes were chosen from the RNA sequencing results using significance criteria.  All 
Gene Ontology results have a p-value of <0.001.  
 
Gene Ontology Total # Genes Bayes factor Gene Ontology Total # Genes Bayes factor
Cell 
communication
311 27 Cell proliferation 108 73








Morphogenesis 132 22 DNA metabolism 65 49
Transcription 57 22





53 21 Mitotic cell cycle 40 47
Cellular 
metabolism





























Regulation of cell 
cycle
44 28



















































































DNA packaging 19 7

























Kyoto Encyclopaedia of genes and genomes (KEGG) analysis on 1889 
differentially expressed genes.  
KEGG analysis was performed using GATHER (Chang and Nevins 2006). Genes 
were chosen from the RNA sequencing results using the significance criteria. All 
KEGG results have a p-value of <0.001.  
 
  
KEGG accession number KEGG Pathway Total # Genes Bayes factor 
path:hsa04512 ECM-receptor interaction 20 6
path:hsa04110 Cell cycle 27 39
path:hsa00240 Pyrimidine metabolism 15 12
621 Differentially Expressed Genes Down-regulated





Appendix M.  
MCF10a methylation 450K array gene data.  
Methyl array significant β-value average difference with Wilcox test relative to CpG, 
North shores, South shores, Gene bodies and Transcription start site were compare 
with RNA-Seq data expression. Green coding indicated a significance criteria were 
met. Gene body section showing only average β-values >0.02 and <-0.01. 















CpG             
PLEC1 0.0102           
PCDHA6 0.0094           
ATP11A 0.0075           
CPEB2 -0.0098           
North shores             
BCL6 0.0251 3 1.02 4.84 ns -7.97 
GNL1 0.0241 6 1.39 6.1 6.14E-05 4.85 
CAV2 0.0236 7 0.84 8.11 2.10E-03 -0.47 
KIAA1949 0.0179           
DAXX 0.0169           
BCOR 0.0134           
ATP11A 0.0099           
SLC12A7 0.0082           
MAD1L1 0.0071           
South shores             
ATP11A 0.01           
Transcription 
start site 
            
BNC1 0.0275 15 1.09 7.61 ns -6.49 
FAM59A 0.0223 18 1.41 5.74 7.42E-03 -1.81 
Gene bodies             
GNAQ 0.0353 9 1.02 6.46 ns -8.26 
KIAA1324L 0.0342 7 1.39 4.03 2.22E-02 0.12 
LIMD1 0.0311 3 0.65 5.22 4.23E-04 2.15 
SLMO2 0.0305 20 0.9 7.68 2.54E-02 -3.69 
MYCBP2 0.0298 13 0.83 6.36 ns -7.18 
PDIA6 0.0288 2 1.01 8.31 ns -8.53 
HECW2 0.028 2 3.02 -0.02 1.72E-03 1.25 
SLC25A33 0.0274 1 0.63 4.11 1.66E-04 3.74 
CAMK4 0.027 5 5.2 1.5 2.03E-04 3.85 
WDFY2 0.027 13 1.28 4.75 2.77E-02 -3.31 
MAP4K3 0.0269 2 0.86 5.53 3.26E-02 -3.66 
BICC1 0.026 10 2.09 4.36 3.79E-05 5.85 
DIXDC1 0.0254 11 1.58 5.8 7.24E-04 1.31 
OSBPL1A 0.0252 18 0.93 5.88 ns -5.98 
LNX1 0.0248 4 1.1 2.68 ns -6.96 
MCTP1 0.0247 5 1.39 5.11 5.32E-04 1.86 
DHRS3 0.0246 1 0.55 6.54 2.70E-05 6.15 
MYH15 0.0245 3 2.42 1.81 3.30E-03 0.21 
USP31 0.0238 16 1.06 6 ns -7.19 
SRGAP1 0.0236 12 0.97 5.29 ns -8.07 
GFOD1 0.0234 6 0.92 5.19 ns -7.37 
FOXO1 0.0232 13 0.89 6.3 3.90E-02 -4.08 




EIF3H 0.0229 8 1.09 8.89 ns -5.99 
SGPP2 0.0227 2 1.73 5.55 2.30E-04 3.17 
NRM 0.0225 6 1.15 4.43 ns -5.24 
ZAK 0.0223           
MCC 0.0222 5 0.61 6.2 4.19E-04 2.02 
ASAP1 0.0217 8 0.93 7.45 ns -7.94 
NALCN 0.0215 13 0.91 3.78 ns -6.82 
PLXDC2 0.0215 10 1.74 3.76 1.46E-03 0.71 
C7orf10 0.0214           
C5orf36 0.0213           
SGIP1 0.0209 1 20.97 -2.81 3.65E-03 0.36 
FAM190A 0.0208 4 3.82 0.99 3.04E-04 3.37 
MDN1 0.0207 6 0.6 6.37 6.01E-02 -4.57 
FMNL2 0.0206 2 1.39 7.11 2.89E-03 -0.77 
CDKAL1 0.0205 6 0.81 3.99 3.02E-02 -3.24 
PADI4 0.0204 1 11.17 0.94 5.41E-04 2.64 
ZNF385D 0.0203 3 5.55 -0.54 1.23E-02 -1.03 
PTPRR 0.0203 12 1.71 -2.06 ns -4.74 
EXT1 0.0202 8 1.45 7.36 1.72E-04 3.14 
BNIP3 0.02 10 1.16 5.52 5.32E-03 -1.31 
WNK4 -0.0114 17 3.63 -1.29 1.68E-03 1.29 
 
